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General introduction
Introduction
Pregnancy is considered an immunological phenomenon since the pregnant mother needs 
to accommodate the fetal allograft. This requires profound changes of the maternal immune 
system. In this scope it has been hypothesized that the improvement of autoimmune diseases 
like rheumatoid arthritis (RA) is a result of adaptations of the immune system during preg-
nancy. The mechanism underlying this phenomenon and factors that can predict improve-
ment or deterioration of RA are still largely unknown, but multiple hypotheses have been 
proposed 1-9. It has been suggested that the adaptive immunity declines during pregnancy, 
enabling the pregnant body to tolerate the fetus as a semi-allograft. As a consequence, it can 
be hypothesized that innate immunity compensates during this state of reduced adaptive 
immunity. Mannose-binding lectin (MBL), a complement factor of innate immunity, has been 
hypothesized to play a role in the clearance of pathogenic autoantibodies from the circula-
tion, in particular those autoantibodies that lack galactose sugar residues. An increase in 
MBL levels during pregnancy would therefore result in decreased levels of pathogenic auto-
antibodies and hence may be associated with decreased disease activity, and the reverse in 
the postpartum period. Furthermore, if the susceptibility to RA as well as to certain adverse 
pregnancy outcome measures are associated with low MBL levels, the increased incidence of 
RA or pre-eclampsia, preterm birth and other adverse pregnancy outcome measures could be 
the result of shared pathogenic factors.
The aim of the research described in this thesis is to determine whether MBL plays a role 
in healthy (pregnant) controls as well as in pregnancy-induced improvement of RA and de-
terioration postpartum. Moreover it is investigated whether MBL polymorphisms are a com-
mon pathogenic factor involved both in RA as well as in certain adverse pregnancy outcome 
measures.
The main objectives of this thesis are:
1. To determine whether pregnancy has an eff ect on MBL serum levels and IgG galactosyl-
ation
2. To determine whether MBL in concert with IgG galactosylation is involved in the patho-
genesis of RA in general and more specifi cally in the pregnancy-induced improvement of 
RA 
3. To determine whether MBL is involved in pregnancy outcome in healthy controls and 
RA-patients
Next the background, concepts and hypotheses of this thesis will be discussed in more detail. 
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Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disorder characterized by 
infl ammations of the joints, most notably of the hands and feet. However, also extra-
articular manifestations are found in some patients, for example in the lungs, heart and 
vessels. RA has a great impact on patients, not only because of stiff ness, loss of energy, 
impairment of movement and loss of work participation, but also because of the increas-
ing treatment costs and income losses. 
RA occurs in 0.5-1% of the world population. It is three times more common in women 
and it is often diagnosed during women’s fertile years 10. Prevalence increases with age 
and has an annual incidence of approximately 0.5 per 1000 in males and 0.9 per 1000 in 
females, resulting in about 150000 patients with RA in The Netherlands (in 2003) 11. Large 
budgets on national healthcare costs are spent on management of rheumatic diseases, 
refl ecting the serious implications of the disease. 
RA is not a disease of recent times. Evidence of polyarthritis was found in archeological 
remains dating back to the beginning of our era. The fi rst medical description of rheu-
matoid arthritis dates to the early 18th century. However, evidence of the existence of RA 
already appeared in early 17th century art, especially in the form of paintings by Flemish 
masters (Figure 1). Garrod (1819-1907) was the fi rst to defi ne the disease as ‘rheumatoid’ 
arthritis, to distinguish it from rheumatoid fever and gout 12. 
The classifi cation criteria for RA are defi ned by the American College of Rheumatol-
ogy (ACR) in 1987 13 and comprise the fulfi llment of at least four out of seven criteria 
that describe the disease. These criteria are mainly based on clinical parameters. Since 
these parameters are often only partly evident when the damaging eff ects of the infl am-
matory process has already initiated, the ACR criteria are not very suitable for the early 
diagnosis of RA. More indicative for early disease would be the presence of antibodies 
to cyclic citrullinated peptide (anti-CCP), which occur earlier in the disease course than 
rheumatoid factor (RF) and are more specifi c for RA 14, 15. For prognosis and follow up 
of the patient the Disease Activity Score (DAS28), acute phase reactants like C-reactive 
protein (CRP), radiographic detection of erosive disease in the hand and feet joints and 
the Health Assessment Questionnaire (HAQ) are important. 
Treatment
In 1950 major treatment options for RA became available after the discovery of Nobel 
Prize laureates Hench and Kendal that corticosteroids modify the disease course of RA 
patients. Nowadays, RA is treated with (a combination of ) non-steroidal anti-infl ammato-
ry drugs, corticosteroids, disease-modifying antirheumatic drugs (DMARDs) and the rela-
tively new biological agents. Only disease-modifying agents, biologicals, and to some 
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extent corticosteroids, can impede or halt the infl ammatory and destructive processes 16, 
17. The most widely used DMARD is methotrexate (MTX), a cornerstone of most treatment 
regimens. In the last decade, the treatment of RA has improved considerably due to the 
widely implemented use of the combination of DMARDs and biologicals (like TNF inhibi-
Figure 1. The Three Graces by Peter Paul Rubens (1636-1638). Findings suggestive of the existence of rheumatoid 
arthritis appear in 17th century European art. Note swelling of the metacarpophalangeal and proximal 
interphalangeal joints of the right hand on the outer left fi gure. Copyright permission obtained by Prado Museum 
Madrid Spain.
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tors). Aggressive early treatment with DMARDs and biologicals results in lower disease 
activity, prevention of erosions and preserved physical function in RA-patients.
During pregnancy, prednisone, sulfasalazine, hydroxychloroquine and gold injections, 
and in some cases ciclosporine and azathioprine, are the only RA drugs that can be pre-
scribed safely 18. Even before conception, all other RA drugs have to be discontinued and 
washed out to reduce the risk of teratogenicity. Infrequently anti-TNF biologicals are con-
tinued until the fi rst trimester of pregnancy, but solid safety data are not yet available. 
Pathogenesis of RA
The etiopatho genesis of RA remains largely unclear, but may result from infectious, 
environmental, genetic and hormonal factors 12, 19. The geographic distribution of RA is 
worldwide, with a notably low prevalence in rural Africa and high prevalence in specifi c 
tribes of Native Americans 20. There is no clear association between the prevalence of 
RA and socioeconomic status 20. Recently smoking was identifi ed as another causative 
agent to the development of anti-CCP-positive RA in HLA-DR shared epitope gene posi-
tive individuals 21. Population- and twin studies have shown that genetic factors have 
some contribution to the pathogenesis of RA. There is excess disease concordance be-
tween monozygotic (15%) when compared with dizygotic (3.6%) twins in RA 22. Genes 
encoding human leukocyte antigen (HLA-DRB1) shared epitope molecules also have an 
important contribution to this genetic risk, as well as the protein tyrosine phosphatase 
non-receptor 22 (PTPN22) gene, which is involved in multiple autoimmune diseases and 
plays an essential role in signal transduction and is integral in the T-cell antigen receptor 
signaling pathway 23. The eff ect of other individual genes to RA is small, probably since 
the genetic contribution to the pathogenesis of RA is a result of the interplay of various 
genes altogether. Hormonal factors could also play a role in RA susceptibility since RA 
is most prevalent in women. Moreover, a reduced incidence is seen during pregnancy 
24 and the onset of RA is sometimes triggered after pregnancy, when the protective im-
munosuppressive conditions of pregnancy subside 25, 26. Also nulliparity, breastfeeding 
and delayed pregnancy have been suggested as risk factors for RA development 22-24. This 
is in contrast to oral contraceptive use, which is thought to protect against disease onset 
and disease progression 25, 27-29.
Adaptive immunity of RA
The presence of autoantibodies produced by B-cells (plasma cells) and the presence of 
autoreactive T-cells in blood and synovial fl uid, is one of the hallmarks of RA that distin-
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guishes this disease from other infl ammatory and degenerative joint diseases. In the RA-
joints, proliferation of synovial cells and infi ltration of the synovium by infl ammatory cells 
takes place. The cell types that occupy the infl amed joint include T-cells, B-cells (plasma 
cells), neutrophils, fi broblast-like synoviocytes, monocytes, macrophages and mast cells 
30. Autoantibodies are already present in the earliest disease stages and may precede 
disease onset by several years 31. Rheumatoid factors (RF), i.e. autoantibodies against the 
Fc moiety of IgG, are the oldest established marker-antibodies in RA and high serum 
titers of IgG-RF, IgM-RF and IgA-RF are moderately specifi c for RA. Likewise, the more 
recently described anti-citrullinated protein antibodies, commonly called ACPA, are even 
more specifi c for RA and present even earlier before the fi rst disease manifestation and 
are abundant in synovial tissue 31. Both diagnostic tools are associated with more severe 
and erosive disease and have prognostic value 22. The somewhat disputed role of B-cells 
in the pathogenesis of RA is further supported by the fact that B-cell depletion therapy 
in the form of rituximab (Mabthera®) is quite successful. 
Also T-cells are thought to play a role in the pathogenesis of RA. T-cells have several 
distinct functions in RA like antigen recognition, activation of other cell types through 
cell-cell interaction and cytokine production, which is also reported in the joints. At least 
two functional subsets of T-cells can be distinguished according to their cytokine secre-
tion profi les: T helper 1 (Th1) cells, which produce interleukin-2 (IL-2), interferon-γ (IFN-γ) 
and lymphotoxin and some TNF-α, and T helper 2 (Th2) cells, which secrete IL-4, IL-5 and 
IL-10. In RA a shift toward T-lymphocytes with a Th1 cytokine secreting profi le in the 
joints can be observed 32. Pregnancy is associated with a more pronounced Th2 profi le. 
Moreover, also the recently described so-called T helper 17 (Th17 cells), which secrete 
IL-17 are implicated with pathogenesis and severity in RA 33. Blockade of cytokines like 
TNF-α is currently established as an eff ective therapy for RA 34. 
Innate immunity - Complement system
Innate immunity, as opposed to adaptive immunity, provides immediate and early host de-
fence. In innate immune defence all barriers and arms are already in place. This is in contrast 
to adaptive immune defence which needs several hours to days to recruit appropriate and 
specifi c immune cells to mediate an immune response. One of the components of innate im-
munity next to, for example toll-like receptors (TLRs), dendritic cells (DCs) and macrophages, 
is the complement system (Figure 2). Three distinct pathways of complement have been iden-
tifi ed, i.e. the classical pathway, the alternative pathway and the lectin or mannose-binding 
lectin (MBL) pathway. The classical complement pathway is triggered by complement com-
ponent C1q, which can bind to IgG or IgM antibodies that are bound to bacteria or other 
antigens forming antigen-antibody immune complexes. The alternative pathway is triggered 
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by direct recognition of microbial surface structures by C3 and properdin. This pathway is 
independent of immunoglobulins and C1q. Lastly, the lectin or MBL pathway is triggered 
by MBL bound to carbohydrates on microbial and antigen glycoproteins and glycolipids. 
In addition, the lectin pathway can be activated by a family of related proteins, the fi colins. 
These known as L-Ficolin, M-Ficolin and H-Ficolin, also called Ficolin-2, Ficolin-1 and Ficolin-3, 
respectively 35, 36. Upon binding of MBL to its target surfaces, MBL-associated serine proteases 
(MASPs) become activated to serve the same function as C1r:C1s complex in the classical 
pathway and then activate the complement cascade by cleaving and activating C4 and C2. 
After C2-activation, the lectin complement pathway is further activated, fi nally resulting in 
the formation of the membrane attack complex C5b-9 (MAC). The MAC is the end product 
CLASSICAL PATHWAY MB LECTIN PATHWAY ALTERNATIVE PATHWAY
Antigen:antibody complexes
(pathogen surfaces)
Mannose binding lectin binds
mannose on pathogen surfaces
Pathogen surfaces
C1q, C1r, C1s
C4
C2
MBL, MASP-1, MASP-2
C4
C2
C3 convertase
C3
B
D
C3a, C5a
Peptide mediators of inflammation,
phagocyte recruitment
Membrane-attack complex,
lysis of certain pathogens and cells
C3b
Binds to complement receptors
on phagocytes
Opsonization of pathogens
Removal of immune complexes
Terminal complement components
C5b
C6
C7
C8
C9
Figure 2. Schematic representation of the activation pathways of the complement system. The (mannose-binding) 
lectin pathway of complement is activated by MBL and fi colins. On binding to appropriate targets, MBL-MASP 
complexes cleave C4 and C2 to form C3 convertase. The classical and alternative pathways also generate C3 
convertase enzymes, although via diff erent intermediates. These ultimately cleave C3 into C3a and C3b, which have 
distinct anti-infl ammatory properties. The lytic pathway (C5b-C9) is common to all three routes after C3 cleavage. 
Abbreviations: MBL, mannose-binding lectin; MASP, MBL-associated proteases. Adapted from Janeway 2006. 
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of the common terminal pathway of all three complement pathways and has many eff ector-
functions including defence against microbes, opsonization of pathogens and the clearance 
of immune complexes, cellular debris and antigens. The cleavage of C5 results in C5a and C5b. 
C5b bound to C3b is involved in the common terminal pathway. C5a forms potent anaphyla-
toxins together with C3a. These anaphylatoxins are chemotactic for neutrophils and phago-
cytes and induce the release of infl ammatory mediators from mast cells. The other splicing 
product of C3, next to C3a, is C3b that binds to complement receptors on phagocytes, which 
leads to opsonization of pathogens and also to the removal of (auto-)immune complexes.
Mannose-binding lectin (MBL)
MBL (mannose-binding lectin, but also referred to as mannan-binding lectin and mannose-
binding protein) is one of the complement components that activates the lectin complement 
pathway. MBL is a calcium dependent (or C-type) lectin that is synthesized by the liver. Its pro-
duction is increased 2- to 3-fold in response to infection and it is rapidly sequestered to sites 
of infl ammation 37. MBL has many functional and structural similarities to C1q, the compara-
tive protein of the classical complement pathway. Both molecules form a trimeric structure 
resembling a bunch of tulips 36, 38 (Figure 3), which further oligomerize to form higher order 
multimers which are able to activate the complement cascade. The concentration of MBL in 
serum ranges 1000-fold; from 5 ng/ml to more than 5 μg/ml in diff erent individuals, with a 
median of 1.5 μg/ml 36. The cut-off  level of MBL defi ciency is not well established and used 
to be assay dependent, but generally MBL serum concentrations below 100 ng/ml (0.1 μg/
ml) are considered defi cient. Therefore approximately 10% of Caucasians are in this MBL defi -
cient group. Additionally, individuals with intermediate MBL serum levels are also considered 
as having suboptimal MBL serum concentrations, namely approximately 30% of Caucasians, 
resulting in a large portion of the population being borderline MBL defi cient (Table1). 
The concentration of MBL in an individual is to a large degree determined by single 
nucleotide polymorphisms (SNPs) on chromosome 10 region 10q 21-24, in the promoter 
region and in exon 1 of the MBL2 gene. The numbering of the gene is due to the existence 
of a pseudogene, MBL1, not giving rise to protein. The MBL2 wildtype, common allele is the 
A-allele. The three SNPs of the fi rst (of four) exon(s) are positioned on codon 52 (D-allele, 
rs5030737), codon 54 (B-allele, rs1800450) and codon 57 (C-allele, rs1800451). Individuals 
with the homozygous wildtype AA-genotype have the highest MBL serum concentrations. 
Individuals who are homozygous for the B, C or D alleles are MBL defi cient. Individuals who 
are heterozygous, i.e. who have an A-allele together with a B, C or D-allele, have intermediate 
MBL serum concentrations. The O-allele represents the variant alleles B, C and D together, 
resulting in the AA-, AO- and OO-genotype. Basal MBL serum levels are also modifi ed by the 
SNPs in the promoter region of the MBL2 gene (H/L or X/Y) 39. The two SNPs in the promoter 
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region are positioned on codon -550 (H/L, rs11003125) and codon -221 (X/Y, rs7096206) of 
the MBL2 gene. Linkage disequilibrium of the exon 1 mutations with the promoter polymor-
phisms results in six possible haplotypes (i.e. HYA, LYA, LXA, LYB, LYC and HYD) and every 
individual will express two out of these six haplotypes. The HYA and HYD haplotype induces 
high MBL concentrations, while the LXA haplotype cause reduced MBL concentrations.
Based upon the haplotypes individuals can be categorized into three groups that cor-
relate best with MBL serum levels 40 and is therefore commonly used and accepted 41: the 
high MBL production group A, (H or L)YA/(H or L)YA and (H or L)YA/LXA; the intermediate 
MBL production group B, LXA/LXA and (H or L)YA/O and the low or defi cient MBL produc-
tion group C, LXA/O and O/O (Table 1). 
Figure 3. A) Structure of the human MBL-2 gene and the encoded protein product. Positions of the exon 1 and 
promoter polymorphisms are shown, including the location of the SNPs described in this thesis. Diff erent regions 
of the polypeptide are encoded by diff erent exons of the MBL-2 gene. Three idendical 32-kDa polypeptides form a 
structural subunit, based on the formation of a collagenous triple helix. In serum, MBL consists of oligomers ranging 
from dimers to hexamers in a bouquet-like structure. B). Hexamer of human mannose-binding lectin structural 
subunits which resembles a bunch of tulips. The MBL subunits are cross-liked by disulphide bonds in the N-terminal 
regions. Each MASP molecule is believed to bind close to the hinge point of the collagenous region. Oligomerization 
(less structural subunits) results in increased clearance from the serum and reduced activity of the protein. 
Abbreviations: MBL, mannose-binding lectin; MASP, MBL-associated proteases; SNPs, single nucleotide 
polymorphisms. Copyright permission obtained from Blackwell Publishing United Kingdom.
Table 1. Distribution of the MBL genotype groups in relation to the MBL genotypes
MBL genotype groups MBL serum levels Incidence Genotypes
Group A High 1.3 - 5.0 μg/ml 57.0% (H or L) YA / (H or L) YA and (H or 
L) YA / LXA 
Group B Intermediate 0.6 - 1.3 μg/ml 27.5% LXA / LXA and
(H or L)YA / O
Group C Low 0 – 0.6 μg/ml 15.5% LXA / O and O / O
Fleur BW 7.indd   18 10/22/2009   3:51:59 PM
19
General introduction
MBL and disease associations
MBL has been intensively studied on associations with multiple medical conditions (i.e. 
increased risk for disease or for a more complicated course of disease). These association 
studies may be divided into studies on associations between MBL and infectious dis-
eases, MBL and autoimmune diseases and, lastly, MBL with other diseases or conditions, 
like pregnancy and pregnancy outcome. 
Infections
Reduced MBL concentrations are associated with an increased frequency of infections 
of both viral and bacterial origin, particularly in children and patients with co-existing 
immune defects, including primary and secondary immunodefi ciencies like after organ 
transplantation or chemotherapy 42-46. Other studies have identifi ed specifi c pathogens 
to which MBL-defi cient individuals are more susceptible, like human immunodefi ciency 
virus (HIV), Plasmodium falciparum, Cryptosporidium parvum and Neisseria meningitidis. 
However, there are also intracellular parasites (e.g. Mycobacteria, Leishmania and Legio-
nella) to which MBL-defi cient individuals may actually be protected 47.
Autoimmune diseases
In some autoimmune diseases such as systemic lupus erythematosus (SLE) cell debris 
derived from apoptotic cells might trigger an autoimmune response. Since MBL and the 
fi colins play a role in the clearance of apoptotic cell material removal, defi cient serum 
concentrations of MBL or of the fi colins may lead to ineffi  cient removal of apoptotic cells 
and therefore increased levels of pathogenic antigens 48. In SLE MBL defi ciency is asso-
ciated with increased disease activity 49. Additionally, in RA MBL gene polymorphisms 
that result in low MBL levels have been associated with disease susceptibility and also 
disease severity, but results have been confl icting 19, 50-53. For RA it is not clear yet whether 
MBL polymorphisms predispose to the (early) development of severe disease since the 
patient cohorts investigated have been quite diverse and relatively small. Interestingly, 
it has been shown that MBL-defi cient mice displayed defective apoptotic cell clearance, 
but did not develop autoimmune diseases 37. 
Other conditions, pregnancy and pregnancy outcome
Lastly, MBL has also been studied in relation to other diseases and conditions. High levels 
of MBL are actually a risk factor to the rejection of a transplanted organ in the setting of 
ischemia and reperfusion 54. MBL gene polymorphisms have also been studied in relation 
to outcome in pregnancy. Low MBL, demonstrated either by measuring the actual serum 
protein or by determining the relevant genotypes, has been associated with adverse 
pregnancy outcomes, like recurrent miscarriages, risk for chorioamnionitis, preterm 
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delivery and pre-eclampsia 55-62. Pre-eclampsia is a common but severe pregnancy disor-
der. It is characterized by hypertension and de novo proteinuria 63 and is associated with 
high maternal and foetal morbidity and mortality. Abnormal formation of the placenta, 
placentation, is thought to play an important role in its pathophysiology 64, 65. During 
early pregnancy apoptosis is an essential process in the continuous remodelling of the 
placenta. It has been speculated that MBL, as a scavenger of cellular debris and apoptotic 
material, might play a role in placentation. Defi cient maternal MBL concentrations have 
also been described as being a risk factor for preterm birth and reduced birth weight 56. 
One study showed an association of MBL gene polymorphisms with gestational diabetes 
mellitus, resulting in heavier infants 66. 
To recapitulate, MBL can be regarded as immunomodulatory factor with pleiotropic 
functions that infl uences the disease course whether it is present in high or in low con-
centrations in the serum. It can play an infl ammatory role by initiating the lectin pathway 
of complement, but it can also act anti-infl ammatory in the clearance of (auto)immune 
complexes and cell debris from apoptosis. Finally, MBL may also directly suppress pro-
infl ammatory cytokine production by monocytes 67, 68, a function which is not yet clearly 
established. 
Glycosylation of immunoglobulins and RA
MBL has been hypothesized to play a role in the clearance of pathogenic autoantibodies 
from the circulation in RA, in particular those autoantibodies that lack galactose sugar 
residues. An increase in MBL levels during pregnancy would therefore result in decreased 
levels of pathogenic autoantibodies and hence may be associated with decreased dis-
ease activity in RA-patients.
Autoantibodies, such as those found in autoimmune diseases like RA, belong to the 
family of immunoglobulins (Ig’s), which are glycoproteins. The Ig’s are divided into fi ve 
isotypes based on the diff erences in the immunoglobulin heavy chains (IgG, IgM, IgA, 
IgE and IgD). The IgG molecule has two Fab moieties and one Fc moiety, which are built 
up from two heavy chains and two light chains. The Fab moieties comprise the antigen-
binding site formed each by the variable regions of one heavy chain and one light chain. 
The Fc part in the constant region is formed by dimerization of part of the heavy chains 
and has the mechanistic ability to bind to complement and also to bind the Fc receptor 
on various cells. 
Immunoglobulins carry variable sugar moieties on their heavy chains, which are as-
sociated with age, gender and disease(activity) 69, 70. Immunoglobulin glycosylation varia-
tion has been best described in IgG, but also occurs in IgM and IgA 71, 72. In IgG each of 
the heavy chains of the immunoglobulin carries a single N-glycan chain, which can show 
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variable glycosylation patterns 73 (Figure 4). This variable glycosylation pattern is a result 
of diff erences in the presence or absence of the core-linked fucose, the bisecting N-
acetylglucosamine (GlcNAc) and/or galactose and sialic acid sugar residues on the outer 
arms. The outer arms of the N-glycan chains can contain 0, 1 or 2 galactose residues. 
These sets of oligosaccharides are commonly known as Gal-0 or agalactosyl IgG, Gal-1 
or Gal-2, respectively, and the galactose molecules may be situated on either the α1,3 or 
α1,6 arm of the sugar molecule. On each galactose residue, one sialic acid residue can be 
present. If the α1,3 or α1,6 arm of the N-glycan does not contain a galactose residue, no 
sialic residue will be on that arm either. 
Abnormal serum IgG glycosylation patterns are observed in RA and in a restricted 
number of other autoimmune diseases 69, 73-75 and tuberculosis 76. Compared to healthy 
controls, higher levels of the agalactosyl IgG are found in RA-patients and these are asso-
ciated with increased disease activity and a more progressive disease course 19, 73, 77. These 
agalactosyl IgG’s have also been shown to play a pathogenic role in a mouse model of 
arthritis 78. As a result of the absence of galactose, agalactosyl IgG also lacks terminal si-
alic acid residues. It has been hypothesized that these sialic acid residues are involved in 
suppressing infl ammation by infl uencing the balance between activating and inhibitory 
Fcγ-receptors 79. Therefore, the pathogenicity of agalactosyl IgG may not primarily be due 
to a lack of galactose residues but due to the absence of sialic acid residues. 
α(1-3)
Gal
SA
GlcNAc
Man
α(1-6)
Gal
SA
✻
✻
✻
✻
✻
✻
GlcNAc
Man
GlcNAc
Man
GlcNAc
GlcNAc FUCOSE
ASN (297)
Figure 4. Schematic representation of the bi-antennary complex oligosaccharide structure attached to the 
asparagine 297 in the CH2 domain of each IgG Fragment crystalizable (Fc) portion. Diff erences in glycosylation are a 
result of the presence or absence of the sugar moieties marked with an asterisk (*). Abbreviations: SA, sialic acid; Gal, 
galactose; GlcNAc, N-acetylglucosamine; Man; mannose; ASN, asparagine. The GlcNAc between the two mannose 
structures is called the bisecting GlcNAc. Agalactosyl IgG or Gal-0 IgG refers to oligosaccharides completely lacking 
galactose (Gal).
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Pregnancy-induced improvement of RA
In most RA-patients (53-90%) disease activity decreases spontaneously during preg-
nancy and increases early in the postpartum period 10. Multiple studies have been under-
taken in order to explain the benefi cial eff ect of pregnancy on RA and many hypotheses 
have been postulated 1-9. Nevertheless, the exact mechanisms are still unknown. Previ-
ously, physicians have tried to copy the favorable eff ect by treating patients with blood, 
placental products, or serum from pregnant women without much success 4. Regarding 
hormone-based hypotheses, studies revealed that increased cortisol levels did not ex-
plain the improvement of RA because of the concomitant elevation of steroid binding 
globulin and the fact that the timing of gestational improvement does not coincide with 
the rise of the cortisol levels 80-82. The elevated levels of sex hormones like estrogens, an-
drogens and progesterone also could not satisfactorily explain the pregnancy-induced 
remission of RA. Treatment with female hormones exerts no or only a modest eff ect on 
disease activity in RA 83. Prolactin, which is elevated during pregnancy and also during 
breastfeeding, could not explain pregnancy-induced improvement of RA as well 84. 
Many other hormones, but also cytokine levels are increased during pregnancy. 
Changes in hormone levels have been associated with shifts in cytokine levels and other 
immunological (cellular) adaptations. Pregnancy is associated with decreased produc-
tion of Th1 (T-helper 1 cell) associated cytokines (like IL-1, IL-2 and interferon-γ (IFN-γ)) 
and an increased production of Th2-associated cytokines (like IL-4, IL-5, and IL-10) and a 
decreased production of pro-infl ammatory cytokines (like TNF-α and IL-12) 5. Since RA is 
marked by a Th1 cytokine profi le, a shift towards a Th2 cytokine profi le is an attractive 
explanation of a pregnancy-induced remission of RA 6. 
Another immunological hypothesis for the eff ect of pregnancy on disease activity in 
RA is the maternal-fetal disparity in HLA class II alloantigens 7. The exposure of fetal (pa-
ternal) non-self HLA antigens, and in particular HLA-DR and HLA-DQ antigens, urges the 
maternal immune system to tolerate this semi-allograft in order to maintain pregnancy 7. 
This tolerance may result in decreased disease activity. These fi ndings would explain why 
not all patients would improve during pregnancy. Also the specifi c expression of HLA-
G by the syncytiotrophoblast of the fetus may inhibit maternal NK cells and therefore 
reduce cytotoxicity by its binding to the killer-cell immunoglobulin-like receptors (KIRs) 
of the NK cells. This mechanism might play a role in pregnancy-induced improvement of 
RA as well 2, 7, 8, 73, 85, 86.
Also, during pregnancy, increased levels of α-2 pregnancy-associated protein 46 have 
been associated with decreased RA-disease activity as well and the reverse postpartum 
85, 86. An alternative hypothesis to explain pregnancy-induced improvement of RA is the 
action of regulatory T-cells (Tregs), which are induced during pregnancy. Regulatory T-
cells may suppress activation and proliferation of conventional T cells and are able to 
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suppress autoimmunity by secretion of IL-10 1, 9. Moreover, in two small studies a de-
crease in pathogenic agalactosyl IgG has been associated with the pregnancy-induced 
improvement of RA 2, 3. 
In conclusion, it is likely that multiple mechanisms work in concert to induce RA-im-
provement during pregnancy.
Pregnancy outcome and RA
Pregnancy outcome might be infl uenced by RA. An association has been described 
between several rheumatic diseases and unfavorable pregnancy outcome measures 
87-91. However, only a small number of studies examined pregnancy outcome specifi -
cally in RA. An increased risk of hypertensive disorders (gestational hypertension and 
pre-eclampsia) in women with RA has been demonstrated 92, 93, but not all studies sup-
port this fi nding 94-96. A higher rate of prematurity 91, 95, 96, caesarean sections 93, 95, 96 and 
spontaneous abortions 97 is also reported, although results on the rate of spontaneous 
abortions are confl icting 95,98. Newborns of women with RA were reported to have lower 
birth weight, especially newborns of women who have a high disease activity 94. In con-
trast, the risk of low birth weight (less than 2500 gram) does not seem to be increased 
in women with RA 94, 95,98, but a higher rate of small for gestational age and intra-uterine 
growth retardation is reported 92, 93. Possibly, prednisone use is also associated with lower 
birth weight 98,99. Most previous studies were small, retrospective and did not specifi cally 
analyze RA-patients as a subgroup. 
Aims of this thesis
Pregnancy is the only natural situation that results in spontaneous improvement of RA 
and a fl are of the disease after delivery 1. Insight into the underlying mechanisms may 
not only increase our knowledge on the phenomenon of pregnancy-induced remission 
in RA but may also contribute to a better understanding of pathogenic mechanisms un-
derlying RA in general. 
Until today it is unclear which mechanisms or what factors could induce this remission. 
It has been hypothesized that the complement factor mannose-binding lectin (MBL) 
might play a benefi cial role that results from its binding to pathogenic agalactosyl IgG 
antibodies and may therefore function as a scavenger molecule involved in the effi  cient 
removal of pathogenic agalactosyl IgG containing immune complexes 19. For that reason, 
if pregnancy causes a rise in MBL serum concentrations, this might provide an alternative 
hypothesis to explain the phenomenon of pregnancy-induced improvement of RA.
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Furthermore MBL may be associated with pregnancy outcome. Therefore, if the sus-
ceptibility both for RA as well as certain adverse pregnancy outcome measures are as-
sociated with low MBL levels, the increased incidence in RA of pre-eclampsia, preterm 
birth and other pregnancy outcome measures could be the result of shared pathogenic 
factors. 
The aim of this thesis is to determine whether MBL plays a role in healthy pregnancy 
and in pregnancy-induced improvement of RA and deterioration postpartum. Moreover 
it is investigated whether MBL polymorphisms are a common pathogenic factor involved 
both in RA as well as in certain adverse pregnancy outcome measures.
In the next chapter, chapter 2, the MBL serum concentrations and the lectin comple-
ment pathway activity during pregnancy and postpartum in healthy controls is described. 
Since there are indications that MBL is associated with pregnancy outcome and is 
also associated with RA, fi rst the role of MBL genotype groups in relation to pregnancy 
outcome in healthy controls is investigated in the next chapters; The third chapter con-
siders a possible association with MBL genotype groups with pre-eclampsia in healthy 
controls and chapter 4 reports a possible association between MBL genotype groups 
and preterm birth in healthy controls.
In chapter 5 the question whether MBL genotype groups are associated with RA disease 
susceptibility and disease severity is addressed. In order to give a more defi nite answer 
to previous non-conclusive literature, two large cohorts are studied on the association 
between MBL genotype groups and RA disease susceptibility and RA disease severity, as 
defi ned by the need for anti-TNF therapy. 
Chapter 6 reports a simultaneous increase in the glycosylation of IgG (in particular ga-
lactosylation and sialylation) and improvement of RA during pregnancy. After delivery 
the IgG glycosylation decreases and RA disease activity fl ares. Possible factors that might 
infl uence this glycosylation are studied.
In chapter 7 the role of MBL during pregnancy and in the postpartum period is studied 
in RA. The possible association between maternal MBL genotypes on pregnancy-induced 
remission of RA is investigated, but also the possible association between MBL and IgG 
galactosylation changes during pregnancy and postpartum. Moreover, the role of MBL 
on pregnancy outcome in RA, like birth weight, gestational age, miscarriage and hyper-
tensive disorders is described. 
Chapter 8 is dedicated to the discussion of the main fi ndings of this thesis in the light 
of the study objectives, followed by methodological considerations. New insights arising 
from this thesis into MBL, RA and pregnancy are described. Finally, recommendations for 
future studies are presented.  
Fleur BW 7.indd   24 10/22/2009   3:52:02 PM
25
General introduction
References
1. Ostensen M, Villiger PM. The remission of rheumatoid arthritis during pregnancy. Semin Immuno-
pathol 2007;29:185-91.
2. Rook GA, Steele J, Brealey R, Whyte A, Isenberg D, Sumar N, et al. Changes in IgG glycoform levels are 
associated with remission of arthritis during pregnancy. J Autoimmun 1991;4:779-94.
3. Alavi A, Arden N, Spector TD, Axford JS. Immunoglobulin G glycosylation and clinical outcome in 
rheumatoid arthritis during pregnancy. J Rheumatol 2000;27:1379-85.
4. De Man YA, Hazes JMW. Pregnancy. In: Isenberg DA, Maddison PJ, Woo P, Glass D, Breedveld FC, edi-
tors. Oxford Textbook of Rheumatology. 3 ed. Oxford: Oxford University Press; 2004. p. 117-126.
5. Kanik KS, Wilder RL. Hormonal alterations in rheumatoid arthritis, including the eff ects of pregnancy. 
Rheum Dis Clin North Am 2000;26:805-23.
6. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal 
relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993;14:353-6.
7. Nelson JL, Hughes KA, Smith AG, Nisperos BB, Branchaud AM, Hansen JA. Maternal-fetal disparity in 
HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J 
Med 1993;329:466-71.
8. Ostensen M, Villiger PM. Immunology of pregnancy-pregnancy as a remission inducing agent in rheu-
matoid arthritis. Transpl Immunol 2002;9:155-60.
9. Forger F, Marcoli N, Gadola S, Moller B, Villiger PM, Ostensen M. Pregnancy induces numerical and 
functional changes of CD4+CD25 high regulatory T cells in patients with rheumatoid arthritis. Ann 
Rheum Dis 2008;67:984-90.
10. Nelson JL, Ostensen M. Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am 1997;23:195-
212.
11. Van der Linden S, Poos M. Hoe vaak komt RA voor en hoeveel mensen sterven eraan? In: Volksgezond-
heid Toekomst Verkenning, Nationaal Kompas Volksgezondheid, www.nationaalkompas.nl, website 
last visited May 14, 2009. In. 3.14 ed. Bilthoven: RIVM; 2007.
12. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheuma-
tism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum 
1988;31:315-24.
14. Vossenaar ER, van Venrooij WJ. Citrullinated proteins: sparks that may ignite the fi re in rheumatoid 
arthritis. Arthritis Res Ther 2004;6:107-11.
15. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP Antibody, a Marker for the Early Detection of Rheu-
matoid Arthritis. Ann N Y Acad Sci 2008;1143:268-85.
16. Venkateshan SP, Sidhu S, Malhotra S, Pandhi P. Effi  cacy of biologicals in the treatment of rheumatoid 
arthritis. a meta-analysis. Pharmacology 2009;83:1-9.
17. Zwerina J, Redlich K, Schett G, Smolen JS. Pathogenesis of rheumatoid arthritis: targeting cytokines. 
Ann N Y Acad Sci 2005;1051:716-29.
Fleur BW 7.indd   25 10/22/2009   3:52:02 PM
Chapter 1
26
18. Hazes JM, De Man YA. Antirheumatic drugs in pregnancy and lactation. In: Isenberg DA, Maddison 
PJ, Woo P, Glass D, Breedveld FC, editors. Oxford textbook of Rheumatology. 3 ed. Oxford: Oxford 
University Press; 2004. p. 126-134.
19. Garred P, Madsen HO, Marquart H, Hansen TM, Sorensen SF, Petersen J, et al. Two edged role of man-
nose binding lectin in rheumatoid arthritis: a cross sectional study. J Rheumatol 2000;27:26-34.
20. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11.
21. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an 
etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune 
reactions to autoantigens modifi ed by citrullination. Arthritis Rheum 2006;54:38-46.
22. Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman M. Rheumatology. 4 ed: Mosby Elsevier; 2008.
23. Bowes J, Barton A. Recent advances in the genetics of RA susceptibility. Rheumatology (Oxford) 
2008;47:399-402.
24. Da Silva JA, Spector TD. The role of pregnancy in the course and aetiology of rheumatoid arthritis. Clin 
Rheumatol 1992;11:189-94.
25. Hazes JM. Pregnancy and its eff ect on the risk of developing rheumatoid arthritis. Ann Rheum Dis 
1991;50:71-2.
26. Silman A, Kay A, Brennan P. Timing of pregnancy in relation to the onset of rheumatoid arthritis. Ar-
thritis Rheum 1992;35:152-5.
27. Doran MF, Crowson CS, O’Fallon WM, Gabriel SE. The eff ect of oral contraceptives and estrogen 
replacement therapy on the risk of rheumatoid arthritis: a population based study. J Rheumatol 
2004;31:207-13.
28. Hazes JM, Dijkmans BC, Vandenbroucke JP, de Vries RR, Cats A. Reduction of the risk of rheumatoid 
arthritis among women who take oral contraceptives. Arthritis Rheum 1990;33:173-9.
29. Hazes JM, van Zeben D. Oral contraception and its possible protection against rheumatoid arthritis. 
Ann Rheum Dis 1991;50:72-4.
30. Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, Tak PP. Analysis of the cell infi ltrate and expres-
sion of proinfl ammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: 
comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. 
Ann Rheum Dis 2003;62:635-8.
31. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning 
MH, et al. Specifi c autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial 
measurements in blood donors. Arthritis Rheum 2004;50:380-6.
32. Dolhain RJ, van der Heiden AN, ter Haar NT, Breedveld FC, Miltenburg AM. Shift toward T lymphocytes 
with a T helper 1 cytokine-secretion profi le in the joints of patients with rheumatoid arthritis. Arthritis 
Rheum 1996;39:1961-9.
33. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 
2008;41:84-91.
34. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 
2006;355:704-12.
35. Matsushita M, Endo Y, Hamasaki N, Fujita T. Activation of the lectin complement pathway by fi colins. 
International Immunopharmacology 2001;1:359-363.
Fleur BW 7.indd   26 10/22/2009   3:52:02 PM
27
General introduction
36. Thiel S. Complement activating soluble pattern recognition molecules with collagen-like regions, 
mannan-binding lectin, fi colins and associated proteins. Mol Immunol 2007;44:3875-88.
37. Stuart LM, Takahashi K, Shi L, Savill J, Ezekowitz RA. Mannose-binding lectin-defi cient mice display 
defective apoptotic cell clearance but no autoimmune phenotype. J Immunol 2005;174:3220-6.
38. Dommett RM, Klein N, Turner MW. Mannose-binding lectin in innate immunity: past, present and 
future. Tissue Antigens 2006;68:193-209.
39. Madsen HO, Satz ML, Hogh B, Svejgaard A, Garred P. Diff erent molecular events result in low protein 
levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol 
1998;161:3169-75.
40. Madsen HO, Garred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP, et al. Interplay between promoter 
and structural gene variants control basal serum level of mannan-binding protein. J Immunol 
1995;155:3013-20.
41. Biezeveld MH, Geissler J, Weverling GJ, Kuipers IM, Lam J, Ottenkamp J, et al. Polymorphisms in the 
mannose-binding lectin gene as determinants of age-defi ned risk of coronary artery lesions in Kawa-
saki disease. Arthritis Rheum 2006;54:369-76.
42. Frakking FN, van de Wetering MD, Brouwer N, Dolman KM, Geissler J, Lemkes B, et al. The role of 
mannose-binding lectin (MBL) in paediatric oncology patients with febrile neutropenia. Eur J Cancer 
2006;42:909-16.
43. Koch A, Melbye M, Sorensen P, Homoe P, Madsen HO, Molbak K, et al. Acute respiratory tract infections 
and mannose-binding lectin insuffi  ciency during early childhood. Jama 2001;285:1316-21.
44. Summerfi eld JA, Sumiya M, Levin M, Turner MW. Association of mutations in mannose binding pro-
tein gene with childhood infection in consecutive hospital series. Bmj 1997;314:1229-32.
45. Summerfi eld JA, Ryder S, Sumiya M, Thursz M, Gorchein A, Monteil MA, et al. Mannose binding protein 
gene mutations associated with unusual and severe infections in adults. Lancet 1995;345:886-9.
46. Bouwman LH, Roos A, Terpstra OT, de Knijff  P, van Hoek B, Verspaget HW, et al. Mannose binding lectin 
gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenter-
ology 2005;129:408-14.
47. Jack DL, Klein NJ, Turner MW. Mannose-binding lectin: targeting the microbial world for complement 
attack and opsonophagocytosis. Immunol Rev 2001;180:86-99.
48. Nauta AJ, Castellano G, Xu W, Woltman AM, Borrias MC, Daha MR, et al. Opsonization with C1q and 
mannose-binding lectin targets apoptotic cells to dendritic cells. J Immunol 2004;173:3044-50.
49. Monticielo OA, Mucenic T, Xavier RM, Brenol JC, Chies JA. The role of mannose-binding lectin in sys-
temic lupus erythematosus. Clin Rheumatol 2008;27:413-9.
50. Barton A, Platt H, Salway F, Symmons D, Lunt M, Worthington J, et al. Polymorphisms in the mannose 
binding lectin (MBL) gene are not associated with radiographic erosions in rheumatoid or infl amma-
tory polyarthritis. J Rheumatol 2004;31:442-7.
51. Saevarsdottir S, Vikingsdottir T, Vikingsson A, Manfredsdottir V, Geirsson AJ, Valdimarsson H. Low 
mannose binding lectin predicts poor prognosis in patients with early rheumatoid arthritis. A pro-
spective study. J Rheumatol 2001;28:728-34.
52. Graudal NA, Homann C, Madsen HO, Svejgaard A, Jurik AG, Graudal HK, et al. Mannan binding lectin 
in rheumatoid arthritis. A longitudinal study. J Rheumatol 1998;25:629-35.
Fleur BW 7.indd   27 10/22/2009   3:52:02 PM
Chapter 1
28
53. Graudal NA, Madsen HO, Tarp U, Svejgaard A, Jurik G, Graudal HK, et al. The association of variant 
mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis. Arthritis 
Rheum 2000;43:515-21.
54. de Vries B, Walter SJ, Peutz-Kootstra CJ, Wolfs TG, van Heurn LW, Buurman WA. The mannose-binding 
lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion in-
jury. Am J Pathol 2004;165:1677-88.
55. Than NG, Romero R, Erez O, Kusanovi JP, Tarca AL, Edwin SS, et al. A role for mannose-binding lectin, a 
component of the innate immune system in pre-eclampsia. Am J Reprod Immunol 2008;60:333-45.
56. Annells MF, Hart PH, Mullighan CG, Heatley SL, Robinson JS, Bardy P, et al. Interleukins-1, -4, -6, -10, 
tumor necrosis factor, transforming growth factor-beta, FAS, and mannose-binding protein C gene 
polymorphisms in Australian women: Risk of preterm birth. Am J Obstet Gynecol 2004;191:2056-67.
57. Kruse C, Rosgaard A, Steff ensen R, Varming K, Jensenius JC, Christiansen OB. Low serum level of man-
nan-binding lectin is a determinant for pregnancy outcome in women with recurrent spontaneous 
abortion. Am J Obstet Gynecol 2002;187:1313-20.
58. Kilpatrick DC, Starrs L, Moore S, Souter V, Liston WA. Mannan binding lectin concentration and risk of 
miscarriage. Hum Reprod 1999;14:2379-80.
59. Christiansen OB, Kilpatrick DC, Souter V, Varming K, Thiel S, Jensenius JC. Mannan-binding lectin defi -
ciency is associated with unexplained recurrent miscarriage. Scand J Immunol 1999;49:193-6.
60. Annells MF, Hart PH, Mullighan CG, Heatley SL, Robinson JS, McDonald HM. Polymorphisms in immu-
noregulatory genes and the risk of histologic chorioamnionitis in Caucasoid women: a case control 
study. BMC Pregnancy Childbirth 2005;5:4.
61. Celik N, Ozan H. Maternal serum mannose-binding lectin in severe preeclampsia. Clin Exp Obstet 
Gynecol 2008;35:179-82.
62. Thevenon AD, Leke RG, Suguitan AL, Jr., Zhou JA, Taylor DW. Genetic polymorphisms of mannose-
binding lectin do not infl uence placental malaria but are associated with preterm deliveries. Infect 
Immun 2009;77:1483-91.
63. Lain KY, Roberts JM. Contemporary concepts of the pathogenesis and management of preeclampsia. 
Jama 2002;287:3183-6.
64. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001;357:53-6.
65. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005;308:1592-4.
66. Megia A, Gallart L, Fernandez-Real JM, Vendrell J, Simon I, Gutierrez C, et al. Mannose-binding lec-
tin gene polymorphisms are associated with gestational diabetes mellitus. J Clin Endocrinol Metab 
2004;89:5081-7.
67. Fraser DA, Bohlson SS, Jasinskiene N, Rawal N, Palmarini G, Ruiz S, et al. C1q and MBL, components of 
the innate immune system, infl uence monocyte cytokine expression. J Leukoc Biol 2006;80:107-16.
68. Sprong T, Jack DL, Klein NJ, Turner MW, van der Ley P, Steeghs L, et al. Mannose binding lectin en-
hances IL-1beta and IL-10 induction by non-lipopolysaccharide (LPS) components of Neisseria men-
ingitidis. Cytokine 2004;28:59-66.
69. Parekh R, Roitt I, Isenberg D, Dwek R, Rademacher T. Age-related galactosylation of the N-linked oli-
gosaccharides of human serum IgG. J Exp Med 1988;167:1731-6.
Fleur BW 7.indd   28 10/22/2009   3:52:02 PM
29
General introduction
70. Yamada E, Tsukamoto Y, Sasaki R, Yagyu K, Takahashi N. Structural changes of immunoglobulin G oli-
gosaccharides with age in healthy human serum. Glycoconj J 1997;14:401-5.
71. Arnold JN, Wormald MR, Suter DM, Radcliff e CM, Harvey DJ, Dwek RA, et al. Human serum IgM 
glycosylation: identifi cation of glycoforms that can bind to mannan-binding lectin. J Biol Chem 
2005;280:29080-7.
72. Oortwijn BD, Roos A, Royle L, van Gijlswijk-Janssen DJ, Faber-Krol MC, Eijgenraam JW, et al. Diff erential 
glycosylation of polymeric and monomeric IgA: a possible role in glomerular infl ammation in IgA 
nephropathy. J Am Soc Nephrol 2006;17:3529-39.
73. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological 
function and structure of human immunoglobulins. Annu Rev Immunol 2007;25:21-50.
74. Watson M, Rudd PM, Bland M, Dwek RA, Axford JS. Sugar printing rheumatic diseases: a potential 
method for disease diff erentiation using immunoglobulin G oligosaccharides. Arthritis Rheum 
1999;42:1682-90.
75. Axford JS. Glycosylation and rheumatic disease. Biochim Biophys Acta 1999;1455:219-29.
76. Pilkington C, Yeung E, Isenberg D, Lefvert AK, Rook GA. Agalactosyl IgG and antibody specifi city in 
rheumatoid arthritis, tuberculosis, systemic lupus erythematosus and myasthenia gravis. Autoimmu-
nity 1995;22:107-11.
77. van Zeben D, Rook GA, Hazes JM, Zwinderman AH, Zhang Y, Ghelani S, et al. Early agalactosylation of 
IgG is associated with a more progressive disease course in patients with rheumatoid arthritis: results 
of a follow-up study. Br J Rheumatol 1994;33:36-43.
78. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associ-
ated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 
1995;1:237-43.
79. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-infl ammatory activity of immunoglobulin G resulting from 
Fc sialylation. Science 2006;313:670-3.
80. Wolfson WQ, Robinson WD, Duff  IF. The probability that increased secretion of oxysteroids does not 
fully explain improvement in certain systemic diseases during pregnancy. J Mich State Med Soc 
1951;50:1019-22.
81. Oka M. Activity of rheumatoid arthritis and plasma 17-hydroxycorticosteroids during pregnancy and 
following parturition: report on two cases. Acta Rheumatol Scand 1958;4:243-8.
82. Ostensen M. Glucocorticosteroids in pregnant patients with rheumatoid arthritis. Z Rheumatol 
2000;59 Suppl 2:II/70-4.
83. Hazes JM, Dijkmans BA, Vandenbroucke JP, Cats A. Oral contraceptive treatment for rheumatoid ar-
thritis: an open study in 10 female patients. Br J Rheumatol 1989;28 Suppl 1:28-30.
84. Masi AT, Feigenbaum SL, Chatterton RT. Hormonal and pregnancy relationships to rheumatoid 
arthritis: convergent eff ects with immunologic and microvascular systems. Semin Arthritis Rheum 
1995;25:1-27.
85. van der Horst-Bruinsma IE, de Vries RR, de Buck PD, van Schendel PW, Breedveld FC, Schreuder GM, 
et al. Infl uence of HLA-class II incompatibility between mother and fetus on the development and 
course of rheumatoid arthritis of the mother. Ann Rheum Dis 1998;57:286-90.
86. Thellin O, Coumans B, Zorzi W, Igout A, Heinen E. Tolerance to the foeto-placental ‘graft’: ten ways to 
support a child for nine months. Curr Opin Immunol 2000;12:731-7.
Fleur BW 7.indd   29 10/22/2009   3:52:02 PM
Chapter 1
30
87. Julkunen H, Jouhikainen T, Kaaja R, Leirisalo-Repo M, Stephansson E, Palosuo T, et al. Fetal outcome 
in lupus pregnancy: a retrospective case-control study of 242 pregnancies in 112 patients. Lupus 
1993;2:125-31.
88. Lima F, Buchanan NM, Khamashta MA, Kerslake S, Hughes GR. Obstetric outcome in systemic lupus 
erythematosus. Semin Arthritis Rheum 1995;25:184-92.
89. Steen VD. Scleroderma and pregnancy. Rheum Dis Clin North Am 1997;23:133-47.
90. Steen VD. Pregnancy in systemic sclerosis. Scand J Rheumatol Suppl 1998;107:72-5.
91. Steen VD, Medsger TA, Jr. Fertility and pregnancy outcome in women with systemic sclerosis. Arthritis 
Rheum 1999;42:763-8.
92. Skomsvoll JF, Ostensen M, Irgens LM, Baste V. Obstetrical and neonatal outcome in pregnant patients 
with rheumatic disease. Scand J Rheumatol Suppl 1998;107:109-12.
93. Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with 
systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:899-907.
94. Bowden AP, Barrett JH, Fallow W, Silman AJ. Women with infl ammatory polyarthritis have babies of 
lower birth weight. J Rheumatol 2001;28:355-9.
95. Reed SD, Vollan TA, Svec MA. Pregnancy outcomes in women with rheumatoid arthritis in Washington 
State. Matern Child Health J 2006;10:361-6.
96. Skomsvoll JF, Ostensen M, Irgens LM, Baste V. Pregnancy complications and delivery practice in 
women with connective tissue disease and infl ammatory rheumatic disease in Norway. Acta Obstet 
Gynecol Scand 2000;79:490-5.
97. Kaplan D. Fetal wastage in patients with rheumatoid arthritis. J Rheumatol 1986;13:875-7.
98. De Man YA, Hazes JM, Van der Heide H, Willemsen SP, De Groot CJ, Steegers EA, Dolhain RJ. Association 
of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight. Results of a 
national prospective study. Arthritis Rheum 2009; 60: in press.
99. Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Pregnancy outcome after fi rst trimester exposure 
to corticosteroids: a prospective controlled study. Reprod Toxicol 2004;18:93-101.
Fleur BW 7.indd   30 10/22/2009   3:52:02 PM
Chapter 2
Mannose-binding  lectin levels during 
pregnancy: a longitudinal study
F.E. van de Geijn, A. Roos, Y.A. de Man, J.D. Laman, C.J.M. de Groot, M.R. Daha, 
J.M.W. Hazes, R.J.E.M. Dolhain
Hum Reprod 2007;22(2):362-71
Fleur BW 7.indd   31 10/22/2009   3:52:03 PM
Chapter 2
32
Abstract
Background: Pregnancy is associated with changes in the immune system. Although 
previous studies have focused mainly on adaptive immunity, there are indications that 
components of innate immunity, such as mannose-binding lectin (MBL), are associated 
with pregnancy outcome. Although this would suggest that pregnancy also involves ad-
aptations in innate immunity, there are few studies in this area. Therefore, we aimed to 
determine whether MBL concentrations and the following steps in complement pathway 
activation are infl uenced by pregnancy.
Methods: MBL and Ficolin-2 concentrations, MBL–MBL-associated serine protease 
(MASP) complex activity, MBL pathway activity and classical complement pathway ac-
tivity were determined by enzyme-linked immunosorbent assay (ELISA) in sera from 
pregnant women (n = 32) during each trimester and postpartum. MBL genotyping was 
performed by PCR.
Results: During pregnancy, MBL concentrations increased to 140% (interquartile range 
(IQR) 116–181%, p < 0.0001). This increase was already present at 12 weeks of pregnancy 
and was most pronounced in the high-production AA-genotype. Directly postpartum 
MBL concentrations dropped to 57% of baseline (IQR 44–66%, p < 0.0001). Variations 
in MBL levels were refl ected by similar changes in the following steps of complement 
activation, (r > 0.93, p < 0.01). Ficolin-2 levels and classical complement pathway activity 
were not similarly infl uenced by pregnancy. 
Conclusion: Pregnancy and the postpartum period profoundly infl uence MBL serum 
concentration and MBL complement pathway activity.
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Introduction
Pregnancy is considered as an immunological phenomenon because the pregnant 
mother needs to accommodate the fetal allograft. This requires profound changes of the 
maternal immune system 1, 2. Up to now, the majority of laboratory research has been 
focused on possible modifi cations in the adaptive immune system during pregnancy. 
In this scope, it has been hypothesized that autoimmune diseases such as rheumatoid 
arthritis and multiple sclerosis tend to improve during pregnancy due to adaptations 
of the immune system 3-6. However, some clinical studies demonstrate that also certain 
components of innate immunity are associated with pregnancy outcome. This would 
suggest that innate immunity requires adaptations during pregnancy too. Mannose-
binding lectin (MBL) is one of the components of the lectin pathway of complement that 
is associated with pregnancy outcome. The way in which innate immunity, and MBL in 
particular, changes during pregnancy has hardly been investigated 7. 
MBL and Ficolin-2 are complement factors that are mainly produced in the liver. Both 
MBL and Ficolin-2 can activate the lectin pathway of complement. The lectin pathway 
can be activated by binding of MBL and Ficolin-2 to carbohydrate ligands followed by 
activation of MBL-associated serine proteases (MASPs) (MBL–MASP-2 complex). MASP-2 
is the complement-activating enzyme that is complexed with MBL. This MBL–MASP-2 
complex has the ability to activate complement factor C4. After C4 activation, the com-
plement cascade is further activated resulting in the formation of the membrane attack 
complex (MAC) C5b-9. The MAC is the end product of the lectin pathway of complement 
and has many eff ector functions such as microbial defense. The classical and alternative 
pathways of complement also result in the formation of MAC, but by using a diff erent 
mechanism.
Several reports suggest a role for MBL during pregnancy based on studies compar-
ing MBL levels or MBL genotypes with pregnancy outcome. For example, low maternal 
serum levels of both MBL and Ficolin-2 have been found in women with recurrent mis-
carriages 8-11. Defi cient maternal MBL concentrations have also been described as a risk 
factor for preterm birth and reduced birth weight 12, although one report showed an 
association of MBL gene polymorphisms with gestational diabetes mellitus, resulting in 
heavier infants 13. Chorioamnionitis is another measure for pregnancy outcome that has 
been associated with certain MBL gene polymorphisms which result in lower MBL serum 
concentrations 14. 
These fi ndings imply that high levels of MBL are benefi cial for pregnancy outcome; 
therefore it is of great interest to determine the infl uence of pregnancy itself on circulat-
ing MBL levels. Up to now, this question has only been addressed in one small study by 
Kilpatrick 7 in which MBL levels were determined in the fi rst trimester of pregnancy in 
eight women with a history of recurrent miscarriages. Little or no modulation of MBL 
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levels during the critical fi rst trimester of pregnancy was found when compared with the 
pre-pregnant status. However, one healthy woman without an adverse medical history 
was studied during all trimesters of pregnancy and showed increased MBL levels in her 
third trimester 7. 
The MBL serum concentration is strongly determined by its single nucleotide substitu-
tions (SNPs) in the structural gene and in the promoter region 15, 16. In exon 1 of the MBL2 
gene, the wildtype allele is referred to as A, whereas the O-alleles represent the variant 
alleles B, C and D together. Individuals with the AA wildtype genotype have higher MBL 
serum concentrations, whereas individuals with the AO- or OO-genotype show lower 
MBL serum concentrations. This is because of disturbed multimer formation, resulting in 
impaired function 17. Moreover, basal MBL serum levels are also modifi ed by the SNPs in 
the promoter region of the MBL gene 18. Depending on genotype, the MBL serum con-
centration can therefore diff er largely between individuals, but the basal level of MBL in 
each individual is reasonably stable throughout life 19. Interestingly, about 30% of the 
general population with the AO- or OO-genotype has very low to defi cient MBL levels. 
These individuals could be clinically considered as MBL defi cient and at risk for infec-
tions. In the Ficolin-2 gene, 10 SNPs have been demonstrated recently 20, and a relation-
ship between these SNPs and biological activity of Ficolin-2 has also been suggested 21.
The aim of the present study was to determine the infl uence of pregnancy on MBL 
serum concentrations and to investigate whether MBL exon 1 genotypes and promoter 
polymorphisms aff ect MBL levels during pregnancy. We verifi ed whether changes in MBL 
concentrations during pregnancy result in comparable changes in the subsequent steps 
in the lectin pathway of complement activation. This was studied via measurements of 
the MBL–MASP complex activity and the MBL pathway activity. Finally, to investigate 
whether pregnancy-induced changes are specifi c for MBL, we determined the infl uence 
of pregnancy on Ficolin-2 levels and classical complement pathway activity as well. To 
address these questions, we used a prospective longitudinal study design of healthy 
pregnant women (n = 32) with uncomplicated pregnancies and determined SNPs in exon 
1 and in the promoter region of the MBL2 gene.
Patients and Methods
Human materials
Healthy pregnant Caucasian women without adverse obstetric history (n = 32) were re-
cruited by a local midwifery practice and prospectively monitored. 
Blood was taken during home visits three times during pregnancy (12, 20 and 30 
weeks of gestation) and three times postpartum (6 and 12 weeks and between 6 and 9 
months). The fi rst fi ve visit timepoints were all met within a deviation of 1 week. The last 
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timepoint at 6–9 months postpartum was set as baseline value. At that time, we consid-
ered the participants as being recovered from their pregnancies.
Serum was cooled, frozen at −80°C and thawed once for aliquotting. Genomic DNA of the 
mother was isolated from heparinized blood, and genomic DNA of the child was isolated 
from umbilical cord blood as described below. For three participants and four children, 
DNA was isolated from cells obtained from the buccal mucosa cells by brushing with a 
padded stick 22.
The women participated in the study after informed consent was given. The study was in 
accordance with the Helsinki II declaration and was approved by the local ethical com-
mittee.
Enzyme-linked immunosorbent assay protocol
For all enzyme-linked immunosorbent assays (ELISAs), Nunc Maxisorb plates (Nunc, 
Roskilde, Denmark) were coated using relevant antibodies in coating buff er (100 mM 
Na
2
CO
3
/NaHCO
3
, pH 9.6) for 16 hrs at room temperature. After each step, plates were 
washed three times with phosphate-buff ered saline (PBS) containing 0.05% Tween 20. 
Residual binding sites were blocked by incubation with PBS containing 1% bovine serum 
albumin (BSA). Unless otherwise indicated, all subsequent steps were incubated for 1 
hr at 37°C in PBS containing 0.05% Tween 20 and 1% BSA. Detection antibodies were 
conjugated to digoxygenin (Dig) using Dig-3-O-methylcarbonyl-ε-aminocaproic acid-N-
hydroxysuccinimide ester (Boehringer Mannheim, Germany), according to instructions 
provided by the manufacturer. Detection of binding of antibodies conjugated to Dig was 
performed by horseradish peroxidase (HRP)-conjugated sheep anti-Dig antibodies (Fab, 
Boehringer Mannheim). Enzyme activity of HRP was detected using 2,2-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid) (Sigma). The optical density (OD) at 415 nm was 
measured using a microplate biokinetics reader (EL312e; Biotek Instruments, Winooski, 
VT, USA). All incubation volumes were 100 μl/well.
All sera were analysed in duplicates in at least two dilutions. Concentration was ex-
pressed in ng/ml. Functional activity was expressed in U/ml on the basis of serial dilu-
tions of a human pool serum used as a standard (set at 1000 U/ml).
MBL detection ELISA
Assessment of MBL concentration in serum was performed by sandwich ELISA, as de-
scribed previously 23. In brief, plates were coated with monoclonal antibody (mAb) 3E7 
(anti-MBL mouse IgG1, kindly provided by T. Fujita, Fukushima Medical University School 
of Medicine, Fukushima, Japan) at a concentration of 5 μg/ml. Serum samples were incu-
bated for 1 hr at 37°C, followed by detection with Dig-conjugated mAb 3E7. A calibration 
line was produced using pooled serum from healthy donors with a known concentration 
of MBL.
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Measurement of Ficolin-2 serum concentration by ELISA
Plates were coated with mAb GN5 (mouse mAb anti-human Ficolin-2, kindly provided 
by T. Fujita, Fukushima Medical University School of Medicine, Fukushima, Japan) at a 
concentration of 5 μg/ml. Samples were incubated for 1 hr at 37°C, followed by incuba-
tion with Dig-conjugated mAb GN5. Detection of binding of antibodies was as described 
in the ELISA protocol. A calibration line was produced using pooled human serum from 
healthy donors with a known concentration of Ficolin-2 (kindly provided by Dr D.C. Kil-
patrick, Scottish National Blood Transfusion Service Edinburgh, UK).
Assessment of MBL-MASP complex activity by ELISA
MBL-MASP complex activity was assessed, as described previously 24, based on a protocol 
developed by Petersen 25. Activity of the MBL–MASP complex is determined by its ability 
to activate exogenously added complement factor C4. In brief, MBL–MASP complexes 
were allowed to bind to immobilized mannan (from Saccharomyces cerevisiae; Sigma 
(M7504)) overnight at 4°C in the presence of GVB++ buff er (Veronal-buff ered saline 
containing 0.5 mM MgCl
2
, 2 mM CaCl
2
, 0.05% Tween 20 and 0.1% gelatin; pH 7.5) supple-
mented with 1 M NaCl. This was followed by the addition of purifi ed haemolytically active 
C4 and the detection of deposited activated C4 binding using Dig-conjugated anti-C4 
mAb. The detection limit of the MBL–MASP complex activity was 20 U/ml.
Assessment MBL pathway activity by ELISA
MBL pathway activity was assessed by ELISA as described by Roos et al. 16 with some 
modifi cations. Concentrations of the MAC C5b-9 are determined in the presence of anti-
C1q antibodies to exclude activation by the classical complement pathway. In brief, plates 
were coated with mannan dissolved in PBS at a concentration of 10 μg/ml. Samples were 
diluted and pre-incubated in GVB++ buff er containing mAb85 (mAb anti-human C1q, 
kindly provided by Prof. E. Hack, Sanquin, Amsterdam, the Netherlands) at a concentra-
tion of 5 μg/ml. After this pre-incubation of 15 min at room temperature, the samples 
were added to the plate and incubated for 1 hr at 37°C. Complement activation was de-
tected using Dig-conjugated mAb AE11 (mAb anti-human C5b-9, kindly provided by Dr 
T.E. Mollnes, Oslo, Norway). The detection limit of MBL pathway activity was 200 U/ml.
Assessment of classical complement pathway activity by ELISA 
Classical complement pathway activity was also assessed by ELISA, as previously de-
scribed 16. In this assay, plates were coated with human IgM at a concentration of 2 μg/ml. 
Samples were diluted in GVB++ buff er and added directly to the plates to allow incubation 
for 1 hr at 37 ºC. Complement binding was assessed using Dig-conjugated mAb directed 
against C5b-9.
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DNA isolation
Heparinized whole blood or umbilical cord blood was lysed with lysis buff er NH
4
Cl. Nuclei 
were washed in sterile MilliQ water. The pellet was resuspended in salt/EDTA (SE) buff er 
(75mM NaCl, 25mM EDTA, pH 8.0), and pronase (concentration 20 mg/ml) was added. Af-
ter addition of sodium dodecyl sulfate (SDS) buff er, the extracted DNA was left overnight 
at room temperature. Then, proteins were precipitated by adding NaCl and ethanol and 
later dissolved in Tris/EDTA (TE) buff er (10 mM Tris/Cl, 1 mM EDTA, pH 8.0). 
For three participants and four children, we isolated DNA from cells obtained from 
the buccal mucosa by brushing with a padded stick 22. The sticks were returned to us by 
mail in a buff er of Salt/Tris/EDTA (STE), SDS and proteinase K. Upon arrival, proteinase K 
was added to the samples until a fi nal concentration of 0.2 mg/ml. After the sticks had 
been spun, KAc and choloroform/isoamylalcohol were added. DNA was precipitated with 
ethanol and dissolved in TE buff er. 
DNA concentrations were measured, and its purity was assessed on basis of UV absorp-
tion. Samples were frozen in –80° C until they were used. 
MBL genotyping 
The PCR and the melting curve profi le were performed in LightCycler capillaries (Roche 
Diagnostics) with a fi nal volume of 20 μl, containing 10 ng of genomic DNA, 0.5 μM of 
each primer, 0.15 μM of each hybridization probe, 1x LightCycler DNA Master Hybridisa-
tion Probes (Roche Molecular Biochemicals, Mannheim, Germany) and 2 mM MgCl2. The 
PCR amplifi cation profi le of both experiments consisted of 10 min at 95°C, followed by 45 
cycles of 95°C for 3 sec, 60°C (63°C in case of detection of the MBL exon 1 polymorphism) 
for 15 sec and 72°C for 10 sec. Next, the melting curve profi le was performed, which 
consisted of 1 cycle of 95°C for 3 min, 55°C for 1 min, 45°C for 30 sec and 40°C for 3 min, 
after which the temperature was slowly increased (0.1°C/s) to 80°C under continuous 
detection of the emitted light. 
For the detection of the three exon 1 SNPs in codon 52, 54 and 57 of the structural 
gene, the forward primer 5-TGAGTATGGTCAGCGTCTTA-3 and the reverse primer 
5-TGGGCTGGCAAGACAACTATTAG-3p were used for amplifi cation. For genotyping, the 
5-LC Red 640-TTCTTCCTTGGTGCCATCACACCCA-3-p detection probe and the fl uores-
cein-labelled anchor probe 5-CAGCCCAACACGTACCTGGTTCCCCCT-3FLU were used 
(Tib-MolBiol, Berlin, Germany). For the detection of these SNPs, one set of hybridization 
probes was suffi  cient.
The detection of the (−550) H/L and (−221) X/Y promoter polymorphisms requires two 
sets of hybridization probes. The forward primer 5-GCCAGAAAGTAGAGAGGTATTTAGC-3 
and the reverse primer 5TGTGACATGCATGCGTGACTACTAGTAC-3 were used to amplify 
a fragment spanning the two SNPs in the promoter region. For genotyping the H/L poly-
morphism at position −550, the fl uorescein-labelled detection probe 5-TTTTAGACAG-
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GCAGGCTTGCCTGCCTGGGT-3 FLU, which is complementary to the L allele, and the 5-LC 
Red 705-AGCATTTTCTCTGGAAATTTCTTACTACGTTGG-3-phosphorylated anchor probe 
were used. The 5-CTATAAACATGCTTTCGGTGGCAGT-3FLU detection probe and the LC 
Red 640-AACAAATGGGACCGTGCATTGCCA-3-p anchor probe were used for genotyping 
the X/Y SNP. In each experiment, sequence-verifi ed control donors for each genotype 
were used.
Statistical analysis
All analyses were carried out using two-tailed non-parametric tests, and results were 
considered statistically signifi cant when p-values were <0.05.
The diff erence in MBL serum concentrations between the AA- and AO-/OO-genotype 
groups at all timepoints was evaluated using the Mann–Whitney U-test.
The medians of the pregnancy-induced increases in MBL serum concentration, MBL–
MASP complex activity, MBL pathway activity and classical complement pathway activity 
were calculated as follows. First the mean value per participant was calculated of the 
three timepoint measurements during pregnancy; these means were used to calculate 
the median value of all participants together, categorized per genotype. The Wilcoxon 
signed rank test was used to compare the median value during pregnancy with the re-
spective baseline values at 6 months postpartum.
The postpartum drop was calculated by dividing the value of the timepoint 6 weeks 
postpartum by the baseline value at 6 months postpartum and expressed in percent-
ages. The Wilcoxon signed rank test was used to evaluate the diff erence between this 
timepoint and the baseline value.
Correlations were calculated using the Spearman rank test between the various mea-
surements of MBL serum concentration, MBL–MASP complex activity and MBL pathway 
activity.
It has been indicated in the text for how many participants it has been possible to mea-
sure their baseline values.
Results
Description of cohort
The demographic and clinical characteristics of the study group (n = 32) are described in Table 
1. Four women developed pregnancy complications: one woman developed pre-eclampsia 
defi ned according to the International Society for the Study of Hypertension in Pregnancy 
(ISSHP) criteria 26; two women developed pregnancy-induced hypertension, for which no 
medication was prescribed. One woman delivered preterm (34 weeks gestation) due to pre-
mature rupture of membranes with unknown cause. Furthermore, four women developed 
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other (infl ammatory) complications during pregnancy: monoarthritis of the knee, sinusitis and 
cystitis (twice). The mean gestational age at delivery was 283 days, range 238–294 days. All 32 
neonates were born healthy without asphyxia. Two Caesarean sections were performed, one 
of which for maternal indication because of severe pre-eclampsia and one because of breech 
presentation.
MBL serum concentrations increase during pregnancy
MBL serum concentrations were measured at all six timepoints in 31 women. During 
pregnancy, the MBL serum concentration increased to 140% (median, interquartile range 
(IQR) 116-181%, p < 0.0001) compared with baseline, which is defi ned as the concentra-
tion at 6 months postpartum. The increase in MBL serum concentration was present in 
the fi rst trimester of pregnancy (12 weeks) and did not signifi cantly increase further dur-
ing pregnancy. Directly postpartum (6 weeks) MBL concentrations dropped sharply to 
57% of the baseline value (IQR 44-66%, p < 0.0001, Figure 1A).
Ficolin-2 serum concentrations are not infl uenced by pregnancy
Ficolin-2 serum concentrations were measured at all six timepoints in 29 women. Fico-
lin-2 serum concentrations did not show signifi cant variations during pregnancy or post-
partum (median Ficolin-2 serum concentration 1950 ng/ml, IQR 1429–2451 ng/ml, Figure 
1B). Clearly, no decline in postpartum values could be appreciated.
Classical complement pathway activity changes only slightly during pregnancy
The classical complement pathway activity was measured at all six timepoints in 30 
women. The classical complement pathway activity was infl uenced by pregnancy, but to 
a lesser extent than the MBL pathway activity, which is described later in the text. Preg-
nancy increased the classical pathway activity to 129% of the baseline value (median, 
IQR 116–138%, p < 0.0001). Postpartum (6 weeks), the activity of the classical comple-
Table 1. Clinical characteristics of the study group
Characteristics Cases (n = 32)
Mean age at fi rst trimester (years) (SD) 32 (4.4)
Number of nulliparous women (%) 14 (43.8)
Mean number of previous pregnancies (SD) 1.0 (1.1)
Number of previous miscarriages (%)
0 27 (84.4)
1 4 (12.5)
2 1 (3.1)
Women who smoked during pregnancy (n) (%) 3 (9.4)
Mean gestational age at delivery (days) (range) 283 (238-294)
Mean birth weight (gram) (SD) 3492 (80)
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ment pathway decreased to 115% of the baseline value (median, IQR 101–120%, p < 0.01, 
Figure 1C). Clearly, for the classical complement pathway activity as well, no signifi cant 
postpartum drop could be appreciated.
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Figure 1. Median serum concentrations of mannose-binding lectin (MBL) and Ficolin-2 and complement activation 
via the classical pathway during pregnancy and postpartum. A) MBL serum concentrations were measured at 
indicated timepoints. Pregnancy increased MBL serum concentrations to 468 ng/ml (median, interquartile range 
(IQR) 143–1144 ng/ml, p < 0.0001). Directly postpartum (6 weeks) the MBL concentration dropped sharply to 168 
ng/ml (median, IQR 42–381 ng/ml, p < 0.0001). B) Ficolin-2 serum concentrations did not show signifi cant variations 
during pregnancy or postpartum. Clearly, no decline in postpartum values was observed. C) Pregnancy increased 
classical complement pathway activity to 1428 U/ml (median, IQR 1184–1668 ng/ml, p < 0.0001). Postpartum, the 
activity of the classical pathway gradually decreased. Data are presented as medians with IQRs. 
Abbreviations: Trim, trimester; wk, weeks; mo, months; pp, postpartum.
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Infl uence of the MBL genotype and promoter polymorphisms on basal MBL serum 
levels
As expected, MBL serum levels show a major inter-individual variation, but all showed 
the same pattern during pregnancy and postpartum (Figure 2). Therefore, we assessed 
the MBL genotypes of the subjects to examine whether the intraindividual fl uctuations 
in MBL serum levels were dependent on the MBL genotypes. MBL genotypes were de-
termined in 31 of the 32 women. MBL genotypes and median baseline values of comple-
ment pathway components are described in Table 2. The maternal MBL genotype and 
MBL promoter polymorphism frequencies summarized in Table 2 are in accordance with 
results from previous studies 15, 24. As was expected, the median baseline MBL serum con-
centrations in the individuals with the AA-genotype were signifi cantly higher than those 
with the AO- and OO-genotypes, p < 0.0001. Moreover, within the group of women with 
the AO-genotype, the AD subgroup showed higher baseline MBL serum concentrations 
than the AB subgroup, as described previously 15. 
The eff ect of the various promoter polymorphisms on MBL serum concentrations was 
minimal within the group with the AA-genotype. Exceptions within this group were the 
two women who carried the LXA/LXA promoter polymorphism, who showed very low 
baseline concentrations of MBL (118 and 51 ng/ml). In women with the AO-genotype, the 
highest MBL levels were observed in women with the HYA/O-genotype, and women with 
the LXA/O-genotype showed the lowest MBL serum concentrations. The OO-genotype 
showed minimal MBL serum concentrations (83 ng/ml). 
It can therefore be concluded that the AA-genotype shows the highest MBL levels, fol-
lowed by the AO- and the OO-genotypes, supplemented with the eff ects of the promoter 
polymorphisms. 
Increase in MBL serum concentration is related to maternal genotype
The increase in MBL serum concentrations during pregnancy was highest in the mothers 
with the AA-genotype (177% increase, IQR 124–212%, p < 0.001). Mothers with the AO-
genotype showed a more moderate increase of 126% (IQR 91–144%, p < 0.04), as did the 
mother with the OO-genotype (117% increase), compared with their respective baseline 
values (Figure 3A).
The eff ect of the promoter polymorphisms could also be observed on the increased 
MBL levels during all trimesters of pregnancy. The frequency of the specifi c combinations 
of the diff erent genotypes related to the various promoter polymorphisms was not suf-
fi cient to allow statistical analysis.
Postpartum drop in MBL concentration occurred equally in all genotypes
Although all women had detectable levels of MBL during pregnancy, a postpartum drop 
was observed in all women, independent of their MBL genotypes, that is, 55% in AA-
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genotype subjects (p < 0.0001), 60% in AO-genotype subjects (p < 0.03) and 65% in the 
OO-genotype subject. In some women, this drop in MBL serum concentrations resulted 
into MBL serum levels that would be clinically considered as MBL defi cient.
For example, in one of the two women with the LXA/LXAgenotype, MBL levels remained 
very low (33, 36 and 51 ng/ml) at 6 weeks, 12 weeks and 6 months postpartum, respec-
tively, in contrast to her higher MBL levels during pregnancy (156, 122 and 157 ng/ml in 
the fi rst, second and third trimester, respectively).
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Figure 2. Mannose-binding lectin (MBL) serum concentration in healthy women during pregnancy and postpartum 
depicted by genotypes AA and AO + OO, separately. MBL serum levels show a major inter-individual variation, but 
MBL serum levels in all individual subjects showed the same pattern during pregnancy and postpartum, namely 
an increase during pregnancy (median to 140% of baseline value, interquartile range (IQR) 116–181%, p < 0.0001), 
and a signifi cant decline postpartum (to 57% of baseline value, median, IQR 44–66%, p < 0.0001). MBL serum 
concentrations were measured at indicated timepoints. Each symbol represents one individual. The baseline value is 
defi ned as the MBL serum concentration at 6 months postpartum. Note that the Y-axes have diff erent scales. 
Abbreviations: Trim, trimester; wk, weeks; mon, months; pp, postpartum.
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The other woman with the LXA/LXA-genotype had the following MBL levels: 364, 411 
and 632 ng/ml in the fi rst, second and third trimester of pregnancy, respectively, and 8, 
16 and 118 ng/ml at 6 weeks, 12 weeks and 6 months postpartum, respectively.
Fetal MBL genotype and maternal MBL serum concentrations 
We hypothesized that fetal production of MBL might possibly contribute to the maternal 
MBL levels, involving feto–maternal transport via unknown passive or active mecha-
nisms. By determining the genotype of the fetus and correlating it with the MBL concen-
Table 2. MBL genotype and median baseline values of complement pathway components
Genotypes 
MBL exon 1 genotype n, (%) AA AO OO
18 (58) 12 (39) 1 (3)
AB 7
AC 1
AD 4
DD 1
MBL promoter polymorphisms (n) 
HY/LY 8 2
2
5
3
-
-
-
LY/LY 1 -
LX/LY 2 -
HY/HY 3 1
LX/HY 2 -
LX/LX 2 -
Median baseline values
MBL concentration (IQR) (ng/ml)  533 (259-1197) AO  90 (21-139) 83
AB  35 (13-110)a
AC  15
AD  269 (16-423) a
MBL-MASP complex activity (IQR) (U/ml) 694 (432-2787) AO  20 (20-1693) a <20b
AB  20 (20-238) a
AC  20 
AD  585 (491-1693) a
MBL pathway activity (IQR) (U/ml) 1031 (634-1665) AO  200 (200-907) a <200 b
AB  200 (200-453) a
AC  200 
AD  577 (406-907) a
Ficolin-2 (IQR) (ng/ml) 2401 (1936-2947)  2403 (2041-2767) 2398
Classical complement pathway activity (IQR) (U/ml) 1061 (908-1204)  941 (859-1245) 992
IQR, interquartile range.
a Owing to the low numbers not the IQR, but the range is given.
b These values are below detections limits.
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tration in maternal serum, we wanted to investigate if the level of maternal MBL is related 
to the fetal MBL genotype.
The MBL exon 1 genotype and promoter polymorphisms were determined in the samples 
obtained from 30 children of the cohort. The fetal genotype did not show an additional 
contribution to the maternal MBL serum concentration or MBL activity levels during 
pregnancy or postpartum (data not shown).
Pregnancy-related changes in MBL concentrations are followed by similar changes in 
MBL-MASP complex activity
The MBL–MASP complex activity was measured at all six timepoints in 28 of the 32 
women. In six women (AO- and OO-genotypes), all measurements were below detection 
limits, that is, 20 U/ml (Table 2). Statistical analyses were performed in the series in which 
the baseline values at 6 months postpartum were above detection limits (n = 22 women).
Changes in MBL serum concentrations were refl ected by similar changes in the activ-
ity of the MBL–MASP complex. During pregnancy, there was an increase up to 172% in 
MBL–MASP complex activity (median of the cohort, IQR 144–238%, p < 0.0001) compared 
with baseline; directly postpartum this activity dropped to 70% of the baseline activity 
level (median, IQR 49–119%, p < 0.0001, Figure 3B). In some women, MBL–MASP complex 
activity decreased to undetectable levels postpartum.
In women with the AA-genotype, the MBL–MASP complex activity increased to 158% 
during pregnancy (median, IQR 133–215%, p < 0.001) compared with their baseline level. 
The MBL–MASP complex activity of the AO-genotype subjects that was above detection 
limit showed an increase of 175% (IQR 146–224%, p < 0.05). The postpartum drop was 
57% (AA-genotype) and 75% (AO-genotype) of the baseline level, which was signifi cant 
in the AA-genotype (p < 0.03, Figure 3B). 
At all timepoints, there was a very good correlation between MBL concentration and 
MBL-MASP complex-activity (r > 0.93, p < 0.01).
MBL pathway activity increases during pregnancy
The activity of the MBL pathway, assessed on the basis of formation of the C5b-9 com-
plex, was measured at all six timepoints in 31 women. In six women (AO-genotype and 
OO-genotypes) all measurements were below detection limit, that is, 200 U/ml (Table 2). 
Statistical analyses were performed in the series in which the baseline values at 6 months 
postpartum were above detection limit (n = 25 women).
A highly signifi cant increase in MBL pathway activity was observed during pregnancy 
(median 164% increase, compared with baseline level, IQR 139-215%, p < 0.0001, Figure 
3C). The MBL pathway activity increased to 160% in the mothers with the AA-genotype 
(median, IQR 132-179%, p < 0.0001, compared with their baseline value). The MBL path-
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C) The MBL pathway was activated 
signifi cantly during pregnancy (to 164%, 
median, IQR 139–179%, p < 0.0001), all 
genotypes taken together. The AA-genotype 
increased to 163% (median, IQR 132–179%, 
p < 0.0001, compared with baseline). The 
AO-genotype increased to 171% (median, 
IQR 146–206%, p < 0.03, compared with 
baseline). There was no postpartum drop in 
MBL pathway activity 92% (AA-genotype, ns) 
and 98% (ns) of baseline value. AA-genotype 
(n = 18), AO-genotype (n = 6) and OO-
genotype (n = 1). 
Abbreviations: Trim, trimester; week, weeks; 
mon, months; pp, postpartum; ns: not 
signifi cant.
p<0.0001 (AA), p<0.03 (AO)
p<0.0001, all genotypes taken together
MBL serum concentration ratios0
0.5
1.0
1.5
2.0
2.5
ra
tio
A
 AA
 AO
 OO
0
0.5
1.0
1.5
2.0
2.5
3.0
ra
tio
B
MBL complex activity ratios
p<0.0001 (AA), AO, OO: ns
p<0.0001, all genotypes taken together
0
0.5
1.0
1.5
2.0
2.5
ra
tio
1st trim 2nd trim 3rd trim 6 wk pp 3 mon pp 6 mon pp
time points
all: ns
p<0.0001, all genotypes taken together
MBL pathway activity ratios
C
Figure 3. Mannose-binding lectin (MBL) serum concentration, MBL–MASP complex activity and MBL pathway 
activity in healthy women during pregnancy and postpartum categorized per genotype. Ratios were calculated 
by dividing the concentration or activity at indicated timepoints by the baseline concentration or baseline activity. 
Baseline is defi ned as the value at 6 months postpartum. Data are presented as median ratios with interquartile 
ranges (IQRs). 
A) MBL serum concentrations were signifi cantly 
increased during pregnancy, p < 0.0001, all 
genotypes taken together. The AA-genotype 
increased to 177% (median, IQR 124–212%, p 
< 0.001), the AO-genotype to 126% (median, 
IQR 91–144%, p < 0.04) and OO-genotype to 
117%, all compared with baseline value. The 
postpartum drop (6 weeks postpartum versus 
baseline) occurred equally in all genotypes 
(55, 60 and 65% of baseline concentration, AA-
genotype (p < 0.0001), AO-genotype (p < 0.03) 
and OO-genotype, respectively). AA-genotype n 
= 18, AO-genotype n = 11, OO-genotype n = 1.
B) The MBL–MASP complex was activated 
signifi cantly during pregnancy (to 172%, 
median, IQR 144–238%, p < 0.0001), all 
genotypes taken together, compared with 
baseline. The AA-genotype increased to 
158% (median, IQR 133–215%, p < 0.001, 
compared with baseline), the AO-genotype 
to 175% (median, IQR 146–224, p < 0.05, 
compared with baseline). The postpartum 
drop was 57% (AA-genotype, p < 0.03) and 
75% (AO-genotype, ns) of baseline value. 
AA-genotype n = 15, AO-genotype n = 6, 
OO-genotype n = 1. 
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way activity of the AO-genotype mothers that was above the detection limit showed an 
increase to 171% (IQR 146-206%, p < 0.03). 
A signifi cant decline in MBL pathway activity directly postpartum was not observed 
in any of the genotypes (92% and 98% of the baseline value, AA- and AO-genotypes, re-
spectively, Figure 3C). However, in one woman (LXA/LXA-genotype), MBL pathway activ-
ity levels remained below detection limit postpartum in contrast to her well-detectable 
activity levels during pregnancy (735, 453 and 810 U/ml in the fi rst, second and third 
trimesters, respectively).
There was a very strong correlation between MBL concentration, MBL–MASP complex 
activity and MBL pathway activity at all six timepoints (r > 0.93, p < 0.01).
No observed association between MBL genotype and pregnancy complications 
The women who encountered complications during pregnancy, that is, pre-eclampsia 
(n = 1), premature birth (n = 1) and various infections (n = 4), all had diff erent genotypes 
and suffi  cient MBL levels during pregnancy, comparable with the remainder of the study 
group. The number of women with pregnancy complications is too small to draw any 
conclusions on any association between MBL genotype and pregnancy complications.
Discussion
In this study, we show that MBL serum concentrations signifi cantly increase during 
pregnancy from the fi rst trimester onwards and decline at six weeks postpartum. Be-
cause Ficolin-2 levels and classical complement pathway activities are not infl uenced in 
a similar way during pregnancy and in the postpartum period, it can be concluded that 
pregnancy has a specifi c eff ect on MBL and its complement pathway.
During pregnancy, mothers with the wildtype AA-genotype showed higher MBL 
concentrations and higher MBL–MASP complex activity and MBL pathway activity than 
those with the AO- or OO-genotypes. There was no additional infl uence of the fetal MBL 
genotype on maternal MBL serum concentration. The fact that increased MBL concentra-
tions result in clearly increased MBL pathway activity suggests a functional role of this 
molecule during pregnancy.
We have chosen the six months postpartum timepoint as our baseline value for all 
measurements. We are aware of the fact that our threshold point of six months postpar-
tum as a baseline value may not be an accurate baseline for all participants. There might 
be some women who need more than six months to recover from their pregnancies. 
Taking into account that MBL values are subject to change in the postpartum period, we 
would suggest that MBL measurements in the context of research and clinical diagnos-
tics should not be performed before a minimum of six months postpartum. 
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The observed increase in MBL during pregnancy in our study group of 32 women with-
out adverse pregnancy history is in line with an observation of Kilpatrick 7, who described 
an increase in MBL during pregnancy in one woman with no obstetric history. The author 
described that in women with a history of recurrent spontaneous miscarriage (n = 8), no 
increase in MBL could be observed during the fi rst trimester of pregnancy. It is therefore 
tempting to speculate that a rise in MBL contributes to normal placentation and ongoing 
pregnancy.
The functions of increased MBL levels during pregnancy are unknown. From what is 
known about the mode of actions of MBL, one can consider the following. It has been 
suggested that adaptive immunity declines during pregnancy, enabling the pregnant 
body to tolerate the fetus as a semi-allograft. As a consequence, the mother is more 
susceptible to infections, especially with viruses and (intracellular) microorganisms, such 
as Neisseria and Mycoplasma 27. Therefore, it can be hypothesized that increased levels 
of MBL during pregnancy may be necessary to compensate for reduced T-cell function 
during a state of reduced adaptive immunity 28-30. The increased MBL levels may therefore 
refl ect a shift from adaptive to innate immunity during pregnancy. Another role of MBL 
during pregnancy could reside in its ability to bind to apoptotic cells to enhance their 
opsonization and subsequent removal 31-33. At the fetal-maternal interface, apoptosis and 
degradation are normal physiological constituents of trophoblast turnover to establish 
normal placentation. This process of apoptosis is of major importance during placenta-
tion and subsequent growth and development of placenta and fetus. Therefore, an in-
crease in MBL levels might be necessary to remove the increasing presence of apoptotic 
material during pregnancy. 
It is interesting to note that in certain autoimmune diseases, such as rheumatoid ar-
thritis and multiple sclerosis, higher MBL serum levels are associated with lower disease 
activity and more favorable disease outcome 34. Because it is known that these diseases 
tend to improve during pregnancy 3-6, one could speculate that a higher level of MBL 
during pregnancy could be one of the factors responsible for the pregnancy-induced 
amelioration of these diseases.
The factors that are responsible for the increased production of MBL during preg-
nancy are not known. It has been shown that human growth hormone is able to induce 
MBL in vitro 35 and in non-pregnant humans 36-38. In line hereupon, it can be hypothesized 
that placental growth hormone acts in a similar way during pregnancy. Placental growth 
hormone shows several similarities with human growth hormone and is produced in 
large quantities during pregnancy 39. An alternative candidate responsible for the induc-
tion of MBL during pregnancy might be cortisol. Increased cortisol levels during human 
pregnancy have been described, and the corticosteroid dexamethasone has been shown 
to induce MBL mRNA in cultured hepatocytes 40. One study shows no eff ect of the corti-
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costeroid hydrocortisone on in vitro MBL production 35. A pregnancy-induced increase in 
cortisol might consequently results in higher MBL levels 41. 
Fetal production of MBL has been reported, as MBL could be detected in the amniotic 
fl uid 42 and in umbilical cord blood 43, 44. Therefore, the increase in MBL in the maternal 
circulation may also be a (partial) result of fetal production. We did not fi nd an additional 
infl uence of the fetal MBL genotype on maternal MBL serum concentration in our study. 
Hence, a major contribution of fetal MBL production to maternal MBL serum concentra-
tions during pregnancy can be ruled out. Furthermore, it is unknown if maternal–fetal 
transfer of MBL during pregnancy exists.
This study shows that MBL serum concentrations signifi cantly increase during preg-
nancy from the fi rst trimester onwards and drop sharply at six weeks postpartum. The 
fact that not only MBL concentrations are increased, but that this also results in increased 
activity of the entire MBL pathway, suggests an important immunological role for MBL 
during pregnancy. Suffi  cient MBL levels during (early) pregnancy might be an essential 
condition for maintaining a pregnancy and for protecting the mother against infections 
during pregnancy. Moreover, the pregnancy-induced increase in MBL concentrations 
might play a role in the improvement of autoimmune diseases during pregnancy, there-
by providing conditions for a more favourable pregnancy outcome. These results off er 
unique opportunities to study the regulation of MBL and its role in the (patho)physiology 
of pregnancy in the future and the role of pregnancy in the amelioration of autoimmune 
diseases.
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Abstract
Background: Both immunological and placental factors are involved in the pathogene-
sis of pre-eclampsia. The complement factor mannose-binding lectin (MBL) is associated 
with adverse pregnancy outcomes and has been suggested to play a role in abnormal 
placentation. We investigated whether MBL genotypes are associated with the systemic 
maternal syndrome pre-eclampsia.
Methods: MBL2 gene polymorphisms were determined in a case-control study includ-
ing 157 women with pre-eclampsia (case subjects) and 157 women with uncomplicated 
pregnancies (control subjects). Considering MBL polymorphisms, case and control sub-
jects were categorized in groups of high (A), intermediate (B), and low (C) MBL production.
Results: No association was found between MBL genotypes and pre-eclampsia; ad-
justed odds ratios and 95% confi dence intervals (95% CI) for group B were 0.97 (95% CI 
0.46–2.07) and for group C were 1.44 (95% CI 0.52–3.94). A trend was found between MBL 
genotype groups B and C and severe pre-eclampsia or eclampsia.
Conclusions: MBL genotypes were not found to be associated with pre-eclampsia; 
however, low-MBL production genotypes might be considered as disease modifi er. This 
suggests that MBL may play a role in modulating placental infl ammation by facilitating 
clearance of apoptotic cells and cell debris. 
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Introduction
Pre-eclampsia is a common but severe pregnancy disorder that is unique to pregnancy 
and is associated with high maternal and fetal morbidity and mortality. Pre-eclampsia 
becomes clinically manifest in the second half of pregnancy and is characterized by hy-
pertension and de novo proteinuria 1. Abnormal formation of the placenta (placentation) 
is thought to play an important role in its pathophysiology 2, 3. 
In uncomplicated pregnancies placentation involves trophoblast invasion and angio-
genesis. Its success is dependent upon some degree of uterine infl ammation, as has been 
shown by several studies both in humans and animals 4-6. The importance of the immune 
system in placentation is further underscored by the detection of infl ammatory cells 7 and 
mediators, such as cytokines 8, 9 and components of the complement system 10 in placentas 
of normal uncomplicated pregnancies. Because of the local presence of complement regu-
lators, deposition of complement in the placenta usually does not lead to tissue damage 11. 
However, if infl ammation becomes too excessive, it might cause pregnancy complica-
tions such as miscarriage and pre-eclampsia 6, 12. Uterine natural killer cells are the main 
regulators to balance the degree of infl ammation at the feto-maternal interface 13. Tro-
phoblast debris, apoptotic cells, and progesterone have been proposed to regulate or 
stimulate infl ammatory cytokines production by these uterine natural killer cells 6. 
Mannose-binding lectin (MBL) is a component of innate immunity. It is produced in 
the liver and it is an oligo- or polymeric protein that circulates in serum. Its serum concen-
tration is strongly determined by single nucleotide polymorphism (SNP) substitutions in 
the structural gene and in the promoter region 14. In exon 1 of the structural region of the 
MBL2 gene, the wildtype allele is referred to as A, and the O-alleles represent the variant 
alleles B, C, and D together. 
Individuals with the AA wildtype genotype have higher MBL serum concentrations, 
whereas individuals with the AO- and OO-genotype show lower MBL serum concentra-
tions. This is caused by disturbed multimer formation, resulting in impaired function 15. 
In addition basal MBL serum levels are infl uenced by the SNPs in the promoter region of 
the MBL gene 14. 
MBL can cause activation of the lectin pathway of complement by binding to carbo-
hydrate moieties on microorganisms and altered cells 16, 17. In addition to complement 
activation, the protein has several distinct functions, including promotion of comple-
ment-independent opsonophagocytosis, modulation of infl ammation, and promotion of 
apoptosis 18. These properties make MBL an important mediator of immunity.
During normal healthy pregnancy, MBL concentrations are increased from the fi rst 
trimester onwards until term and drop sharply directly after delivery 19. This suggests a 
benefi cial physiologic role for high MBL levels during normal pregnancy. It was shown 
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that this rise in MBL levels during pregnancy occurs in all pregnant women, but is most 
pronounced in mothers with the high-production MBL genotypes.
Considering the important role of infl ammation in the pathophysiology of pre-
eclampsia and the suggested benefi cial role of high levels of MBL in normal healthy 
pregnancy, it was hypothesized that women with low-MBL production genotypes are 
more likely to develop pre-eclampsia. To elucidate the pathogenesis of pre-eclampsia, 
MBL polymorphisms both in the structural gene and in the promoter region were de-
termined in women with pre-eclampsia and healthy pregnant control subjects using a 
case-control design.
Patients and Methods
Study group
The subjects for this case-control study have been described previously 20, 21 and are sum-
marized in Table 1. Pre-eclampsia was defi ned by means of strict criteria: blood pressure 
≥140 mm Hg systolic or diastolic blood pressure ≥90 mm Hg measured on at least two 
occasions in women who were normotensive before 20 weeks of gestation, and protein-
uria (≥2+ [1 g/l]) on a voided specimen or (≥1+ [0.3 g/l] on a catheterized specimen, 
according to the criteria of the International Society for the Study of Hypertension and 
Pregnancy 22. Severe pre-eclampsia was defi ned as an absolute diastolic blood pressure 
of ≥110 mm Hg and proteinuria (≥2+ [1 g/l]) on a catheterized specimen on admission. 
Eclampsia was clinically defi ned by pre-eclampsia complicated by seizures. Gestational 
age was calculated in days and weeks and preterm birth was defi ned as delivery at <37 
weeks of gestation. 
In brief, consecutive women who had pre-eclampsia during their fi rst pregnancy were 
selected from a computer database and patient charts. Women were included who deliv-
ered on the obstetric service of the Leiden University Medical Center (n = 117) or at the St 
Joseph Hospital Veldhoven (n = 81), both in the Netherlands in the period from January 
1, 1991, through December 31, 1996. Women (cases and control subjects) who had more 
than one pregnancy, multiple pregnancies, or had chronic hypertension, renal disease, dia-
betes, collagen vascular diseases, cancer, or thrombosis before their fi rst pregnancy were 
excluded from the study 20. None of the women with pre-eclampsia had venous thrombo-
sis before (or during) the fi rst pregnancy and thus none were excluded by this criterion. 
We found 198 consecutive pre-eclampsia case subjects that were eligible for the 
study according to the criteria of the American College of Obstetrics and Gynaecology. 
Of these women, 163 (82%) were willing to participate in the study: 35 (18%) women 
with pre-eclampsia did not enter the study for various personal reasons (18 from the 
Leiden University Medical Center and 17 from the St. Joseph Hospital, Veldhoven): not 
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willing to spend time (10), unknown address (6), not willing to have a venipuncture (3), 
expected insurance problems after DNA analysis (7), current pregnancy (3) language 
problems (2), or did not want to be remembered of the period of pre-eclampsia (4). The 
163 patients who did participate all met the criteria of the American College of Obstetrics 
and Gynaecology. After the inclusion period several international studies advocated the 
International Study of Hypertension in Pregnancy criteria 22 as better and stricter criteria 
for selection and inclusion criteria for research studies. As a result women with only an 
increase in blood pressure values and not reaching the systolic 140 mm Hg and/or dia-
stolic ≥ 90 mm Hg had to be excluded (n = 6). Therefore a total of n = 157 case subjects 
were included in our study. 
Women with an uncomplicated pregnancy were used as control subjects and were 
consecutively selected from the same computer database according to the following 
criteria: fi rst pregnancy, no rise in blood pressure, no hypertension or proteinuria, similar 
age (± 5 years), no biological relationship with cases or other controls, and a delivery 
date as close as possible to the delivery date of a case subject. Control subjects were 
not selected according to gestational age, as strictly speaking it is not a risk factor (or 
confounder) for pre-eclampsia. However to avoid an infl uence of preterm birth on the 
analyses, we also analyzed our data with the exclusion of preterm births of case and con-
trol subjects. In total 229 control subjects were asked to enter the study, 66 (29%) refused 
Table 1. Characteristics of study subjects
Control subjects Case patients
Number of subjects 157 157
Maternal age at delivery (years) 28.5 (3.8) 28.5 (4.9)
Gestational age (days) 278 (17.8) 238 (29.7)
Gestational age < 37 weeks 14 (8.9) 109 (69.4)
Gestational age < 34 weeks 5 (3.2) 73 (24.8)
Body Mass Index (kg/m2) 23.6 (4.2) 24.6 (4.4)
Smoking (%) 28 (17.8) 16 (10.2)
Systolic blood pressure
<20 weeks gestation (mm Hg) 118 (11) 127 (92)
>20 weeks gestation (mm Hg) 121 (10) 153 (16)
Diastolic blood pressure
<20 weeks gestation (mm Hg) 69 (7) 72 (7)
>20 weeks gestation (mm Hg) 75 (7) 103 (9)
Proteinuria (mg/dl) <30 30-100
Sex of child (male/female) 74/82* 83/71*
Race/ethnicity (% caucasian) 96 96
Data are represented as n (%) or mean (SD)
* The data of the gender of one child in the control group was missing and three children in the case patients group 
were missing.
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to enter the study for various reasons: (46 from the Leiden University Medical Center and 
20 from the St. Joseph Hospital, Veldhoven): not willing to spend time (19), unknown 
address (23), not willing to have a venipuncture (7), expected insurance problems after 
DNA analysis (7), current pregnancy (7) or a language problem (3).
In total, n = 157 case and n = 157 control subjects were included. A relatively higher 
proportion of women with severe pre-eclampsia and eclampsia were included, as both 
hospitals where the women delivered are tertiary referral centers. 
Of the women included in the study, 96% were Caucasian. The Committee on Ethics in 
Human Research of both hospitals approved the study protocol. Data were analyzed 
anonymously.
Laboratory methods
Venous blood was collected into Monovette tubes (Sarstedt, Nümbrecht, Germany) con-
taining 0.106 mol/L trisodium citrate. DNA was isolated from leukocytes and stored at -20°C.
MBL genotyping
Genotyping was performed using PCR LightCycler techniques as described previously 
19. Genotyping included the wildtype (A-allele) and the three SNPs of the fi rst exon of 
the structural gene: codon 52 (D-allele), codon 54 (B-allele) and codon 57 (C-allele) and 
two of the polymorphisms in the promoter region at codons -550 (H/L) and -221 (X/Y) of 
the MBL2 gene. In each experiment, genotype matched and sequence-verifi ed control 
donors were used. The researcher who performed the genotyping was blinded to case or 
control status. A 10% portion of the samples was reanalyzed at random, and the results 
were confi rmed.
Categorization of the individuals upon MBL structural gene genotypes in conjunction 
with promoter genotypes
The three SNPs of the fi rst exon of the structural gene are in linkage disequilibrium with 
the two promoter polymorphisms H/L and X/Y at codons -550 and –221, respectively. This 
results in six possible haplotypes: HYA, HYD, LYA, LYB, LYC, and LXA 14. Each individual ex-
presses two of these haplotypes. The LXA haplotype and the exon 1 polymorphisms (B-, 
C-, or D-allele, jointly the O-allele) cause defi cient or reduced plasma concentrations 14. 
Based on the genotypes the individuals can be categorized into three groups: group A 
((H/L)YA/(H/L)YA and (H/L)YA/LXA), the high-MBL genotype group associated with high MBL 
serum levels; group B (LXA/LXA and (H/L)YA/O), the intermediate-MBL genotype group, as-
sociated with intermediate MBL serum levels; and group C (LXA/O and O/O), the low-MBL 
genotype group associated with MBL defi ciency and hence the lowest MBL serum levels 23. 
This genetic subdivision correlates best with MBL serum levels 14 and is therefore commonly 
used and accepted 23-25. For that reason this subdivision is applied for all analyzes in this study. 
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Statistical analysis
Statistical analysis was performed using SPSS 12.0.01 for Windows (SPSS Inc, Chicago, IL). 
To test the hypothesis that women who develop pre-eclampsia have a higher probability 
of belonging to one of the two lower MBL genotype groups C or B compared with normal 
pregnant women, a χ2 analysis or contingency table was used. In this case-control design 
it was calculated that (based on the MBL genotype group C frequency of 14.8% and on 
the MBL genotype group B frequency of 34.1% 25 with a power 80% and α value of 0.05, 
an odds ratio (OR) of 2.35 could be detected for diff erences in expression between MBL 
genotype groups A and C; when both groups B and C are taken together, an OR of 2.00 
could be detected for diff erences in expression compared with the MBL genotype group A.
We used logistic regression analysis with the risk of pre-eclampsia, severe pre-eclampsia 
or eclampsia as dependent variable and the diff erent MBL genotype groups as inde-
pendent variables. Based on literature we considered the following variables a priori to 
be possible confounders for the prevalence of pre-eclampsia, severe pre-eclampsia or 
eclampsia: gestational age (analyzed in weeks), maternal smoking during pregnancy, 
maternal body mass index, maternal age at delivery, and gender of the child. Simple 
regression analyses were performed to determine which confounders had to be included 
in the multiple regression analyses. 
Results
We found no diff erences of the SNPs in the MBL2 structural gene, taken together as the 
O-allele, in women with pre-eclampsia and control group (O-allele 0.22 and 0.21 respec-
tively, OR 1.02, 95% confi dence interval (CI) 0.69 –1.49).
Association of MBL genotype groups and pre-eclampsia
Table 2 shows the crude and adjusted ORs and CIs for the association between MBL 
genotype groups and women with pre-eclampsia (n = 157). The crude and adjusted ORs 
did not show a statistically signifi cant association between MBL genotype groups and 
women with pre-eclampsia.
We did not see a diff erent eff ect when the intermediate- and low-MBL genotype 
groups B and C were grouped together in all analyses (data not shown). Moreover we did 
not fi nd a signifi cant additional eff ect in the ORs after adjustment for all possible con-
founders together (i.e., maternal smoking during pregnancy, maternal body mass index, 
maternal age at delivery, and gender of the child).
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Association of MBL genotype groups and more severe disease (severe pre-eclampsia 
and eclampsia)
A trend in the association toward more severe disease (severe pre-eclampsia or eclamp-
sia) could be appreciated. The simple regression analysis showed that gestational age is 
related to MBL genotype groups and pre-eclampsia. After correction for gestational age 
we found a stronger trend in the association between the low MBL genotype group C 
and severe pre-eclampsia and eclampsia itself. This association even became signifi cant 
after correction for all possible confounders (described below as adjusted OR).
Crude ORs and 95% CIs for severe pre-eclampsia for group B were as follows: OR = 1.12, 
CI = 0.51–2.50; for group C: OR = 0.84, CI = 0.26–2.71. Adjusted ORs for severe pre-eclamp-
sia for group B were: OR = 2.11, CI = 0.49–9.15; for group C: OR = 3.38, CI = 0.47–24.23. 
Crude ORs and 95% CIs for eclampsia for group B were: OR = 3.12, CI = 0.71–13.6; for 
group C: OR = 4.19, CI = 0.79–22.3. Adjusted ORs for eclampsia for group B were: OR = 
9.90, CI = 0.86–114.03; for group C: OR = 14.70, CI = 1.18–182.76.
Table 2. Frequencies of the mannose-binding lectin (MBL) genotype groups and their association with pre-
eclampsia
 MBL group
A B C Missing
Control subjects
(n = 157)
n (%) 88 (56.1) 47 (29.3) 21 (13.4) 1 (0.64)
Women with pre-
eclampsia
(n = 157)
n (%) 86 (55.8) 46 (29.3) 22 (14.0) 3 (1.91)
Crude OR 
(95% CI)a
1 1.00 (0.61-1.66) 1.07 (0.55-2.09)
Adjusted OR (95% 
CI)b
1 0.97 (0.46-2.07) 1.44 (0.52-3.94)
The MBL genotypes are categorized as MBL genotype group A, B and C. High-MBL genotype group A consists of YA/
YA- and YA/XA-genotypes. Intermediate-MBL genotype group B consists of XA/XA- and YA/O-genotypes. The low-
MBL genotype group C consists of XA/O- and O/O-genotypes.
OR = Odds Ratio; CI = confi dence interval
a Crude OR, without any adjustment for possible confounders.
b Adjusted OR, after adjustment for all possible confounders: gestational age (weeks), maternal smoking during 
pregnancy, maternal Body Mass Index, maternal age (years) at delivery, and gender of child.
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Discussion
In the present study MBL genotypes were not associated with pre-eclampsia, indicating 
that MBL is not a risk factor for this syndrome.
Because low-MBL production genotypes have been associated with preterm birth 26, 
one can speculate that a proper analysis is only possible by exclusion of preterm births in 
this study. Even when preterm births were excluded (among case and control subjects), 
we did not fi nd an association between MBL genotypes and pre-eclampsia (data not 
shown). As expected, the women with pre-eclampsia more frequently delivered preterm 
(preterm deliveries in pre-eclampsia group, n = 109/157, 69.4%, severe pre-eclampsia 
group, n = 31/36, 83.8%; eclampsia group, n = 9/11, 81.8%).
Both case and control subjects were included over a large period of time. Therefore it 
is important to know that pregnancy surveillance protocols of the Dutch Society of Ob-
stetrics and Gynaecology did not change signifi cantly during that time. Moreover geno-
types have been studied, and they would not have evolved during this period either. 
Finally, control subjects were selected as close to the delivery date of the case subjects, 
thereby avoiding selection bias in this inclusion time of 6 years.
Previously MBL has been studied in pregnancy. Low MBL, demonstrated either by 
measuring the actual serum protein or by determining the relevant genotypes, has been 
associated with adverse pregnancy outcomes, including recurrent miscarriages, risk for 
chorioamnionitis, and preterm delivery 26-30. Kilpatrick studied MBL serum levels in rela-
tion to pre-eclampsia previously 31; he did not fi nd an association between MBL serum 
levels and pre-eclampsia, but he did fi nd lower MBL serum levels in a group with recur-
rent pre-eclampsia (n = 12). However the data in this study are diffi  cult to interpret, as 
the blood samples taken to measure MBL were drawn either around delivery or in the 
postpartum period. It has been shown that MBL levels vary greatly peri- and postpartum 
and therefore are not indicative of MBL levels before or during pregnancy19. 
In contrast to our data Sziller et al. 32 published data demonstrating that the MBL 
codon 54 gene polymorphism, compatible with low MBL production, protects against 
the development of pre-eclampsia. Diff erences can be explained by diff erences in study 
design. Sziller et al. used a limited number of patients: the number of patients expressing 
the MBL codon 54 gene polymorphism in that study is very low (n = 7), thereby bringing 
into question the power of that study. Furthermore these investigators examined the 
infl uence of only one polymorphism in the structural gene; the other polymorphisms in 
the structural gene and in the promoter region were not examined. Finally, in our study 
only women with fi rst pregnancies were included, whereas Sziller et al. included a high 
percentage of multigravida (43.2%), and studying multigravida introduces covariates 
including obesity, previous pre-eclampsia, and chronic hypertension.
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It is known that MBL is not only involved in predisposition for several diseases but 
that it may also act as a disease modifi er 33-36. Therefore it was investigated whether MBL 
genotypes are associated with the most severe spectrum of pre-eclampsia, namely se-
vere pre-eclampsia and eclampsia. We observed a trend for the association of the low 
(C) and intermediate (B) MBL genotype groups with severe pre-eclampsia and eclampsia. 
Although the subgroups with severe pre-eclampsia (n = 36) and eclampsia (n = 11) are 
small for subanalysis, the association even became signifi cant after correction for all pos-
sible confounders.
To explain the fi nding of an association of low- and intermediate-MBL genotype 
groups with severe pre-eclampsia and eclampsia, the following rationalization can be 
postulated. For normal placentation, a low degree of infl ammation is benefi cial at the 
fetal–maternal interface 6. Several disorders of placentation, including pre-eclampsia, are 
characterized by excess infl ammation at the fetal-maternal junction, resulting in tissue 
damage and inadequate formation of the placenta 6, 12. In regard to pregnancy it is of 
particular interest that MBL facilitates the clearance of apoptotic cells and cell debris 
by phagocytes 37-39. This process of apoptosis is vital for adequate placentation in early 
pregnancy, for example, during the extravillous trophoblast invasion when cell debris 
and apoptotic cells have to be cleared 20, 40-42. Defects in these apoptotic mechanisms 
have been associated with pre-eclampsia 43, 44, as unrecovered cell debris can cause an 
infl ux of immunological cells and thereby excess infl ammatory reactions, resulting in 
abnormal placentation. Because several inhibitors of complement are expressed in the 
placenta, to prevent complement-mediated tissue injury at the fetal-maternal junction 11, 
one can speculate that in the placenta the anti-infl ammatory properties of MBL that do 
not require complement activation, predominate over the proinfl ammatory properties 
that depend on activation of the complement system. High levels of MBL could thereby 
protect against severe pre-eclampsia and eclampsia by downregulating excess infl am-
mation in the placenta.
In summary, we found no association between MBL genotype polymorphisms and 
pre-eclampsia. However a trend in the association between the low- and intermediate-
MBL genotype group C and B and the prevalence of severe pre-eclampsia and eclampsia 
was observed, which might implicate a role of MBL in modulating placental infl amma-
tion by facilitating clearance of apoptotic cells and cell debris. However this latter fi nding 
must be reconfi rmed in studies incorporating larger numbers of patients with severe pre-
eclampsia and eclampsia.
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Abstract
Background: The complement factor mannose-binding lectin (MBL) is associated with 
adverse pregnancy outcome. MBL serum concentrations are increased from early preg-
nancy onwards and depend upon several gene polymorphisms. We investigated whether 
MBL polymorphisms are associated with term and preterm birth, since preterm birth is 
the leading cause of neonatal morbidity and mortality.
Methods: MBL2 gene polymorphisms were determined in 157 nulliparous women. Con-
sidering MBL polymorphisms cases were categorized in groups of high (A), intermediate 
(B) and low (C) MBL production. Kaplan–Meier survival and multiple linear regression 
analysis were performed.
Results: Women with high MBL genotype group A had a shorter gestational age (274 
days ± SD 21) than the women with the intermediate MBL genotype group B (283 days 
± SD 12) and the low MBL genotype group C (284 days ± SD 9). This diff erence in mean 
gestational age is almost totally attributable to premature births in group A, since 12 of 
the 14 preterm births were from women with the high MBL genotype group A and only 
two from the intermediate MBL genotype group B.
Conclusions: We found an association between the maternal high MBL genotype group 
A and premature birth, suggesting that during pregnancy MBL-associated infl ammation 
caused by higher MBL activity may contribute to earlier delivery. Furthermore, this fi nd-
ing might explain why so many individuals are MBL defi cient in the general population.
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Introduction
Despite many medical and social advances of the last decades, the incidence of preterm 
birth has remained almost constant (about 9%) in the modern world 1. Besides concerns 
including prevention, treatment and management of preterm birth, the etiology of ges-
tational age in human parturition needs attention, because of the high neonatal morbid-
ity and mortality associated with preterm birth 2. Many factors are suggested to play 
a role in gestational age at delivery including infectious, immunological, genetic and 
environmental factors (such as stress, smoking, obesity and heavy work) 3. 
The hypothesis that infl ammation might play a role in preterm labor and thus shorter 
gestational age is supported by studies demonstrating that conditions involving in-
creased infl ammation, like infections, e.g. periodontitis 4 and systemic autoimmune 
diseases, e.g. rheumatoid arthritis 5, are associated with shorter gestational age. In line 
with these clinical fi ndings, polymorphisms in infl ammatory response genes contribute 
to infl ammation and result in shorter gestational age. Further evidence in support of 
a genetic role in the pathogenesis of premature birth comes from the observation of 
clustering and recurrence of spontaneous preterm delivery in individual women, families 
and ethnic groups 2, 3, 6.
Mannose-binding lectin (MBL) is a factor of innate immunity and initiates and acti-
vates the lectin pathway of complement. It can therefore be considered as a pro-infl am-
matory protein. MBL serum concentrations are strongly determined by single nucleotide 
polymorphisms (SNPs) in the structural gene (exon 1 of the MBL2 gene: AA-, AO- and 
OO- genotype. The wildtype allele is referred to as A, while the O-allele represents the 
variant alleles B, C, and D together. Individuals with the AA wildtype genotype have the 
highest MBL serum concentrations, and individuals with the OO-genotype the lowest, 
because of disturbed multimer formation, resulting in impaired function 7, 8. Moreover, 
basal MBL serum levels are modifi ed by the SNPs in the promoter region of the MBL2 
gene (H/L or X/Y) 9. 
Maternal MBL serum levels are increased from the fi rst trimester of pregnancy and on-
wards, suggesting a role of MBL in nidation, placentation and maintenance of pregnancy 
10. This rise in MBL levels during pregnancy is strictly related to the maternal genotype. 
Multiple studies have described low maternal MBL levels (or low-MBL production geno-
types) in association with adverse pregnancy outcome 11-16.
We investigated whether MBL polymorphisms are involved in human parturition and 
gestational age.
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Materials and Methods
The women in our study have been described previously as the control group in a case 
(pre-eclampsia)-cohort study 17, 18. Their characteristics are described in Table 1. All wom-
en were selected from a computer database and patient charts. Nulliparous women (n = 
157) were selected according to the following criteria: fi rst pregnancy, no rise in blood 
pressure, no hypertension or proteinuria, no multipara, no multiple pregnancies nor suf-
fered from chronic hypertension, renal disease, diabetes, collagen vascular diseases or 
cancer, nor encountered thrombosis before their fi rst pregnancy 17. Controls were not 
selected according to gestational age. All women who delivered before 37 0/7 weeks of 
gestation were not induced for labor. 
Gestational age is defi ned as the time measured from the fi rst day of the woman’s last 
menstrual cycle or if uncertain by ultrasound before 12 week’s gestation to delivery. Nor-
mal gestational age is between 37 and 42 weeks (259-294 days) of pregnancy. Premature 
birth is defi ned as parturition before 37 0/7 weeks of gestation. 
The local Ethics Review Board approved the study protocol.
MBL genotyping and division in genotype groups
Genotyping was performed using PCR LightCycler techniques as described previously 10. 
Based upon the genotypes, individuals were categorized into three groups: the high-MBL 
genotype group A associated with high MBL serum levels ((H/L)YA/(H/L)YA and (H/L)YA/
LXA); the intermediate-MBL genotype group B associated with intermediate MBL serum 
levels (LXA/LXA and (H/L)YA/O); and the low-MBL genotype group C associated with MBL 
defi ciency and hence the lowest MBL serum levels (LXA/O and O/O) 19. This subdivision 
Table 1. Study group characteristics
Characteristics Cases (n = 157)
MBL genotype group A 88 (56.1)
MBL genotype group B 47 (29.9)
MBL genotype group C 21 (13.4)
Missing (not categorizable) 1 (0.64)
Maternal age at delivery (years) 28.5 (3.8)
Maternal body mass index (kg/m2) 23.6 (4.2)
Maternal smoking 28 (17.8)
Caucasian race (%) 96
Gestational age (days) 278 (17.8) 
Birth weight of child (grams) 3282 (575)
Gender of child (male/female) 74/75
Data are represented as mean (SD) or n (%)
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correlates best with MBL serum levels 7 and is therefore commonly used and accepted 19, 
20 and therefore also applied for all analyzes in this study. 
Statistical analysis
We used the Kaplan-Meier method for evaluating the gestational age in weeks and its 
correlation with the three MBL genotype groups. Diff erences between MBL genotype 
groups were assessed by the log-rank test. Furthermore we used multiple linear regres-
sion analysis to compare gestational age as the dependent variable with the diff erent 
MBL genotype groups as independent variables with adjustment for all selected can-
didate confounders. Based on literature we considered the following variables as pos-
sible confounders: maternal smoking during pregnancy, maternal body mass index and 
maternal age at delivery. None of the possible confounders had a signifi cant eff ect on the 
diff erence between the MBL genotype groups.
Results
Women with high-MBL genotype group A had a shorter gestational age (274 days ± SD 
21 = 39 1/7 weeks ± SD 3 0/7) than the women with the intermediate-MBL genotype 
group B (283 days ± SD 12 = 40 3/7 weeks ± SD 1 5/7) and the low-MBL genotype group C 
(284 days ± SD 9 = 40 4/7 weeks ± SD 1 6/7). Since 12 of the 14 preterm births (86%) were 
from women with the high-MBL genotype group A and only two in the intermediate-
MBL genotype group B, the diff erence in gestational age could almost totally be attrib-
uted to a higher frequency of premature births in MBL genotype group A (13.6% preterm 
births) versus MBL genotype group B and C together (2.9%). Conversely, no signifi cant 
diff erence in gestational age between the diff erent MBL genotype groups was found 
when the analysis was restricted to only women that delivered at term, i.e. 37 0/7 weeks 
of gestation or more. All neonates (n = 5) that were born before 34 weeks of gestation 
were from women with MBL genotype group A.
The relationship between MBL genotype groups and gestational age in weeks was 
assessed using Kaplan-Meier survival analysis. The cumulative probability of delivery and 
the gestational age in relation to the diff erent MBL genotype groups is shown in Figure 
1. MBL genotype groups were signifi cantly associated with the length of gestational age 
(log-rank test, p = 0.01). In further analysis, MBL genotype group A showed a signifi cantly 
shorter gestational age than MBL group B and C together (log-rank test, p = 0.002). How-
ever, the diff erence between the gestational age between MBL genotype group B and C 
was not signifi cant (log-rank test, p = 0.40). 
We performed multiple regression analysis as well, and found a signifi cant overall MBL 
genotype group eff ect on gestational age in days (F-test, p = 0.009), indicating a sig-
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nifi cant diff erence between any of the MBL genotype groups altogether. Further analysis 
indicated a signifi cant diff erence between MBL genotype groups A and B (p = 0.009, 
confi dence interval (CI) 2.1-14.7 days) and also between MBL genotype groups A and C 
(p = 0.02, CI 1.5-18.7 days). There was no signifi cant diff erence between MBL genotype 
groups B and C. None of the possible confounders had a signifi cant eff ect on the diff er-
ence between the MBL genotype groups.
As expected, this shorter gestational age resulted in lower birth weight (high-MBL 
group A 3163 ± SD 621 grams, intermediate-MBL group B 3423 ± SD 526 g and low-MBL 
group C 3454 ± SD 352 grams, p = 0.01 and p = 0.04 vs. A, respectively).
The frequency of premature birth in our study population (about 9%) is the same as 
that found for nulliparous women in the general Dutch population. 21.
Discussion
We found that the high-MBL production genotype group A is associated with preterm 
birth compared to the intermediate-MBL production group B and the low-MBL produc-
tion group C. The diff erence in gestational age between MBL genotype group A versus 
MBL genotype groups B and C together can be almost totally attributed to a higher per-
centage of premature births in women with MBL genotype group A. Since preterm birth 
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Figure 1. Kaplan-Meier survival curve showing gestational age in weeks between the diff erent MBL genotype 
groups. MBL genotype group A is associated with high MBL serum levels; MBL genotype group B with intermediate 
MBL serum levels and MBL genotype group C with MBL defi ciency and hence the lowest MBL serum levels.
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is the leading cause of neonatal morbidity and mortality, this fi nding might have clinical 
implications. 
Previously, low-MBL production maternal genotypes or low MBL serum levels have 
been associated with adverse pregnancy outcomes, including recurrent miscarriages, re-
current pre-eclampsia, risk for chorioamnionitis and preterm delivery 11-16. Up until now 
only Annells et al. 11 published data on preterm delivery and MBL. They demonstrated 
that the MBL codon 54 (B-allele, AO- or OO-genotype) gene polymorphism, compatible 
with low or intermediate MBL production, is associated with preterm delivery in a strati-
fi ed group of women with preterm birth of < 29 weeks of gestation. The diff erence with 
our study outcome may be explained by diff erences in study design. We studied women 
that delivered preterm, defi ned as a gestational age before 37 0/7 weeks of gestation, 
whereas Annells et al. studied a stratifi ed preterm birth group of less than 29 weeks of 
gestation. Also, they investigated only the infl uence of the polymorphisms in the struc-
tural gene; the polymorphisms in the promoter region were not examined. Moreover, 
in our study only women with fi rst pregnancies were included whereas Annells et al. 
included multi- as well as nulliparous women. This might introduce a selection bias of 
recurrent preterm delivery in multiparous women. In addition, we did not select on pre-
term delivery per se, but included healthy nulliparous women. Finally, confounders were 
diff erent in both studies: smoking, which may play a role in placentation and gestational 
age, was more frequent in women described by Annells et al. (35%) compared to our 
study group (18%). 
The mechanism through which high MBL levels could cause shorter gestational age 
might be explained as follows: medical conditions that are associated with local or sys-
temic infl ammation predispose to shorter gestational age/premature delivery 3. For ex-
ample, it has been shown that local reproductive tract infections like chorioamnionitis, or 
periodontitis signifi cantly increase the risk of subsequent preterm birth 22-24. Rheumato-
logical diseases, associated with autoimmune infl ammation of the joints, have also been 
associated with increased preterm delivery and reduced birth weight 5, 25, 26 as well as 
infections like pyelonephritis, pneumonia, syphilis, and malaria 24. For that reason chronic 
higher levels of MBL may predispose to premature delivery by aggravating those local or 
systemic infl ammatory medical conditions that are associated with premature delivery. 
Aside from the association between overt infl ammation during pregnancy and shorter 
gestational age with the role that polymorphisms in infl ammatory response genes play 
herein, it should also be acknowledged that pregnancy itself can be considered as a state 
of increased infl ammation 27. Therefore, gene polymorphisms that increase the magni-
tude or duration of infl ammation can be associated with preterm birth during uncom-
plicated pregnancies 28. In line with this also for polymorphisms associated with higher 
levels of the pro-infl ammatory molecule MBL a similar role can be considered.
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In view of the association between MBL defi ciency and the increased risk for infections 
29, it has puzzled many scientists why so still so many individuals in the general (Cauca-
sian) population are MBL defi cient; up to almost 50% when MBL genotype groups B and 
C are taken together 20. This suggests that MBL defi ciency also might have an evolution-
ary advantage. The association of MBL genotype groups B and C with longer gestational 
age could be advantageous since women with this genotype have pregnancies of longer 
duration and hence give birth to children with a better start in life. 
In summary, we found an association between the maternal high-MBL genotype 
group A and premature birth, suggesting that during pregnancy MBL-associated infl am-
mation caused by higher MBL activity may contribute to earlier delivery. 
Furthermore, this fi nding might explain why so many individuals are MBL defi cient in the 
general population.
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Abstract
Background: In RA, confl icting results have been described on the association between 
genotypes of the complement factor mannose-binding lectin (MBL) and disease suscep-
tibility and severity. This might be due to underpowerment of previous research work 
and the fact that no confi rmation cohorts were used. Therefore a diff erent approach is 
warranted.
Methods: MBL2 gene polymorphisms were determined in two RA cohorts (378 and 261 
cases) and 648 controls. Considering MBL polymorphisms, cases and controls were cat-
egorized in groups of high, intermediate and low MBL production. The total sample size 
allows detection of a potential association between RA susceptibility and MBL groups 
with an odds ratio of 1.37 (α < 0.05; 1-β > 0.8). Disease severity as defi ned by the need for 
anti-TNF therapy was also analyzed for possible associations with MBL groups.
Results: There was no diff erence in the frequencies between MBL genotypes of RA cases 
and controls that are associated with high (cases 54.4%, controls 57.0%), intermediate 
(cases 28.9%, controls 27.5%) or low (cases 16.7%, controls 15.5%) MBL production. Fur-
thermore, there was no association between MBL groups and disease severity.
Conclusions: MBL genotype groups are not associated with RA disease susceptibility 
or severity in this large study including a confi rmation cohort. Compared with previous 
smaller studies these results add to more defi nite conclusions.
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Introduction
Rheumatoid arthritis (RA) susceptibility has been associated with defects in innate im-
munity. Mannose-binding lectin (MBL) defi ciency is one of the defects in innate immu-
nity with the highest prevalence. MBL is a complement component that activates the 
lectin complement pathway. Its serum concentration is strongly determined by single 
nucleotide polymorphisms (SNPs) in the structural gene and the promoter region 1. MBL 
gene polymorphisms have been associated with outcome in multiple diseases 2-4. The 
role of MBL in RA susceptibility and severity is still controversial 4-13.
Contradictory results are a general point of concern in genetic studies. To overcome 
this problem, recently criteria for genetic association studies have been suggested within 
the National Cancer Institute and National Human Genome Research Institute (NCI-NH-
GRI) Working Group on Replication in Association Studies 14. The Working Group pleaded 
for large sample size genotype-phenotype studies that replicate both positive as well 
as negative fi ndings in multiple well-described cohorts with enough power and clear 
statistics and also pleaded for publishing the so-called negative studies. Until now none 
of the research performed on RA and MBL was in accordance with all criteria, especially 
most studies were underpowered and in none of the studies confi rmation cohorts were 
used. Therefore, the association of MBL and RA remains unclear. 
Therefore, we aimed to investigate whether MBL polymorphisms are associated with 
susceptibility for RA using a study design in accordance with the NCI-NHGRI criteria. Sec-
ond, we aimed to determine whether MBL polymorphisms are associated with disease 
severity and clinical characteristics. 
Methods
Cases and controls
DNA samples were obtained from n = 378 consecutive RA-patients followed in an outpa-
tient clinic (Cohort 1). They fulfi lled the ACR 1987 revised criteria for RA and to be even 
more certain of a diagnosis of RA, additionally had at least rheumatoid factor (RF) positiv-
ity, positivity for cyclic citrullinated peptide antibody (anti-CCP) or proof of joint erosions. 
DNA samples from another group of RA-patients (n = 261, Cohort 2) were obtained from 
women who were followed as part of the PARA-study, a nationwide prospective cohort 
study in which women with RA (according to ACR 1987 criteria) are studied during preg-
nancy and postpartum 15. 
All controls (n = 648) have been described previously 2, 16-18. Genomic DNA of n = 461 
healthy voluntary donors was provided by the Sanquin Bloodbank, Rotterdam, The Neth-
erlands 2, 16 and n = 187 controls were healthy pregnant females 17, 18. 
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All cases and controls included in this study are unrelated Dutch Caucasians. This 
study is in compliance with the Helsinki declaration and the local Ethics Review Boards 
approved all study protocols. Data were analyzed anonymously. The characteristics of 
cases and controls are described in Table 1. 
Determination of disease severity markers and MBL serum concentrations
Current or past use of anti-TNF therapy was used as a marker of disease severity in both 
RA-cohorts (n = 120 and n = 35 RA-cases from Cohorts 1 and 2, respectively). Anti-TNF 
therapy was chosen since its prescription is strictly regulated in The Netherlands. Its costs 
are only reimbursed for RA patients that have therapy-resistant disease, which is defi ned 
as failure on at least two disease-modifying anti-rheumatic drugs (DMARDs) including 
methotrexate (MTX) and still active disease (disease activity score (DAS28) > 3.2), despite 
MTX therapy at 25 mg weekly or at maximum tolerated doses. 
Clinical characteristics were determined in a subgroup from RA Cohort 2, which was 
also seen before pregnancy. At that timepoint disease activity was scored using DAS28 (n 
= 129) and serum was obtained to determine the titers of anti-CCP (n = 129, EliATM CCP 
test, Phamarcia Diagnostics, Freiburg, Germany), IgA-, IgM- and IgG-Rheumatoid Factor 
(n = 129, Biognost, Heule, Belgium) and MBL protein concentrations (n = 132, sandwich 
ELISA as described previously 18). 
MBL genotyping and categorization of the individuals upon MBL genotypes
Genotyping was performed using PCR LightCycler techniques as described previously 
18. Genotyping included the wildtype (A-allele) and the three single nucleotide polymor-
Table 1. Cohort characteristics 
Controls
(n = 637)
Cases 
Cohort 1
(n = 375)
Cases
Cohort 2
(n = 259)
Mean age (years) 36.7 (8.23)* 59.3 (13.6) 31.9 (3.88)
Female gender 414 (64.9)** 278 (74.1) 259 (100)
Disease duration (years) 8.0 (0-53) 4.9 (0.1-28.6)
Anti-CCP positive - 104/125 (83.2)*** 162/258 (62.8)
Rheumatoid Factor (IgM) positive - 339/369 (91.8) 184/257 (71.6)
Joint erosions - 291/357 (81.5) 164/253 (64.8)
Median number of DMARDs (min-max) 
current or past use
- 3 (1-13) 2 (0-9)
Current or past use of anti-TNF therapy - 120/375 (32.0) 35/259 (13.5)
Data are represented as n (%) or mean (SD or range)
* Controls versus cases Cohort 1 or cases Cohort 2, both p < 0.0001
** Controls versus cases Cohort 1, p < 0.002; Controls versus cases Cohort 2, p < 0.0001
*** anti-CCP was not routinely analyzed in cases Cohort 1
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phisms (SNPs) of the fi rst exon of the structural gene: codon 52 (D-allele, rs5030737), 
codon 54 (B-allele, rs1800450) and codon 57 (C-allele, rs1800451) and two of the SNPs 
in the promoter region codon -550 (H/L, rs11003125) and codon -221 (X/Y, rs7096206) of 
the MBL2 gene. The B-, C-, and D-allele are jointly referred to as ‘O’. Linkage disequilibrium 
of the structural exon 1 mutations with the promoter polymorphisms results in six pos-
sible haplotypes (i.e. HYA, LYA, LXA, LYB, LYC and HYD). Every individual will express two 
out of these six haplotypes. The HY haplotype induces high MBL concentrations, while 
exon 1 mutations (O variant) and the LX haplotype cause reduced MBL concentrations. 
Therefore, based upon the haplotypes, individuals can be categorized into three 
groups: the high-MBL production group A, (H or L)YA/(H or L)YA and (H or L)YA/LXA; the 
intermediate-MBL production group B, LXA/LXA and (H or L)YA/O and the low- or defi -
cient MBL production group C, LXA/O and O/O. This genetic subdivision correlates best 
with MBL serum levels 1 and is therefore commonly used and accepted 3 and applied to 
all analyses in this study. 
In each experiment, genotype-matched and sequence-verifi ed control donors were 
used. 
Statistical analysis
SPSS 12.0.1 was used for all statistical analyses. Pearson χ2 tests were performed to 
test Hardy-Weinberg equilibrium and to analyze possible associations between MBL 
genotype groups and RA. The Spearman rank and Kruskal–Wallis test was performed for 
comparison between MBL genotype groups and MBL serum levels, DAS28 and anti-CCP 
or RF titers. Logistic regression analysis was used for adjustment for gender and age. Dif-
ferences between continuous variables were analyzed by unpaired t-tests. A signifi cance 
level of p < 0.05 was used for all analyses. 
Power analysis
Power analyses were performed based on published frequencies of the MBL genotype 
groups in Caucasians; MBL genotype group C frequency of 14.8% and MBL genotype 
group B frequency of 34.1% 3. With a power of 80% and α = 0.05 in RA Cohort 1 an odds 
ratio (OR) of 1.60 for MBL genotype group C alone versus MBL genotype group A and 
an OR of 1.44 for MBL genotype group B and C together versus MBL genotype group A 
could be detected for the association of RA susceptibility and MBL genotype groups. For 
RA Cohort 2 an OR of 1.69 for group C versus group A and an OR of 1.51 of group B plus C 
versus A could be detected. When the two groups were taken together, an OR of 1.51 for 
group C versus group A and an OR of 1.37 for group B plus C versus A could be detected 
for the association of RA susceptibility and MBL genotype groups. 
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Results
Accuracy genotyping procedure
Ten percent of the samples were randomly re-analyzed with identical results. The geno-
type distribution was in Hardy-Weinberg equilibrium for all SNPs tested in cases and 
controls. In fi ve cases and nine controls, the exon 1 SNPs could not be determined, and 
in two controls the promoter SNPs could not be determined. Therefore, these cases (n = 
5, <1%) and controls (n = 11, 1.7%) could not be grouped in one of the MBL genotype 
groups and were excluded from analysis, resulting in a total of n = 634 cases and n = 637 
controls to be analyzed. 
As expected, there was a good correlation between MBL genotype groups and MBL 
concentrations, Spearman ρ = 0.82; Group A median 607.5 ng/ml, Group B median 192.1 
ng/ml, Group C median 50.7 ng/ml, n = 132, p < 0.0001. 
Association of MBL genotype groups and disease susceptibility 
Cohort characteristics are summarized in Table 1. There was no diff erence in the frequen-
cies between MBL genotypes of RA-cases and controls that are associated with high 
A (cases 54.4%, controls 57.0%), intermediate B (cases 28.9%, controls 27.5%) or low C 
(cases 16.7%, controls 15.5%) MBL production (Table 2), indicating that there is no as-
sociation between MBL genotype groups and RA susceptibility. 
Table 2. Frequencies of MBL2 genotype groups and their association with disease susceptibility and disease severity
MBL Group
A
n (%)
B
n (%)
C
n (%)
Pearson’s 
p-value
A vs C
OR (95% CI)
A vs B+C
OR (95% CI)
Disease susceptibility
Cohort 1 cases (n = 375) 204 (54.4) 112 (29.9) 59 (15.7) 0.682* 1.06 (0.74-1.53) 1.11 (0.86-1.44)
Cohort 2 cases (n = 259) 141 (54.4) 71 (27.4) 47 (18.1) 0.613* 1.22 (0.82-1.82) 1.11 (0.83-1.48)
All cases (n = 634) 345 (54.4) 183 (28.9)  106 (16.7) 0.648* 1.13 (0.83-1.54) 1.11 (0.89-1.39)
Controls (n = 637) 363 (57.0) 175 (27.5) 99 (15.5) - - -
Subgroup analysis for disease severity (need for anti-TNF therapy)
Cohort 1 anti-TNF (n=120)  64 (53.3) 35 (29.2) 21 (17.5) 0.812** 1.21 (0.66-2.22) 1.07 (0.69-1.65)
Cohort 1 others (n = 255)  140 (54.9)  77 (30.2) 38 (14.9) - - -
Cohort 2 anti-TNF (n = 35) 21 (60.0) 6 (17.1) 8 (22.9) 0.320** 1.17 (0.41-2.86) 0.77 (0.37-1.59)
Cohort 2 others (n = 224) 120 (53.6) 65 (29.0)  39 (17.4) - - -
All cases anti-TNF (n =155) 85 (54.8) 41 (26.5) 29 (18.7) 0.636** 1.15 (0.70-1.89) 0.98 (0.68-1.41)
All cases others (n = 479) 260 (54.3) 142 (29.6) 77 (16.1) - - -
*Cases versus controls, OR = odds ratio, CI = confi dence interval
** RA-cases needing anti-TNF therapy (current or past use) versus RA-cases using conventional DMARDS and never 
used anti-TNF therapy
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Association of MBL genotype groups and disease severity and disease characteristics
No association was found between MBL genotype groups and the current or past use of 
anti-TNF therapy, as marker for disease severity (Table 2). Furthermore, no associations 
were found between MBL genotype groups or serum concentration and the autoanti-
body titers of anti-CCP, IgA-, IgM- and IgG-RF and DAS28 (data not shown). 
Discussion
MBL genotype groups are not associated with disease susceptibility, severity and disease 
characteristics in this large cohort of RA-patients. 
We are aware that cases and controls diff ered regarding age and gender. Therefore, 
all analyses were repeated with correction for these factors, but still no diff erences could 
be observed. It was also not likely that these could have induced bias, since the MBL 
genotype distribution or serum levels are not infl uenced by age or gender 19. It can be 
reasoned that our conclusions may only be applicable to Caucasian populations since in 
non-Caucasian populations the distribution and frequencies of MBL polymorphisms are 
diff erent 8, 13. 
One could argue that in complex genetic diseases like RA ORs between 1.1 and 1.3, for 
disease susceptibility and disease severity, could still be of interest and that therefore the 
present study still might be somewhat underpowered. Based upon the MBL genotype 
group frequencies of this study, one could calculate that the entire study population, i.e. 
cases and controls together, should include at least between 1900 and 14000 subjects 
to obtain signifi cant ORs between 1.1 and 1.3. Besides the fact that it is generally not 
acceptable to add additional cases to a representative sample once analyses are per-
formed, it is not expected that including more cases to our study would result in diff erent 
conclusions, since not even a trend towards statistical signifi cance was observed. 
Another possibility to increase the power is to perform a meta-analysis on all existing 
data. A prerequisite for a meta-analysis is that MBL genotype groups are defi ned identi-
cally in all studies. It has been shown that defi ning MBL genotype groups can be most 
accurately done by combining SNPs in the structural gene with the SNPs in the promoter 
region. Therefore, this approach was chosen in this study. We found only one study on 
MBL genotypes and RA susceptibility in which MBL genotype groups could be defi ned 
identically 4. Unfortunately, the frequencies of the control group were not described in 
detail, therefore making subdivision impossible for the controls. If we combined the RA 
patients of Graudal’s study 4, (n = 140) with the cases in our study (n = 639) and compare 
them to the healthy controls in our study (n = 646) still similar non-statistical signifi cant 
results were obtained; OR 1.16; 95% CI 0.70-1.93 for MBL group A versus group C and OR 
1.12; 95% CI 0.77-1.61 for MBL genotype group A versus MBL genotype group B + MBL 
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genotype group C. Performing a meta-analysis on studies that investigate disease sever-
ity was not possible for the additional reason that previous studies determined disease 
severity diff erently. Furthermore, some studies used markers of disease outcome (ero-
sions) and others disease activity as determinant of disease severity. Since both depend 
upon treatment strategies, which have changed markedly in recent years, recent and 
older literature cannot be combined in one meta-analysis.
Previous studies on MBL in relation to RA susceptibility describe ambiguous results. 
An association with low MBL and RA has been detected in four studies 5-8, two of which 
were performed in Asian populations that are known to have marked diff erences in MBL 
frequencies 6, 8. The other two studies were performed in Caucasians, but did not study all 
promoter polymorphisms next to the exon 1 polymorphisms. No association was found 
in fi ve studies 4, 9-12. However, no defi nitive conclusions can be drawn from these studies, 
since they lack suffi  cient power and not all known MBL variant alleles were analyzed. 
Furthermore, none of the studies confi rmed its results in an independent second cohort. 
MBL in relation to disease severity and disease characteristics like erosions 4-7, 12, 13, auto-
antibody titers 7, 11, 12 and disease activity 7, 8 has been studied in several studies 4-8, 11-13. 
Their results are equivocal and several studies are hampered by a lack of power 4, 11, 12. Also 
in none of these studies confi rmation cohorts were included. 
In conclusion, no association between RA disease susceptibility and MBL genotype 
groups was found. Since the results of this study were obtained in two separate cohorts 
of patients with enough power to demonstrate even small diff erences, a more defi nite 
conclusion can be drawn that MBL genotype groups are not a risk factor for the develop-
ment of RA or disease severity. 
Key Messages
· MBL genotype groups are not associated with susceptibility for RA. 
· No association between MBL genotype groups and disease severity of RA was found.
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Abstract 
Background: Improvement of rheumatoid arthritis (RA) during pregnancy has been 
causatively associated with increased galactosylation of immunoglobulin G (IgG) N-
glycans. Since previous studies were small, did not include the postpartum fl are and did 
not study sialylation, these issues were addressed in the present study. 
Methods: Serum from 148 RA-cases and 32 healthy controls was collected at several 
timepoints before, during and after pregnancy. Improvement during pregnancy and 
postpartum fl are were determined according to the EULAR response criteria. Galactosyl-
ation and sialylation of IgG and the presence of bisecting N-acetylglucosamine (GlcNAc) 
were analyzed by MALDI-TOF-MS. 
Results: IgG1 and IgG2 galactosylation of the cases and controls increased during 
pregnancy with a maximum in the third trimester. Galactosylation decreased directly 
postpartum. IgG galactosylation of controls was at a higher level than cases (p < 0.001 
at all timepoints). A similar pattern was observed for sialylation. Moreover, there was a 
good correlation between galactosylation and sialylation. The increase in galactosylation 
was signifi cantly more pronounced in cases with improvement than in cases without 
improvement during pregnancy. The reverse was true for deteriorators and non-deterio-
rators postpartum. The presence of bisecting GlcNAc was not signifi cantly infl uenced by 
pregnancy or postpartum for cases and controls.
Conclusions: This large cohort study demonstrates the association of changes in ga-
lactosylation with both pregnancy-induced improvement and postpartum fl are in RA-
patients. The good correlation between galactosylation and sialylation implicates that 
the eff ect of galactosylation might be mediated through sialylation. 
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Introduction
Profound changes of the maternal immune system are required to accommodate the 
fetus during pregnancy. In this scope it has been hypothesized that the improvement of 
autoimmune diseases like rheumatoid arthritis (RA) during pregnancy is a result of these 
adaptations of the immune system. Conversely a fl are up of the disease postpartum can 
be observed in RA. Although many hypotheses have been proposed 1-7, the mechanisms 
underlying this phenomenon are still largely unknown 8. In addition, the pathogenesis of 
RA is not fully understood. Evidence is accumulating that autoantibodies are important 
in the pathogenesis of RA 9-11. Autoantibodies belong to the family of immunoglobulins, 
which are glycoproteins. The glycosylation pattern of immunoglobulin G (IgG) has been 
studied most extensively 12. Many diff erent IgG glycoforms can be identifi ed due to the 
presence of a single N-glycan chain attached to the asparagine 297 on the CH2 domain of 
each IgG Fragment crystallizable (Fc) portion 13. This N-glycan shows heterogeneity due 
to the presence or absence of the core-linked fucose, the bisecting N-acetylglucosamine 
(GlcNAc), and galactose residues as well as sialic acid on the N-glycan antennae (Figure 
1) 6, 14. The presence or absence of fucose has not been associated with RA or pregnancy 
15 and the presence or absence of the ‘bisecting’ GlcNAc has not yet been studied during 
pregnancy or in RA-patients. Regarding galactosylation of the outer arms of the N-glycan 
chains (the α1,3 or the α1,6 arm), three subfamilies called IgG-G0 or Gal-0 (agalactosyl 
Figure 1. MALDI-TOF-MS analysis of tryptic glycopeptides of IgG1 and IgG2. Glycopeptides derived from IgG1 and 
IgG2 were analyzed for galactosylation and sialylation in the linear positive mode. A representative sample of an 
RA-patient before pregnancy (A) and in the third trimester (B) is shown. 
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IgG, no galactose), IgG-G1 or Gal-1 (galactose on one arm) and IgG-G2 or Gal-2 (galactose 
on both arms) have been defi ned 16. In the Gal-1 and Gal-2 situation one terminal sialic 
acid residue can be present on each galactose residue. 
Compared to healthy controls, higher levels of the agalactosyl IgG are found in RA-
patients and these are associated with increased disease activity and a more progres-
sive disease course 6, 17. Moreover, in two small studies, increased galactosylation dur-
ing pregnancy has been associated with the pregnancy-induced improvement of RA 7, 
18. Recently, animal studies provided evidence that antibody eff ector functions are not 
merely dependent upon the level of galactosylation but are related to the terminal sialic 
acid residues that can be present on the galactose molecules. (Figure 1) 19. If the same 
hold true for humans, this could provide an alternative explanation for the pregnancy-
induced improvement of RA. 
We investigated the changes in galactosylation (Gal-0, Gal-1, Gal-2) of IgG in a large co-
hort of RA-patients together with controls from pre-pregnancy onwards until six months 
postpartum. This enabled us to study not only the association between galactosylation 
and improvement of RA during pregnancy, but also its association with the postpartum 
fl are. Also factors that infl uence IgG galactosylation were analyzed. The MALDI-TOF-MS 
was applied allowing more accurate detection of N-glycan glycosylation. Furthermore, 
we investigated whether IgG galactosylation levels are associated with sialylation levels 
during pregnancy and in the postpartum period. Finally, we studied whether the pres-
ence of a bisecting GlcNAc on IgG is associated with pregnancy-improved disease activ-
ity or the fl are postpartum in RA-patients. 
Materials and methods
Study population 
The present study is part of the PARA-study (Pregnancy-induced Amelioration of Rheu-
matoid Arthritis). This is an ongoing prospective cohort study in which women with RA 
are followed preferably from preconception until six months postpartum. The outline 
of this study has been described in detail 20. Data of the fi rst 148 Caucasian RA-patients 
(cases) are included in this study. Healthy pregnant Caucasian volunteers without ad-
verse obstetric history (controls, n = 32) were followed from fi rst trimester of pregnancy 
to six months postpartum. The study is in compliance with the Helsinki Declaration and 
approved by the Ethics Review Board at the Erasmus MC University Medical Center, Rot-
terdam, The Netherlands. 
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Data collection
N = 57 cases were followed from pre-pregnancy, n = 65 cases from the fi rst trimester, 
n = 14 cases from the second trimester and n = 12 cases from the third trimester and 
onwards. 
Disease activity was scored using a disease activity score (DAS28) with three variables 
(swollen joint count, tender joint count and a C-reactive protein (CRP) level) 8, 21. 
Categorization of disease activity and clinical response
In accordance with the EULAR criteria remission of RA was defi ned as DAS28<2.6 and 
intermediate and high disease activity as DAS28>3.2 22. Improvement of disease activity 
during pregnancy was defi ned according to the EULAR criteria as ‘good’, ‘moderate’ (com-
bined to ‘responders’) or ‘non-responders’ 22. In line with the EULAR criteria, the response 
criteria can only be applied to those patients with an initial DAS28>3.2 at fi rst trimester 
(n = 75). Deterioration of disease activity after delivery was defi ned according to so called 
‘reversed’ EULAR criteria 20, 22. Since there is no baseline DAS28 requirement for these 
criteria, this classifi cation was applied to all cases. An early fl are was defi ned when dete-
rioration began between six weeks and three months postpartum and a late fl are with 
disease deterioration between three to six months postpartum. 
IgG glycosylation analysis
IgG was purifi ed from serum using Protein A-Sepharose beads and treated with trypsin. 
These beads bind IgG1, IgG2 and IgG4, but not IgG3 14. Glycopeptides were desalted and 
purifi ed from IgG tryptic digests by reverse phase-SPE. Therefore, each well of a Supelco 
DSC-18 plate SPE-96 (25 mg) was pre-treated with 1 ml of 80% acetonitrile (AcN), 0.1% tri-
fl uoroacetic acid (TFA), then 1 ml of 50% AcN, 0.1% TFA, and fi nally 1 ml of 0.1% TFA. The 
total digest (40 μl) was added to the wells, followed by three washes with 1 ml of 0.1% 
TFA. Glycopeptide samples were eluted into a V-bottom 96-well microtiter plate with 300 
μl of 18% AcN containing 0.1% TFA. Glycopeptide samples were dried by vacuum cen-
trifugation and dissolved in 100 l water. 
Galactosylation and the incidence of bisecting GlcNAc were analyzed for all samples: 
aliquots (1 l) of the glycopeptide samples after reverse phase purifi cation were spotted 
on a polished steel 384-positions MALDI-TOF-MS target plate and allowed to dry. Sample 
spots were overlaid with 1 l α-cyanocinnamic acid matrix (5 mg/ml in 50% AcN) and 
allowed to dry at room temperature, resulting in a microcristalline sample preparation. 
Glycopeptides were analyzed in the refl ectron positive mode on an Ultrafl ex II MALDI-
TOF-MS (Massaspectrometer, Bruker Daltonics, Bremen, Germany). The laser power was 
kept constant throughout the measurements, which were performed in the automatic 
mode. N = 100 shots were acquired per position, and spectra were acquired from n = 30 
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diff erent positions per spot, resulting in a sum spectrum obtained by accumulation from 
3000 spectra per sample spot. 
For the analysis of sialylation, 1 μl aliquots of the glycopeptide samples were spotted 
on a MTP AnchorChip 600/384 plate (Bruker Daltonics) and allowed to dry. Sample spots 
were overlaid with 1 μl of 2,5-dihydroxybenzoic acid matrix (5 mg/ml in 50% AcN with 
0.1% TFA) and allowed to dry at room temperature, resulting in a macrocristalline sample 
preparation. Glycopeptides were analyzed by MALDI-TOF-MS in the linear positive mode. 
Per sample spot 2000 spectra were accumulated. These analyses were performed in three 
subgroups: fi rst, n = 10 cases and n = 10 controls randomly selected from our cohort 
at every timepoint before (cases), during and after pregnancy. Second, sialylation was 
determined in n = 15 responders and n = 15 non-responders selected upon the most pro-
nounced and the least-pronounced changes in disease activity during pregnancy. Third, 
sialylation was determined in n = 15 cases with a fl are early postpartum and n = 15 cases 
without a fl are selected upon the most pronounced and the least-pronounced changes 
in disease activity postpartum.
Mass spectra were processed in FlexAnalysis (Bruker Daltonics) with baseline subtraction 
and peak detection of the IgG glycopeptide signals. Peak lists were imported into Excel. 
From the MALDI-TOF-MS measurements in the linear positive mode, IgG1 and IgG2 
signals for six glycoforms were analyzed: Gal-0 without bisecting GlcNAc, Gal-1 without 
bisecting GlcNAc, Gal-2 without bisecting GlcNAc and Gal-0+bisecting GlcNAc (G0+N), 
Gal-1+bisecting GlcNAc (G1+N), Gal-2+bisecting GlcNAc (G2+N).
The levels of galactosylation of IgG1 without bisecting GlcNAc was expressed by avail-
able antenna position using the following term:
(0.5x IgG1-G1 + IgG1-G2) / (IgG1-G0 + IgG1-G1 + IgG1-G2) x 100%
The incidence of bisecting GlcNAc on IgG1 was analyzed using the following term: 
(IgG1-G0+N + IgG1-G1+N + IgG1-G2+N) / (IgG1-G0+N + IgG1-G1+N + IgG1-G2+N + IgG1-
G0 + IgG1-G1 + IgG1-G2) x 100%
Based on the MALDI-TOF-MS measurements in the linear positive mode, the incidence of 
sialic acid (SA) per galactose moiety on IgG1 was determined using the following term:
(IgG1-G1-SA + IgG1-G2-SA) / (IgG1-G1 + IgG1-G1-SA + 2x IgG1-G2 + 2x IgG1-G2-SA)
The terms shown for IgG1 are similar for IgG2. 
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Statistical analysis 
Statistical analysis was performed using SPSS version 15.0 for Windows and SAS 9.1. A 
two-sided p-value ≤ 0.05 was considered statistically signifi cant. 
The IgG galactosylation and sialylation profi les in cases and controls during pregnancy 
and postpartum were estimated using a Linear Mixed Model (LMM) with unstructured 
residual correlation. Using this model we tested for diff erences in the galactosylation 
and sialylation levels between cases and controls at each timepoint and for changes on 
the time intervals from pre-pregnancy to pregnancy, within pregnancy and within the 
postpartum period.
LMM was also applied to compare diff erences in IgG galactosylation and sialylation 
between responders, non-responders, fl are and no-fl are postpartum. A possible associa-
tion between galactosylation and sialylation was analyzed by Spearman rank-test. 
A multivariate analysis, conditional on the timepoint of visit, was performed to inves-
tigate which covariates determine the level of galactosylation. It was assumed that their 
eff ects are constant in time. A two-step selection procedure was used. First each covari-
ate was tested separately by univariate analysis. Secondly, the covariates that had a p-
value lower than 0.2 where combined in a multivariate analysis. The following covariates 
were tested for their eff ect on IgG galactosylation levels: medication use ((dichotomous; 
yes/no): salazopyrine, prednisone, methotrexate or biological(s) use), DAS28, presence 
of erosions, rheumatoid factor positivity and anti-CCP positivity, whether individuals 
breastfed postpartum and age of the mother at time of delivery. 
Finally, to determine whether changes in IgG galactosylation precede changes in dis-
ease activity during pregnancy or in the postpartum period, for every timepoint interval 
the change in IgG galactosylation was divided by the total change in galactosylation. 
The change in disease activity was also calculated per interval and divided by the total 
change in disease activity. This resulted in a percentage of change per timepoint interval. 
A paired sample t-test tested for equality of the changes in galactosylation and disease 
activity. All analyzes were performed for all time intervals mentioned above.
Results
Description of study cohort
All cases (n = 148) fulfi lled the ACR 1987 revised criteria for RA (Table 1). 
MALDI-TOF-MS measurements and accuracy and reproducibility 
The intraday and interday variability for the analyzed glycopeptides of IgG1 and IgG2 was 
below 4% and 6%, respectively. The IgG4 glycopeptides were not analyzed due to their 
low abundance.
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IgG galactosylation profi les during pregnancy and postpartum of cases and controls
For the cases, already in the fi rst trimester the incidence of IgG1 galactosylation was in-
creased signifi cantly compared to preconception levels (mean 43.4% (SD 8.3%) to 48.4% 
(SD 8.4%)). This increase continued until the third trimester (mean 53.7% (SD 8.3%), p 
< 0.0001). At 6 weeks postpartum this incidence was signifi cantly decreased to mean 
46.9% (SD 7.2%). At 6 months postpartum the galactosylation levels further decreased 
(mean 44.9% (SD 7.7%), p < 0.0001, Figure 2a). IgG2 galactosylation profi les show a very 
similar pattern as IgG1 (Figure 2b). 
In the controls, IgG1 and IgG2 galactosylation profi les were at a signifi cantly higher 
level than cases (p < 0.001), and changes were less pronounced than in the cases (Figure 2). 
Table 1. Cohort characteristics
Cases (n = 148) Controls (n = 32)
Mean age at delivery, years (SD) 32.3 (3.8) 32.0 (4.4)
Median disease duration at delivery, years (range) 8.0 (0.7-29.7) -
Number of nulliparous women 70/147 (47.6) 14/32 (43.8)
Mean gestational age at delivery, weeks (range) 39.3 (31.4-42.1) 40.4 (34.0-42.0)
Breastfeeding (6 weeks postpartum), n (%) 62/148 (41.9) 27/32 (84.4)
Anti-CCP positive, n (%) 93/147 (63.3) -
Rheumatoid Factor (IgM) positive, n (%) 108/148 (73.0) -
Erosive disease, n (%) 43/147 (70.7)
DAS28-CRP3 >3.2 in fi rst trimester, n (%) 75 (61.5) -
Classifi cation of disease activity during pregnancy, n (%)
- Good response / moderate response 37/75 (49.3) -
- No response 38/75 (50.7) -
Classifi cation of disease activity during postpartum period (early 
fl are), n (%)
- Severe deterioration / moderate deterioration, 35/141* (24.8) -
- No deterioration 106/141* (75.2) -
Classifi cation of disease activity during postpartum period (late 
fl are), n (%)
- Severe deterioration / moderate deterioration 29/141* (20.6) -
- No deterioration 112/141* (79.4) -
 Median number of DMARDs** (incl prednisone) prior to conceive 
(min-max)
2 (0-7) -
No DMARD** use prior to conceive, n (%) 7/147 (4.8)
Use of methotrexate prior to conceive, n (%) 75/147 (51.0) -
Data are represented as n (%) or mean (SD or range)
*n = 7 cases are missing, since a small proportion of DAS scores are missing
**DMARDs: disease modifying anti-rheumatic drugs
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IgG galactosylation and disease activity levels
IgG1 galactosylation levels are associated with disease activity at every timepoint (Pear-
son correlation R between 0.35 and 0.49, p < 0.005). Lower disease activity levels show 
higher galactosylation levels, and resemble more the levels of the controls. The IgG1 ga-
lactosylation level which is associated with disease remission (DAS28<2.6) is dependent 
on the timepoint of measurement (Figure 3). Similar data were observed for IgG2 (data 
not shown). 
Changes in IgG galactosylation are associated with improvement of disease activity in 
responders and non-responders during pregnancy
The change in galactosylation from the fi rst to the third trimester was signifi cantly diff er-
ent between responders (n = 37) and non-responders (n = 38) for IgG1 (6.8% (SD 0.80%) 
versus 4.2% (SD 0.79%), respectively, p < 0.02), whereas for IgG2 a trend could be ob-
served (5.6% (SD 0.51%) versus 4.5% (SD 0.50%), respectively, p = 0.11, Figure 4a). 
Changes in IgG galactosylation are associated with early and late disease fl are 
postpartum
Cases with a late fl are may also have experienced an early fl are (n = 9). The change in 
galactosylation from six weeks to three months postpartum was signifi cantly diff erent 
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Figure 2. Mean galactosylation of IgG1 (A) and IgG2 (B) (in percentages) in cases and controls during pregnancy 
and postpartum. IgG1 and IgG2 galactosylation levels increase during pregnancy and decline postpartum. IgG1 and 
IgG2 galactosylation profi les of controls are at a signifi cantly higher level than cases (p < 0.001, Linear Mixed Model 
at all timepoints). The vertical bars illustrate the 95% confi dence intervals. 
Abbreviations: trim, trimester of pregnancy; wk, weeks; PP, postpartum; mon, months.
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between the cases with an early fl are (n = 35) and without fl are (n = 106), namely -3.3% 
(SD 0.58%) versus -1.3% (SD 0.33%), respectively for IgG1, p < 0.004; and for IgG2: -2.7% 
(SD 0.42%) versus -1.3% (SD 0.24%), respectively, p < 0.004, Figure 4b. The change in IgG 
galactosylation between three and six months postpartum was signifi cantly diff erent be-
tween the cases with a late fl are (n = 29) and without late fl are (n = 112), namely -1.2% (SD 
0.49%) versus +0.58% (SD 0.33%), respectively for IgG1, p < 0.0001; and for IgG2 -1.1% 
(SD 0.30%) versus +0.16% (SD 0.20%), respectively, p < 0.0004, Figure 4c. 
Galactosylation changes do not precede disease activity changes
When changes in IgG galactosylation and changes in RA disease activity were tested for 
equality, this hypothesis could not be rejected, indicating that IgG galactosylation and 
DAS28 may change synchronically in time.
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Figure 3. Mean IgG1 galactosylation levels in relation to RA disease activity levels. For this purpose at every 
timepoint all cases were divided in two categories; i.e. those with a DAS28>3.2 or DAS28<2.6. Please note that each 
timepoint may include diff erent RA-cases. For comparison controls are added to the graph.  The IgG1 galactosylation 
level which is associated with disease remission (DAS28<2.6) is dependent on the timepoint of measurement. 
Similar data were observed for IgG2 (data not shown). The vertical bars illustrate the 95% confi dence intervals.
Abbreviations: DAS28, disease activity score; trim, trimester of pregnancy; wk, weeks; PP, postpartum; mon, months.
Fleur BW 7.indd   98 10/22/2009   3:52:32 PM
99
IgG galactosylation and sialylation in RA pregnancy
IgG sialylation during pregnancy and postpartum
IgG sialylation was, like galactosylation, determined as total percentage of sialic acid (SA) 
residues per N-glycan. The presence of SA on IgG1 and IgG2 is low in the serum for cases 
and controls (all measurements taken together: mean 5.8% (SD 2.3%) SA per N-glycan for 
IgG1 for cases (controls 7.1%, SD 2.7%) and 6.6% (SD 2.6%) per N-glycan for IgG2 for cases 
(controls 7.9%, SD 2.5%)).
Also the sialylation as percentage of SA per galactose sugar moiety was calculated: mean 
6.0% (SD 2.2%) SA per galactose for IgG1 for cases (controls 6.2%, SD 1.4%) and 7.9% (SD 
2.3%) per galactose for IgG2 for cases (controls 8.2%, SD 1.8%).
In RA-cases N-glycan sialylation levels and IgG galactosylation were signifi cantly corre-
lated (Spearman ρ 0.57 and 0.69 for IgG1 and IgG2, respectively, both p = 0.0001). In 
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Figure 4. Mean change in IgG1 and IgG2 galactosylation (x100%) for responders and non-responders during 
pregnancy and early or late fl are postpartum. A) Mean change in IgG1 and IgG2 galactosylation (x100%) during 
pregnancy in (good and moderate) responders according to the EULAR response criteria (n = 37) and non-
responders (n = 38). The change in IgG galactosylation was signifi cantly diff erent between responders and non-
responders for IgG1 (p < 0.02), whereas for IgG2 a trend towards signifi cance could be observed (p = 0.11). B) Mean 
change in IgG1 and IgG2 galactosylation (x100%) in the postpartum period in cases with an early fl are between 6 
weeks and 3 months postpartum (deterioration, n = 35) and cases without an early fl are (no deterioration, n = 106). 
The change in galactosylation was signifi cantly diff erent between early fl are and no early fl are for IgG1 and IgG2 (p 
< 0.004). C) Mean change in IgG1 and IgG2 galactosylation (x100%) in the postpartum period in cases with a late 
fl are from 3 to 6 months postpartum (deterioration, n = 29) and cases without a late fl are (no deterioration, n = 112). 
The change in galactosylation was signifi cantly diff erent between late fl are and no late fl are for IgG1 and IgG2 (p < 
0.0001 and p < 0.0004, respectively). 
The vertical bars illustrate the 95% confi dence intervals. 
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controls, the correlation between sialylation and IgG galactosylation was 0.77 and 0.72 
for IgG1 and IgG2, respectively, both p = 0.0001). 
The mean sialylation levels per N-glycan increased during pregnancy and decreased 
postpartum for cases and controls, following a similar pattern as the IgG galactosylation 
levels. The controls showed a higher level of sialylation than the cases (data not shown). 
The increase in N-glycan sialylation was larger in responders than in non-responders 
during pregnancy (within responders +1.8%, SD 0.42%, p = 0.0007; within non-respond-
ers +0.3%, SD 0.42%, not signifi cant). The results for IgG2 were similar (data not shown). 
In the postpartum period for IgG1 N-glycan sialylation no signifi cant changes were 
observed between cases with an early fl are and cases without fl are. However, for IgG2 
sialylation a statistically signifi cant decrease in N-glycan sialylation could be observed in 
cases with an early fl are (-0.95%, SD 0.40%, p = 0.024).
Dependent variables of galactosylation 
To investigate which factors determine the level of galactosylation multivariate analyses 
were performed. Univariate analyses revealed the following covariates with a signifi cant 
negative eff ect on IgG galactosylation: sulfasalazine use, prednisone use, DAS28, RF 
positivity, anti-CCP positivity and erosions for IgG1 and sulfasalazine use, prednisone use, 
DAS28, RF positivity, anti-CCP positivity for IgG2. In the multivariate analyses only DAS28 
and sulfasalazine (p = 0.06) for IgG1 and DAS28 and prednisone use (p < 0.05) for IgG2 
still had a signifi cant negative eff ect on IgG galactosylation. 
Interestingly, when a constant eff ect in time of the covariates was not assumed, we 
found that the eff ect of breastfeeding postpartum varied over time in the multivariate 
analyses. This eff ect varied from a slightly positive, but not statistically signifi cant eff ect 
at six weeks postpartum (+0.34%, p = 0.58) to a statistically signifi cant negative eff ect 
thereafter (-1.27% at three months and -2.32% at six months postpartum, p = 0.046 and 
p = 0.041, respectively). The overall average (negative) eff ect of breastfeeding on IgG 
galactosylation was not signifi cant in the multivariate analyses (p = 0.68). All other co-
variates had a constant negative eff ect over all timepoints.
Presence of bisecting GlcNAc and its infl uence on galactosylation
The presence of IgG with a bisecting GlcNAc is low in the serum (fi rst trimester mean 
13.7%, SD 2.8% for IgG1 (both cases and controls) and mean 13.3%, SD 3.2% or mean 
13.5%, SD 3.5% (cases and controls, respectively) for IgG2. The presence of bisecting 
GlcNAc was not infl uenced by pregnancy or postpartum and was similar in cases (range 
min-max IgG1 13.7-14.7%, range min-max IgG2 13.2-14.3%) and controls (range min-
max IgG1 13.7-14.4%, range min-max IgG2 13.0-14.0%). Moreover uni- and multivariate 
analyses did not reveal any eff ect of the previously mentioned covariates on the pres-
ence of bisecting GlcNAc. 
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The presence of the bisecting GlcNAc is related to IgG galactosylation. The levels of ga-
lactosylation of IgG1 or IgG2 with bisecting GlcNAc were at a signifi cant lower level than 
IgG1 or IgG2 without bisecting GlcNAc (range min-max IgG1 with bisecting GlcNAc 38.2-
44.8%, range min-max IgG2 with bisecting GlcNAc 31.8-38.9 %) at every timepoint (p < 
0.0001), but showed a similar pattern in time.
Discussion
This study demonstrates the association between changes in IgG galactosylation and 
changes in RA-disease activity during pregnancy and also postpartum. The most promi-
nent increase in IgG galactosylation was observed in RA-patients that spontaneously 
improved during pregnancy, whereas the reverse was observed for the fl are postpartum. 
IgG galactosylation changes synchronically in time with DAS28 disease activity. A good 
correlation between IgG N-glycan galactosylation and sialylation was demonstrated. 
This could indicate that the association of IgG galactosylation with pregnancy-induced 
improvement of RA and the postpartum fl are may be mediated by N-glycan sialylation. 
IgG galactosylation and RA in relation to pregnancy has been studied previously. Our 
results are in line with a previous study in which galactosylation levels and clinical out-
come in RA are described during pregnancy using the lectin analysis method 18. The ap-
plication of the MALDI-TOF-MS allowed us to analyze both IgG1 and IgG2 and to analyze 
specifi cally the Fc-fragment glycosylation (and galactosylation). This is in contrast to the 
lectin method, which cannot distinguish between IgGs and determines a combined value 
for the Fc and Fab fragment glycosylation. Compared to previous literature, we studied 
a larger cohort with a longer follow-up time postpartum. This enabled the description 
of the postpartum fl ares and the identifi cation of factors that infl uence galactosylation. 
Moreover a control group was added and internationally recognized outcome measures 
like DAS28 and EULAR response criteria were applied 18. Based upon studies in one pa-
tient it had been suggested that pregnancy-induced remission is associated with a fi xed 
galactosylation level 7. In contrast we demonstrated that the level of clinical remission 
was associated with a diff erent level of galactosylation per timepoint during pregnancy 
and postpartum (Figure 3). 
We have shown that the IgG galactosylation changes take place simultaneously with 
the changes in RA disease activity. For that reason one could argue that changes in IgG 
galactosylation are a mere epiphenomenon accompanying changes in disease activity. 
However, the strongest argument that galactosylation of IgG, and in particular agalac-
tosyl IgG itself, indeed plays a pathogenic role, is derived from animal studies. In these 
studies arthritis could only be transferred by infusion of agalactosyl IgG 23. 
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The pro-infl ammatory role of agalactosyl IgG may be explained in multiple ways: fi rst, 
IgG can act as an auto-antigen itself in RA. Since RF preferentially binds to agalactosyl 
IgG, this would result in more pronounced RF-agalactosyl IgG interaction and hence 
more immune complex deposition and infl ammation 24, 25.
Secondly, the pathogenicity of agalactosyl IgG in RA-patients is thought to be as-
sociated with its ability to activate the complement pathway via binding to mannose-
binding lectin (MBL) 26. However, this hypothesis has been questioned recently based 
upon studies in MBL-defi cient mice 13. 
As a result of the absence of galactose, agalactosyl IgG antibodies also lack terminal 
sialic acid residues. These terminal sialic acid residues have recently been implicated in 
suppressing infl ammation via the induction of inhibitory FcγRIIb expression in mice 19, 27. 
Our analysis revealed a good correlation between IgG N-glycan galactosylation and si-
alylation. Moreover, similar profi les of IgG galactosylation levels and N-glycan sialylation 
levels are shown during pregnancy and postpartum, both for IgG1 and IgG2. This im-
plicates that also in humans the eff ect of galactosylation could be mediated through 
the presence of increased N-glycan sialylation of IgG. Although more pronounced, the 
changes in N-glycan sialylation in responders and non-responders during pregnancy and 
cases with an early fl are and cases without a fl are postpartum were not statistically signif-
icant, which is in contrast to the statistically signifi cant IgG galactosylation changes (data 
not shown). This may be since N-glycan sialylation is only present in small percentages 
in the serum and that therefore measurements have large standard deviations from the 
mean. Therefore, for clinical association studies it can still be more practical to determine 
the level of IgG galactosylation instead of sialylation. 
Since we have shown that changes in IgG galactosylation levels and subsequently in 
sialylation levels are associated with improvement of RA during pregnancy and the fl are 
postpartum, identifi cation of factors that infl uence galactosylation might give insight 
into pathogenic mechanisms underlying RA and might be a lead for the development 
of future therapies. For this purpose multivariate analyses were performed. These re-
vealed that only disease activity and timepoint in pregnancy remained as an explanatory 
parameter for lgG galactosylation. Interestingly, when the eff ect of breastfeeding was 
analyzed, with the assumption that its eff ect could vary over time, it was found that its ef-
fect on IgG galactosylation varied from a slightly positive, but not statistically signifi cant, 
eff ect at six weeks postpartum to a statistically signifi cant negative eff ect thereafter. The 
average (negative) eff ect of breastfeeding postpartum was not signifi cant. We do not 
have an explanation for this phenomenon, however, breastfeeding has been associated 
with increased RA-disease activity in earlier studies 28. 
Pregnancy-induced changes in cytokine or hormonal levels could be a possible expla-
nation for the changes in lgG galactosylation during pregnancy and postpartum. It has 
been suggested that IL-6 29 or pregnancy-associated hormones like estrogen 25 or prolac-
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tin 30 could induce altered glycosyltransferase (or other (iso)enzyme) activity in B-cells 
that could result in immunoglobulins with diff erent glycoforms. Prolactin levels are more 
than ten-fold increased during pregnancy and stay at a high level during breastfeeding 
postpartum and could therefore play a role in galactosylation changes 30. 
For the fi rst time it has been shown that the levels of bisecting GlcNAc are not infl u-
enced by pregnancy. Pekelharing et al found no changes in the presence of GlcNAc dur-
ing pregnancy using gas-liquid chromatography 15, not distinguishing between antenna 
GlcNAc and the bisecting GlcNAc on other positions. The clinical relevance of bisecting 
GlcNAc is still unknown. Interestingly, the levels of IgG galactosylation with bisecting 
GlcNAc were signifi cantly lower than the levels of IgG without bisecting GlcNAc. One can 
speculate that steric hindrance by the presence of a bisecting GlcNAc on the binding of 
galactose moieties plays a role. Otherwise yet-unidentifi ed factors of the local micro-
environment of immunoglobulin-secreting plasma cells that might result in increased 
presence of bisecting GlcNAc on immunoglobulins and on the same time decreased lgG 
galactosylation could also play a role.
In conclusion, this large prospective cohort study demonstrates the association be-
tween IgG galactosylation changes with pregnancy-induced improvement and postpar-
tum fl are in RA-patients. Since IgG galactosylation was associated with sialylation, also 
increased sialylation during pregnancy may provide an explanation for the pregnancy-
induced improvement of RA. The levels of IgG galactosylation largely depend on the 
trimester of pregnancy or the timepoint of visit postpartum and disease activity, even 
after correction for medication use. 
Future studies should focus on unraveling the exact mechanism behind the changes 
in IgG galactosylation and sialylation and on the consequences of these changes on the 
function of IgG itself during pregnancy and postpartum. In particular it should be stud-
ied whether its ability to interact with Fc receptors is changed during pregnancy and 
postpartum. 
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Abstract
Background: Rheumatoid arthritis (RA) improves during pregnancy and fl ares after 
delivery. It has been hypothesized that high levels of the complement factor mannose-
binding lectin (MBL) are associated with a favourable disease course of RA by facilitating 
the clearance of pathogenic IgG lacking galactose sugar moieties. During pregnancy 
increased galactosylation of IgG can be observed, whereas simultaneously MBL levels 
increase. The latter being strictly related to maternal MBL genotypes. Therefore, in-
creased MBL levels in concert with increased IgG galactosylation may be associated with 
pregnancy-induced improvement of RA. 
Objectives: To investigate whether MBL genotypes are associated with changes in RA-
disease activity and with changes in IgG galactosylation during pregnancy and post-
partum. Also the association between MBL genotypes and pregnancy outcome in RA is 
studied. 
Methods: Serum from 216 RA-cases and 31 healthy controls of the Pregnancy-induced 
Amelioration of RA (PARA)-study was collected before, during and after pregnancy. IgG 
galactosylation was determined by MALDI-TOF-MS. Disease activity was determined 
using DAS28. MBL genotypes were determined. Pregnancy outcome measures studied 
were gestational age, birth weight, miscarriage and hypertensive disorders.
Results: No association was found between MBL genotype groups and changes in RA-
disease activity (p = 0.89) and changes in IgG galactosylation (cases p = 0.75 and controls 
p = 0.54) during pregnancy and postpartum. Furthermore, MBL genotype groups are not 
related to the studied pregnancy outcome measures.
Conclusion: This study does not provide evidence for a role for MBL in the improvement 
of RA during pregnancy, nor for a role in pregnancy outcome. 
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Introduction
Pregnancy is the only natural situation that results in spontaneous improvement of rheu-
matoid arthritis (RA) and a fl are of the disease after delivery in a substantial number of 
patients. Insight into the mechanism may therefore not only enlarge our knowledge on 
the phenomenon of pregnancy-induced remission in RA, but may also contribute to a 
better understanding of pathogenic mechanisms underlying RA in general. It has been 
hypothesized that high levels of the complement factor mannose-binding lectin (MBL) 
are associated with a favorable disease course of RA by binding to and hence facilitating 
the clearance of pathogenic immunoglobulin G, which lacks galactose sugar moieties 
(called agalactosyl IgG) 1. 
MBL is the initiator of the innate immunity lectin pathway of complement and its se-
rum levels are highly variable between individuals due to the presence of single nucleo-
tide polymorphisms (SNPs) in the promoter region and in exon 1 of the MBL2 gene. It 
has been shown that during pregnancy MBL levels are markedly increased and that this 
increase is strictly related to the high maternal MBL production genotypes 2. 
It has been shown in vitro that MBL can bind to pathogenic agalactosyl IgG 3. In RA-
patients levels of agalactosyl IgG decline during pregnancy and IgG galactosylation 
increases 4, 5. Therefore, it has been suggested that during pregnancy the MBL protein 
could play a role in the clearance of pathogenic (agalactosyl IgG)-immune complexes 
by serving as a scavenger molecule 1. This would decrease RA-disease activity during 
pregnancy and consequently the low levels of MBL postpartum could be responsible for 
the postpartum fl are 2.
Apart from the role of MBL in RA, MBL has also been, in healthy individuals, associated 
with pregnancy outcome like gestational age, birth weight, recurrent miscarriages, risk 
for chorioamnionitis and severe (or recurrent) pre-eclampsia 6-9. Whether the same holds 
true for RA is unknown.
We therefore not only aim to provide evidence for a role for MBL in the improvement 
of RA during pregnancy, but also for a role in the pathogenesis of RA in general, by in-
vestigating whether high MBL production genotypes are associated with improvement 
of RA disease activity and with the changes in IgG galactosylation during pregnancy and 
the postpartum fl are. Moreover, the possible association between MBL genotypes and 
pregnancy outcome in RA is studied. 
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Materials and methods 
Study population 
The current study is embedded in the PARA-study, a prospective cohort study on preg-
nancy and RA 10. In this study RA-patients are visited preferably before pregnancy, three 
times during pregnancy and three times postpartum. Disease activity of RA was scored 
using the internationally recognized disease activity score (DAS28) with three variables 
(swollen joint count, tender joint count and C-reactive protein (CRP) level) since this vari-
ant of the DAS28 is most reliable during pregnancy 11. Some cases were analyzed during 
more than one pregnancy. Controls were followed from fi rst trimester of pregnancy and 
onwards. Data of in total n = 216 Caucasian RA-patients (cases) and n = 31 healthy preg-
nant Caucasian volunteers without adverse obstetric history (controls) are included. The 
study is in compliance with the Helsinki Declaration and approved by the Ethics Review 
Board at the Erasmus MC University Medical Center, Rotterdam, The Netherlands. 
Data collection
Available data of cases diff ered per research question. To investigate whether MBL geno-
types are associated with changes in RA-disease activity during pregnancy and postpar-
tum, data of maximal n = 181 cases were available. Cases that experienced a miscarriage 
were excluded. To investigate whether MBL genotypes are associated with changes in 
IgG galactosylation data of maximal n = 145 cases were available. The association be-
tween MBL genotypes and pregnancy outcome including miscarriages could be studied 
in n = 214 cases. For the analyses of the pregnancy outcome measures birth weight and 
gestational age non-Caucasians, twin pregnancies and pregnancies that resulted in a 
child with a malformation were excluded, resulting in n = 184 cases to be studied. Data 
were analyzed with and without the cases that participated twice or more. 
Categorization of disease activity and clinical response
In accordance with the EULAR criteria remission of RA was defi ned as DAS28<2.6 and 
intermediate and high disease activity as DAS28>3.2. Improvement of disease activ-
ity during pregnancy was defi ned according to the EULAR criteria as ‘good’, ‘moderate’ 
(combined to ‘responders’) or ‘non-responders’. In line with the EULAR criteria, the re-
sponse criteria can only be applied to those patients with an initial DAS28>3.2 at fi rst 
trimester (n = 84). Deterioration of disease activity after delivery was defi ned according 
to so called ‘reversed’ EULAR criteria 10. Since there is no baseline DAS28 requirement for 
these criteria, this classifi cation was applied to all cases. An ‘early fl are’ was defi ned when 
deterioration began between six weeks and three months postpartum and a ‘late fl are’ 
with disease deterioration between three to six months postpartum. 
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MBL genotyping
Genotyping was performed using PCR LightCycler techniques as described previously 
2. Genotyping included the wildtype (A-allele) and the three SNPs of the fi rst exon of 
the structural gene: codon 52 (D-allele, rs5030737), codon 54 (B-allele, rs1800450) and 
codon 57 (C-allele, rs1800451) and two of the SNPs in the promoter region codon -550 
(H/L, rs11003125) and codon -221 (X/Y, rs7096206) of the MBL2 gene. Based upon the 
haplotypes individuals can be categorized into three groups that correlate best with MBL 
serum levels 12: the high-MBL production group A, the intermediate-MBL production 
group B and the low- or defi cient MBL production group C. 
IgG galactosylation analysis
IgG was purifi ed from serum of cases and controls as described before 13. Next, IgG galac-
tosylation was analyzed by MALDI-TOF mass spectrometry (MS) of tryptic glycopeptides 
and massspectra of IgG1 and IgG2 were processed in FlexAnalysis (Bruker Daltonics). 
Pregnancy outcome defi nitions
Preterm birth was defi ned as gestational age of <37 weeks of gestation and low birth 
weight was defi ned as a birth weight of <2500 grams. As described before, the birth 
weights analyzed were corrected for gestational age and gender of the child by using the 
birth weight standard deviation (SD) score. Birth weight SD scores as well as uncorrected 
birth weights are added to the analyses 14. Hypertensive disorders were scored according 
to the criteria of the International Society for the Study of Hypertension and Pregnancy 
(ISSHP) 7. Miscarriage was scored in case of a spontaneous loss of a pregnancy before the 
20th week. 
Statistical analysis
Statistical analysis was performed using SPSS 15.0 and SAS 9.1. A two-sided p-value ≤ 
0.05 was considered statistically signifi cant. 
The disease activity (DAS28, cases) and galactosylation profi le (cases and controls) was 
estimated using a Linear Mixed Model (LMM). Using this model possible associations 
between the MBL genotype groups and DAS28 or IgG galactosylation were investigated. 
A chi-squared analysis was performed to compare MBL genotype groups of responders 
versus non-responders, of cases with a fl are postpartum versus no fl are, of cases which had 
a miscarriage versus no miscarriage, of cases which had a preterm birth versus no preterm 
birth, and of cases with a child with low birth weight versus child with no low birth weight.
Logistic regression analysis was performed for dichotomous variables and linear regression 
was performed for linear data. Based on literature we considered the following variables 
a priori to be possible confounders (when applicable): gestational age, maternal smoking 
during pregnancy, maternal age at delivery, gender of the child, prednisone use in fi rst 
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trimester, parity, disease activity in fi rst trimester (DAS28). First, simple regression analyses 
were performed to determine which confounders had to be included in the multiple 
regression analyses.
Table 1. Cohort characteristics
Cases (n = 214) Controls (n = 31)
MBL genotype group A 114 (53.3) 16 (51.6)
MBL genotype group B 59 (27.6) 8 (25.8)
MBL genotype group C 41 (19.2) 7 (22.6)
Number of Caucasians 207 (96.7) 31 (100)
Number of nulliparous women 113/214 (52.8) 14/31 (45.2)
Mean age at delivery, years, (SD) (range) 32.5, 3.7 
(21.9 – 40.6)
32.1, 4.5
(24.2 - 40.1)
Mean gestational age at delivery, weeks (range) 39.4 (31.4-42.1) 40.0 (34.7-42.0)
Smoking during pregnancy 6/206 (2.9) 3/31 (9.7)
Miscarriage 23 (10.7) -
Hypertension 25/210 (11.7) 2 (6.5)
Pre-eclampsia 4/210 (1.9) 1 (3.2)
Anti-CCP positive 134/213 (62.9) -
Rheumatoid Factor (IgM) positive 161 (75.1) -
Erosive disease 136/210 (64.8)
Median disease duration at delivery, years (range) 7.9 (0.7-29.0) -
Use of prednisone in fi rst trimester 60/164 (36.6)
Median number of DMARDs** (incl prednisone) prior to conceive 
(min-max)
2.3 (0-6) -
Use of methotrexate prior to conceive 120/212 (56.6) -
DAS28-CRP3 >3.2 in fi rst trimester 94/155 (60.6) -
Classifi cation of disease activity during pregnancy n (%)
- Good response or moderate response 40/84 (47.6) -
- No response 44/84 (52.4) -
Classifi cation of disease activity during postpartum period (early 
fl are) n (%)
 - Severe deterioration or moderate deterioration 39/167* (23.4) -
- No deterioration 128/167* (76.6) -
Classifi cation of disease activity during postpartum period (late 
fl are) n (%)
- Severe deterioration or moderate deterioration 28/152* (18.4) -
- No deterioration 124/152* (81.6) -
Data are represented as n (%) or mean (SD or range)
* cases are missing, since in a proportion of DAS scores are missing
**DMARDs: disease modifying anti-rheumatic drugs including prednisone
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Results
Clinical characteristics of the study group
The characteristics of cases and controls are described in Table 1. 
Accuracy genotyping procedure
MBL genotypes were determined in n = 216 cases and n = 31 controls. In two cases the 
promoter SNPs could not be determined. Therefore these cases could not be grouped in 
one of the MBL genotype groups and were excluded form analyses, resulting in a total of 
n = 214 cases and n = 31 controls to be analyzed. 
No association of MBL genotype groups and RA disease activity
No signifi cant diff erence in DAS28 levels is observed between MBL genotype group A, 
B and C at all timepoints during pregnancy and postpartum (p = 0.899, fi gure 1A). Also, 
when cases were categorized in responder and non-responders-status during pregnancy 
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Figure 1. Mean RA disease activity score (DAS28) and mean IgG1 galactosylation in relation to MBL production 
genotype groups during pregnancy and postpartum in RA-cases. A) Mean RA disease activity score (DAS28) during 
pregnancy and postpartum in relation to MBL production genotype groups A (high), B (intermediate) and C (low). 
No signifi cant diff erence in DAS28 levels is observed between MBL genotype groups A, B and C at all timepoints 
during pregnancy and postpartum (p = 0.899). B) Mean IgG1 galactosylation (x100%) of RA-cases during pregnancy 
and postpartum per MBL production genotype group. No signifi cant diff erence in IgG galactosylation levels is 
observed between MBL genotype groups A, B and C at all timepoints during pregnancy and postpartum (p = 0.75). 
Data for IgG2 galactosylation and for the controls show similar results (data not shown). 
The vertical bars illustrate the 95% confi dence intervals. 
Abbreviations: trim, trimester of pregnancy; wk, weeks; PP, postpartum; mon, months.
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or cases that had an early or late fl are postpartum and cases that did not fl are postpar-
tum, no diff erences were observed between the MBL genotype groups (responders/non 
responders: MBL genotype group A versus B+C, Odds Ratio (OR) 0.91, 95% Confi dence 
Interval (CI) 0.58-1.42; early fl are/no fl are: MBL genotype group A versus B+C, OR 0.69, CI 
0.39-1.25; late fl are/no fl are: MBL genotype group A versus B+C, OR 1.00, CI 0.51-1.98). 
Similar results were found when groups A, B and C were analyzed separately (data not 
shown) and when cases that participated twice or more were excluded. 
No association of MBL genotype groups and IgG galactosylation changes 
No signifi cant diff erence in IgG1 galactosylation levels is observed between MBL geno-
type group A, B and C at all timepoints during pregnancy and postpartum as shown in 
fi gure 1B (p = 0.75, cases). Similar non-signifi cant results were obtained for IgG2 as well 
as in controls (data not shown).
Uni- and multivariate analysis revealed that MBL genotype groups do not aff ect IgG 
galactosylation levels, even after correction for possible confounders, like medication 
use, disease activity and clinical characteristics. 
No association of MBL genotype groups and pregnancy outcome in RA
In RA the gestational age or birth weight did not diff er signifi cantly between the MBL 
genotype groups (p = 0.78 and p = 0.95, respectively). Accordingly, there was a similar 
distribution of preterm birth and low birth weight infants among MBL genotype groups 
(p = 0.75 and p = 0.68, respectively). 
The distribution of miscarriages (23 of 201 cases) was also not signifi cantly diff erent be-
tween the MBL genotype groups, p = 0.81. 
All logistic regression and all linear regression analyses could not show an association be-
tween MBL genotype groups and the pregnancy outcome measures preterm birth, low 
birth weight, hypertensive disorders, or miscarriage and gestational age, birth weight SD 
score or birth weight (Table 2), even after correction for multiple possible confounders as 
described above. Subgroup analysis for nulliparous women, as well as for cases that did 
not use prednisone in the fi rst trimester of pregnancy did not reveal any eff ect of MBL on 
gestational age, birth weight or birth weight SD score (data not shown). Grouping of the 
intermediate and low MBL genotype groups B and C did not reveal a diff erent eff ect in all 
linear and logistic analyses (data not shown).
Discussion 
In this study no association was found between MBL genotype groups and improvement 
of RA during pregnancy, nor with levels of IgG galactosylation and changes thereof, 
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thereby questioning a role for MBL not only in the pregnancy-induced improvement 
of RA in particular, but also for a more general role of MBL in the pathogenesis of RA. 
Moreover, MBL genotype groups did not show statistically signifi cant associations with 
gestational age, birth weight, miscarriage and hypertensive disorders in RA-pregnancies.
Table 2. Regression analysis MBL genotype groups and pregnancy outcome measures in RA-patients. The pregancy 
outcome measures studied are gestational age, birth weight, birth weight SD score, miscarriage, hypertension, short 
gestational age and low birth weight
MBL genotype groups ABC (3 strata) MBL genotype group A vs B plus C (dichotomous)
Variable stratifi ed beta-
coeffi  cient
p-value n beta-
coeffi  cient
p-value n
Continuous variables 
Gestational age (weeks)
No correction -0.062 0.739 156 -0.085 0.767 156
Correction for all 
confounders 
-0.27 0.199 126 -0.363 0.260 126
Birth weight (grams)
No correction -25.69 0.672 157 -6.16 0.947 157
Correction for all 
confounders 
-81.76 0.205 127 -69.56 0.480 127
Birth weight SD score
No correction -0.015 0.896 156 0.03 0.865 156
Correction for all 
confounders 
-0.052 0.671 126 0.004 0.983 126
Dichotomous variables
Variable stratifi ed OR 95% CI n OR 95% CI n
Miscarriage
No correction 1.13 0.64 - 1.99 21/205 1.31 0.53 - 3.23 21/205
Correction for all 
confounders
0.99 0.53 - 1.83 20/178 1,12 0.43 - 2.87 20/178
Hypertension
No correction 0.93 0,53 - 1,66 23/174 0.72 0.30 - 1.78 23/174
Correction for all 
confounders
0.76 0.36 - 1.61 16/127 0.58 0.18 - 1.83 16/127
Gestational age <37 wks
No correction 1.30 0.68 - 2.58 14/157 1.20 0.40 - 3.60 14/157
Correction for all 
confounders 
2.12 0.80 - 5.60 13/127 2.38 0.47 - 12.1 13/127
Low birth weight <2500g
No correction 0.93 0.40 - 2.28 10/158 0.76 0.21 - 2.82 10/158
Correction for all 
confounders 
0.92 0.30 - 2.90 9/127 0.87 0.14 - 5.38 9/127
95% CI = 95% confi dence interval 
OR = adds ratio
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Previously, high MBL levels have been associated with less severe disease in RA 1. 
It has been suggested that the benefi cial eff ect of MBL results from its binding to the 
pathogenic agalactosyl IgG antibodies, and MBL may therefore function as a scavenger 
molecule involved in the effi  cient removal of pathogenic agalactosyl IgG containing im-
mune complexes 1. Because pharmaceutical induction of MBL is not yet possible, this 
hypothesis cannot be properly tested in vivo. However, during pregnancy MBL levels in-
crease and RA disease activity improves along with a decrease in the levels of pathogenic 
agalactosyl IgG. This all makes pregnancy in RA the ideal ‘experiment of nature’ to gain 
support for the aforementioned hypothesis. Nevertheless, even this ideal setting did not 
support a role for MBL in the pathogenesis of RA. 
Alternative hypotheses have been proposed to explain the pregnancy-induced im-
provement of RA, like the induction of regulatory T-cells, immunomodulatory properties 
of pregnancy hormones, a shift towards a Th2 associated cytokine profi le and immuno-
suppression as a result of increased fetal-maternal HLA disparity 15. It is likely that mul-
tiple mechanisms may work in concert to induce RA-improvement during pregnancy.
Finally, the possible association between MBL genotypes and pregnancy outcome 
was investigated. Previous literature demonstrated in healthy individuals that MBL is as-
sociated with pregnancy outcome like preterm birth, low birth weight, recurrent miscar-
riages, risk for chorioamnionitis and more severe or recurrent pre-eclampsia 6-9. Our study 
in RA-patients showed no signifi cant association between MBL genotype groups and 
the pregnancy outcome measures gestational age, birth weight, miscarriage and hyper-
tensive disorders. In line with a previous study on the eff ect of MBL on gestational age 
in healthy women 6, an association was found between preterm birth and the maternal 
high-MBL production genotype group A, although in the present study on RA-patients it 
did not reach statistical signifi cance (OR 2.38, 95% CI 0.47-12.1). For the other pregnancy 
outcome measures, like pre-eclampsia, the present study might lack power. 
In conclusion, this study does not suggest a role for MBL in the phenomenon of 
pregnancy-induced improvement of RA, nor in the pathogenesis of RA in general. Future 
studies should focus on other mechanisms to explain the pregnancy-induced remission 
of RA and the fl are postpartum. 
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1. Introduction
Rheumatoid arthritis (RA) is an autoimmune disease that is favorably infl uenced by preg-
nancy but relapses after delivery 1. Insight into this mechanism may not only increase 
our knowledge on the phenomenon of pregnancy-induced remission in RA but may 
also contribute to a better understanding of pathogenic mechanisms underlying RA in 
general. 
Until today it is unclear which mechanism or what factor could induce this remission. 
It has been hypothesized that the complement factor mannose-binding lectin (MBL) 
might play a benefi cial role that results from its binding to pathogenic agalactosyl IgG 
antibodies and may therefore function as a scavenger molecule involved in the effi  cient 
removal of pathogenic agalactosyl IgG containing immune complexes 2. 
This thesis describes the role and function of mannose-binding lectin during preg-
nancy and postpartum in healthy individuals and in RA-patients. The main objectives of 
this thesis were:
1. To determine whether pregnancy has an eff ect on MBL serum levels and IgG galac-
tosylation
2. To determine whether MBL in concert with IgG galactosylation is involved in the 
pathogenesis of RA in general and more specifi cally in the pregnancy-induced im-
provement of RA
3. To determine whether MBL is involved in pregnancy outcome in healthy controls 
and RA-patients
This chapter presents the main fi ndings of this thesis in a broader perspective (paragraph 
2), discusses methodological considerations (paragraph 3), presents the new insights ob-
tained from the fi ndings (paragraph 4) and off ers recommendations for future research 
(paragraph 5).
2. Main fi ndings
Objective 1. To determine whether pregnancy has an eff ect on MBL serum levels and IgG 
galactosylation MBL measurements during pregnancy and postpartum in healthy wom-
en showed that MBL concentrations were increased from the fi rst trimester onwards, fol-
lowed by a sharp decline postpartum, after which levels recovered. These fi ndings were 
unique for MBL, since Ficolin-2, another initiator of the lectin complement pathway was 
not infl uenced similarly. Also, the classical complement pathway was hardly infl uenced 
by pregnancy and in the postpartum period. Moreover, it was shown that the increase in 
MBL levels was strictly related to the maternal MBL genotype (Chapter 2).
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Determination of IgG galactosylation during pregnancy and postpartum in healthy 
women and in RA patients showed an increase in IgG galactosylation during pregnancy 
and a decrease in the postpartum period. These galactosylation changes were also as-
sociated with disease activity changes in RA during pregnancy and postpartum. Namely, 
cases that experience improved disease activity during pregnancy (responders) expe-
rienced a larger increase in galactosylation than non-responders. The reverse was true 
for cases that experienced a postpartum fl are of the disease; these cases experienced a 
larger decrease in lgG galactosylation. Multivariate analysis revealed that both RA dis-
ease activity and timepoint of measurement during pregnancy or postpartum had the 
largest infl uence on IgG galactosylation levels, and not medication use or breast feeding 
postpartum. Moreover it was shown that at all timepoints during and after pregnancy 
there was a good correlation between galactosylation and sialylation of IgG. This is note-
worthy since recent literature suggests that the eff ector functions of IgG are mainly a 
result of changes in sialylation and not of galactosylation 3 (Chapter 6).
Objective 2. To determine whether MBL in concert with IgG galactosylation is involved 
in the pathogenesis of RA in general and more specifi cally in the pregnancy-induced 
improvement of RA
First, the association between RA disease susceptibility and disease severity and MBL 
genotypes was studied. In RA confl icting studies have been described on the associa-
tion between MBL genotypes and disease susceptibility and severity. By studying two 
large cohorts of n = 375 and n = 259 non-pregnant RA-patients, it was shown that MBL 
genotype groups are not associated to RA disease susceptibility and disease severity (as 
defi ned by the need for anti-TNF therapy). MBL genotype groups were neither associated 
with RA disease characteristics like (positive) autoantibody titers of anti-CCP, IgA-, IgM- 
and IgG-RF (Chapter 5). 
Next, the possible association between improvement of RA disease activity during 
pregnancy and MBL genotypes was studied. It was shown that MBL groups are not as-
sociated with improvement of RA disease activity during pregnancy or with the post-
partum fl are. Since literature showed that MBL binds to pathogenic agalactosyl IgG in 
vitro and therefore could possibly act as scavenger of pathogenic IgG during pregnancy, 
this hypothesis was also tested. However, it was shown that MBL genotypes are not as-
sociated with the changes in IgG galactosylation during pregnancy and postpartum in 
RA-cases and controls (Chapter 7). 
Objective 3. To determine whether MBL is involved in pregnancy outcome in healthy con-
trols and RA-patients
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It was shown that MBL levels are increased during healthy pregnancy and that this was 
most pronounced in women belonging to the high-MBL production genotype group. 
This fi nding might suggest a physiological role for MBL in pregnancy. Therefore, the as-
sociation of MBL genotype groups and pregnancy outcome (birth weight, gestational 
age and pre-eclampsia) was studied in healthy women as well as in RA-patients. First, 
pre-eclampsia was studied in relation to MBL genotypes in the cohort of healthy nul-
liparous women. It was demonstrated that low-MBL production genotypes might pre-
dispose to severe pre-eclampsia or eclampsia. MBL genotypes were not associated with 
pre-eclampsia itself. Hypertensive disorders during pregnancy are thought to result from 
inadequate formation of the placenta in the beginning of pregnancy. Adequate forma-
tion of the placenta requires continuous tissue remodeling and apoptosis. Since MBL is 
thought to be involved in the clearance of apoptotic cells and cell debris, the associa-
tion of low-MBL production genotypes with severe pre-eclampsia might be explained 
by the fact that when MBL levels are low, these apoptotic cells are cleared less effi  ciently. 
This could induce excess infl ammation resulting in inadequate formation of the placenta 
(Chapter 3). 
Moreover, in contrast to our hypothesis, in the same cohort of healthy nulliparous 
women, the high-MBL production genotype group is associated with shorter gestational 
age and subsequently lower birth weight (Chapter 4). 
The two main fi ndings of chapter three and four, namely a trend in the association 
between low-MBL production genotype groups and severe pre-eclampsia and eclamp-
sia and the association of high-level MBL genotype groups and preterm birth, could be 
reconciled by acknowledging the fact that placentation in early pregnancy and delivery 
at the end of pregnancy are two distinct immunological processes. In these diff erent pro-
cesses the immune system, and MBL in particular, may play diff erent roles (that is an anti-
infl ammatory and a pro-infl ammatory role), which clearly have to stay in balance during 
the diff erent physiological processes in pregnancy. An anti-infl ammatory role for MBL is 
proposed from early pregnancy onwards in balancing apoptosis and infl ammation. Pre-
viously, healthy pregnancy has been proposed as being dependent on an adequate level 
of infl ammation 4; excessive infl ammation seems to be associated with pre-eclampsia 5. 
The level of infl ammation may be dependent on apoptotic syncytiotrophoblast debris 
shed into the circulation from the placenta: if the shedding of debris becomes excessive 
or if the clearance becomes defi cient, too much infl ammation may result. One function 
of MBL may be clearance of apoptotic cell material in the circulation 6-8 and it is thus pos-
sible that pregnant women with low MBL may be at higher risk of excessive infl ammatory 
responses due to failure of this clearance. On the other hand, towards delivery MBL may 
play a pro-infl ammatory role in the initiation of parturition, since high-MBL production 
genotypes are associated with earlier birth. This pro-infl ammatory eff ect is probably due 
to MBL’s role as initiator of the lectin complement pathway.
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Since MBL was associated with the pregnancy outcome measures gestational age and 
pre-eclampsia in healthy women, this hypothesis was also tested in RA-patients from 
increased clearance
of pathogenic
agalactosyl IgG
interaction of MBL with
pathogenic agalactosyl IgG
interaction of
sialylated IgG
with SA receptor
on macrophage
upregulation of
Fc γ receptor IIb
on macrophage
inhibitory
during pregnancy more IgG sialylation, hence
more inhibitory Fc γ receptor IIb interaction
normal condition
activating
inhibitory activating
increased threshold for
activation by pathogenic
agalactosyl IgG
reduced inflammation reduced inflammation reduced inflammation
Previous hypothesis Proposed hypotheses
agalactosyl IgG galactosylated IgG sialylated IgG inhibitory Fc γ
receptor IIb
MBL macrophage SA receptor activating Fc γ
receptors
Figure 1. Previous and proposed mechanisms of improvement of RA during pregnancy. 
A) MBL binds to (pathogenic) agalactosyl IgG, but not to normally galactosylated IgG. It is hypothesized that 
the agalactosyl IgG-MBL complex can therefore be more effi  ciently cleared. Galactosylated IgG is not cleared, 
since there is no binding to MBL. Clearance of pathogenic agalactosyl IgG leads to reduced infl ammation. B) It 
is hypothesized that sialylated IgG Fc protein interacts with macrophages via a specifi c receptor. As a result the 
macrophages upregulate the expression of the inhibitory Fc gamma receptor IIb on their surface which in turn 
raises the threshold required for pathogenic agalactosyl IgG to engage with activating Fc receptors and to trigger 
the infl ammatory process. Hence, this leads to reduced infl ammation. C) Agalactosyl IgG preferentially binds to 
activating Fc receptors expressed by macrophages leading to macrophage activation (right side of the balance), 
whereas sialylated IgG preferentially binds to inhibitory Fc gamma receptors on the macrophages leading to 
suppression of macrophage function (left side of the balance). During pregnancy, when the ratio of sialylated IgG is 
increased, the balance is tipped towards more interaction with inhibitory Fc gamma receptor IIB, leading to reduced 
infl ammation. 
Abbreviations: FcRIIb: Fragment crystallizable gamma receptor IIb; MBL: mannose-binding lectin; SA: sialic acid 
Adapted from Kaveri 200810 and Anthony 20089
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the PARA-cohort (Pregnancy-induced Amelioration of Rheumatoid Arthritis-cohort). 
However, in contrast to the fi ndings in healthy individuals, MBL genotype groups are not 
related to gestational age, birth weight, miscarriage, and hypertensive disorders within 
the PARA-cohort. These fi ndings might be explained by the fact that the PARA-cohort is 
a quite heterogeneous group of nulli- and multiparous women with diff erent levels of 
disease activity, which can infl uence pregnancy outcome, although correction for these 
confounders still did not reveal a signifi cant correlation (Chapter 7).
When the results of this thesis are taken together, it can be concluded that, despite 
the main hypothesis, MBL does not play a role in RA and pregnancy-induced remission 
of RA and the fl are postpartum. MBL does play a role in pregnancy outcome in healthy 
controls, but not evidently in RA-patients. It was shown that improvement of RA during 
pregnancy was associated with increased galactosylation of IgG. This increased galacto-
sylation also resulted in increased sialylation during pregnancy. These sialic acid sugar 
moieties can infl uence the balance between activating and inhibitory Fc  receptors to-
wards the inhibitory receptors IIb by preferential binding and therefore lead to a reduced 
infl ammatory profi le 9. Moreover enhanced expression of the inhibitory Fc  IIb receptor 
on macrophages after interaction with sialylated IgG can raise the threshold required to 
trigger an infl ammatory response leading to reduced infl ammation10. These mechanisms 
could provide alternative hypotheses to explain the pregnancy-induced improvement of 
RA and the postpartum fl are (Figure 1). 
3. Methodological considerations
This paragraph describes the strengths and limitations of the research described in this 
thesis, divided into specifi ed subjects. 
3.1 MBL genotype groups
MBL can be studied by measuring its protein level in serum or by determining its geno-
type. Chapter 2 shows that MBL serum levels are infl uenced by pregnancy and the post-
partum period and that MBL levels during pregnancy are dependent on the maternal 
and not the fetal MBL genotypes. Both chapter 2 and 5 show an excellent correlation 
between MBL serum levels and MBL genotypes. Therefore in subsequent studies MBL 
genotypes were categorized into three groups that are associated with high, intermedi-
ate or low MBL protein concentrations in the serum, which correlate best with MBL levels 
in the serum, as was also shown by other researchers previously 11, 12. The advantage of 
combining and hence reducing all known SNPs in the MBL gene into three MBL genotype 
groups, is that in statistical analyses multiple testing can be avoided. The disadvantage is 
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that it is not always possible to compare the results with previous literature that used a 
diff erent categorization, as discussed in chapter 5. 
The majority of the participants of the PARA-study is Caucasian (96%), indicating that 
the results of the studies may only be generalized to Caucasian populations, since the 
frequency of MBL polymorphisms diff ers between populations. It should be noted that 
the frequencies of MBL polymorphisms are not related to gender or age, and that there-
fore the results of chapter 5 can be applied to the general Caucasian population of all 
gender and age.
3.2 Candidate gene approach
In this thesis a candidate gene approach was chosen to unravel the role of MBL in RA 
disease susceptibility and severity and various pregnancy outcome measures in healthy 
controls as well as in RA-patients. By choosing one promising protein and studying its ef-
fect clear conclusions can be drawn from research. This is also a strong point of our stud-
ies. This is in contrast to the increasingly prevalent genome wide association studies in 
which identifi cation of multiple genetic risk alleles without prior knowledge of function 
is performed because of technological advances in high-throughput genotyping 13. This 
approach sometimes leads to multiple candidate genes with unknown functions, the 
risk of false positive results and of yet unknown importance, demanding further studies.
3.3 Study cohorts 
3.3.1 The PARA-study cohort
Size
The PARA-study cohort (Pregnancy-induced Amelioration of Rheumatoid Arthritis) is an 
unique cohort that prospectively followed n = 350 RA-patients from pre-conception, 
during pregnancy and up to six months postpartum with not only clinical data, but also 
blood and urine samples. This has never been done before. It was possible to compose 
this large(st) cohort of RA-patients with a pregnancy-wish or an early pregnancy due to 
a committed network of national rheumatologists that work closely together and the 
good infrastructure in the Netherlands that enabled us to visit all participants at home. 
Dedication by the participants of the PARA-study was overwhelming, since the drop-
out rate was less than 1% and some women even participated more than one pregnancy. 
This was even more noteworthy since all women underwent six or seven home visits, 
while fi lling in questionnaires and donating blood- and urine samples each time. This 
dedication might be explained by the severe impact of the disease on daily life. The need 
for more information on RA and pregnancy is great; there are still many questions that 
need answers, not only for RA-patients, but also for rheumatologists and others. 
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Validated instruments to determine disease activity 
One of the strengths of our studies is that within the PARA-study cohort internationally 
recognized outcome measures like DAS28 and EULAR response criteria were used. The 
variant of the DAS28 used in these studies was also validated for use during pregnancy 14. 
Responders and non-responders
Since a large number of RA-cases could be studied, it was feasible to divide the cohort 
(using internationally recognized criteria) into cases that have reduced disease activity 
during pregnancy (named responders) and cases that do not improve during pregnancy 
(named non-responders). Conversely, in the postpartum period also cases could be 
identifi ed as experiencing a fl are (early or late) postpartum and cases that do not experi-
ence an (early or late) fl are postpartum. Thus far it had never been possible to create 
this subdivision. It is important to make this subdivision since it enables us to determine 
whether the observed changes in the immune system during pregnancy were merely a 
result of pregnancy or clearly associated with the phenomenon of pregnancy-induced 
improvement of RA. 
Reference group
By comparing our data with a control group of 32 healthy pregnant women within the 
PARA-study, which were followed from the fi rst trimester and onwards, it was feasible to 
diff erentiate which pregnancy-induced changes were unique to pregnancy and which 
were distinctive in RA. This strengthened the results found compared to previous litera-
ture.
Recovery from pregnancy
The PARA-study cohort had a longer follow-up time in the postpartum period than 
earlier studies, which enabled the description of the early and late postpartum fl ares. 
However, it became apparent that at the last visit at six months postpartum the RA-cases 
and controls might not have fully recovered from their pregnancies. Therefore it could be 
questioned whether this would be the best endpoint of measurement in the study. This 
should be taken into consideration when interpreting the results. 
Heterogeneity and generalizability 
The PARA-study cohort is a heterogeneous cohort, since nulli- and multiparous women 
were included with diff erent RA-disease durations, using diff erent medications result-
ing in diff erent RA-disease activities. Since all RA-patients were included provided they 
fulfi lled the ACR 1987 criteria, the conclusions based on this cohort can consequently be 
extrapolated to a large population.
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3.3.2 Cohorts to study the association between MBL and RA disease susceptibility and severity
Replication cohort
In chapter 5 the possible association between MBL and RA disease susceptibility and 
severity was studied. To allow confi rmation of the (negative) results found, also a large 
replication cohort was recruited. Including a replication cohort is in line with the recent 
recommendations of the National Cancer Institute and National Human Genome Re-
search Institute (NCI-NHGRI) Working Group on Replication in Association Studies 15. The 
Working Group pleaded for large sample size genotype-phenotype studies that replicate 
both positive as well as negative fi ndings in multiple well-described cohorts with enough 
power and clear statistics and also pleaded for publishing the so-called negative studies. 
3.3.3 The pre-eclampsia and healthy nulliparous controls cohort
Homogeneity
The last cohort studied in this thesis, the retrospective cohort of 157 nulliparous cases 
with pre-eclampsia and 157 healthy nulliparous controls, had a very homogeneous 
composition due to strict inclusion criteria, which increased the strength of power and 
enabling to make strong conclusions. However no replication cohort was available to 
confi rm the results found. 
4. New insights 
The studies in this thesis have contributed to multiple new insights into MBL, RA and 
pregnancy. 
First, it has been shown that MBL protein levels increase from the fi rst trimester of 
pregnancy onwards and decrease sharply postpartum. It was also apparent that it took at 
least six months after delivery for MBL levels to reach the levels from before conception. 
Therefore, taking into account that MBL levels are subject to change in the postpartum 
period, it would be recommended that MBL measurements in the context of research and 
clinical diagnosis should not be performed before a minimum of six months postpartum. 
Second, the early rise in MBL levels during early healthy pregnancy may indicate that 
MBL contributes to normal placentation and ongoing pregnancy, as is underscored by 
our fi ndings of a trend in the association between low-MBL production genotype groups 
and severe pre-eclampsia. Normal placentation requires apoptosis and turnover of tro-
phoblasts. One of the roles of MBL could be to bind to apoptotic cells to enhance their 
opsonization and subsequent removal. 
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Third, it was shown that the maternal high MBL genotype group predisposes to pre-
mature birth in healthy individuals, suggesting that during pregnancy MBL-associated 
infl ammation caused by higher MBL activity may contribute to earlier delivery and con-
sequently to lower birth weight. Individuals with MBL defi ciency are more prone to infec-
tions, however the high prevalence of MBL defi ciency in the general population (up to 
50%) suggests an evolutionary advantage of MBL-defi ciency as well 12. The fi nding of this 
study that women with MBL defi ciency have pregnancies of longer duration and hence 
give birth to children with a better start in life could be such an advantage. 
Next, the increase in MBL during pregnancy, as a central component of innate im-
munity, may also refl ect a shift from adaptive to innate immunity during pregnancy, to 
compensate for reduced T-cell function during a state of reduced adaptive immunity as 
pregnancy is. 
Also, it was shown for the fi rst time that maternal, and not fetal, MBL genotypes are 
associated with MBL protein levels during pregnancy, making maternal-fetal transfer of 
MBL across the placenta less likely. 
Another new insight is the fact that MBL genotype groups are not associated with 
RA susceptibility and severity and that those MBL genotypes that result in the most 
prominent rise in MBL levels are not associated with improvement of RA disease activity 
during pregnancy. Therefore modulation of MBL serum levels will not be the lead for the 
development of new therapeutics in RA. 
Moreover, the fi nding that not only IgG galactosylation but also IgG sialylation 
changes are associated with RA disease activity during pregnancy and in the postpartum 
period is a new insight. IgG galactosylation has a good correlation with IgG sialylation. 
One could speculate that when the factors that actually infl uence IgG galactosylation as 
well as sialylation are known, that this could have clinical consequences for RA-patients. 
In other auto-immune diseases like Guillain-Barré syndrome, immune-mediated throm-
bocytopenia or Kawasaki disease it has recently been shown that increased sialylation of 
intravenous immunoglobulin (IVIG) signifi cantly enhanced the therapeutic eff ect of IVIG 
by reducing infl ammation 3, 10, 16, 17.
5. Future directions 
This chapter will elaborate on some of the opportunities for future research on the follow-
ing topics: 1) the PARA-study: RA and pregnancy; 2) elucidation of pregnancy-induced 
improvement of RA; 3) IgG galactosylation and sialylation and their anti-infl ammatory 
eff ects; and 4) MBL and pregnancy outcome. 
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PARA-study: RA and pregnancy
The PARA-study cohort provides extensive clinical and serological data. Still many rele-
vant research questions on RA and pregnancy can be answered with the information not 
yet analyzed. For example or it could be determined whether disease activity or medi-
cation use plays a role in fecundity or fertility within RA-patients. In the population of 
women that participated twice in the PARA-study, it can be investigated whether women 
experience the same change in disease activity during pregnancy and postpartum in 
subsequent pregnancies and what could be possible infl uential factors. 
Elucidation of pregnancy-induced improvement of RA
Other theories on pregnancy-induced improvement and RA are also worthwhile to test, 
like pregnancy-induced hormones, regulatory T-cells, Th1/Th2 cytokine balances, the 
role of IL-17 and IgG sialylation. It can be hypothesized that diff erential levels of preg-
nancy-induced hormones between responders and non-responders of the PARA-study 
could provide directions to study the pregnancy-induced remission of RA. Regulatory T-
cells (Treg) are induced during pregnancy and secrete IL-10, which provides an enhanced 
suppression of pro-infl ammatory cytokines produced by eff ector T cells 18. Whether Tregs 
are diff erentially expressed in responders and non-responders is not yet known. The Th1/
Th2 cytokine balance, with the associated T-cell derived cytokines during pregnancy and 
in the postpartum period can be studied in the materials available. Additionally, the role 
of the promising interleukin-17, which may play an infl ammatory role in RA 19 could be 
studied in a state of reduced infl ammation like during pregnancy and conversely post-
partum. 
IgG galactosylation and sialylation and their anti-infl ammatory eff ects
This thesis proposes a new hypothesis that IgG galactosylation and consequently IgG 
sialylation might play a role in pregnancy-induced improvement of RA (Figure 1). It 
would be interesting to further study factors that may infl uence IgG galactosylation or 
sialylation. The enzymatic activity responsible for glycosylation (galactosylation and si-
alylation) within these B-cells during pregnancy could be studied in vitro, by culturing 
the cells with pregnancy-associated hormones or cytokines. Identifi cation of the mecha-
nism behind sialylation during pregnancy would enable us to pharmaceutically induce 
sialylation in vivo. It could be hypothesized that factors that increase sialylation would be 
more abundant in responders than in non-responders during pregnancy, and the reverse 
postpartum.
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MBL and pregnancy outcome 
It has been shown that MBL may play a role in pregnancy outcome, like gestational age, 
birth weight and pre-eclampsia. It could be studied further whether there are other 
pregnancy outcomes with which MBL is associated. 
In conclusion, future studies should focus on unraveling the mechanism behind improve-
ment of RA during pregnancy and the fl are postpartum. It may be that changes in IgG 
galactosylation and sialylation play a role during pregnancy and postpartum. The role of 
MBL in RA has been studied in detail and may need no further elaboration. It should be 
noted though, that it is still unsure whether there is actually one factor to be identifi ed 
that induces remission of RA during pregnancy. It might be more likely that multiple 
factors work in concert to infl uence disease activity.
6. Final remarks
The studies performed in this thesis do not fully elucidate the phenomenon of pregnan-
cy-induced improvement of RA and the fl are postpartum. It has been shown that MBL 
levels rise during pregnancy and decrease postpartum, but MBL did not induce improve-
ment of RA during pregnancy and a fl are of the disease after delivery. Moreover, MBL is 
not a risk factor for the susceptibility of RA and disease severity in RA.
Another hypothesis for the pregnancy-induced improvement of RA and the fl are post-
partum was therefore studied. It has been shown that the changes in IgG galactosylation 
and sialylation during pregnancy and postpartum were associated with improvement 
and deterioration of RA disease activity, respectively. It is hypothesized that the sialic acid 
sugar moieties can infl uence the balance between activating and inhibitory Fc-gamma 
receptors towards the inhibitory receptors by preferential binding and therefore lead to 
a reduced infl ammatory profi le. Moreover enhanced expression of inhibitory Fc-gamma 
receptor on macrophages after interaction with sialylated IgG can raise the threshold 
required to trigger an infl ammatory response.
MBL genotype groups are associated with pregnancy outcome measures, showing an 
anti-infl ammatory role for MBL in early pregnancy and a pro-infl ammatory role towards 
delivery. Healthy women with low-MBL production genotypes seem to have an increased 
risk for severe pre-eclampsia or eclampsia, but have  a longer duration of pregnancy. This 
eff ect was not reproduced in the RA-patients of the PARA-cohort, probably because of 
the heterogeneity of this cohort.
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Summa ry
This thesis aimed to describe the role of mannose-binding lectin (MBL) during pregnancy 
and postpartum in healthy individuals and in RA-patients (Chapter 1). The main objec-
tives of this thesis were: (1) To determine whether pregnancy has an eff ect on MBL serum 
levels and IgG galactosylation, (2) To determine whether MBL in concert with IgG galac-
tosylation is involved in the pathogenesis of RA in general and more specifi cally in the 
pregnancy-induced improvement of RA, and (3) To determine whether MBL is involved in 
pregnancy outcome in healthy controls and RA-patients.
The fi rst objective is addressed in Chapter 2 and 6, the second objective is addressed in 
chapters 5 and 7, and the last objective in Chapter 3, 4 and 7. 
Chapter 2 describes MBL levels during healthy pregnancy. In healthy women MBL 
concentrations were increased from the fi rst trimester of pregnancy onwards. In the AA-
genotype MBL serum concentrations increased to 177% (median, interquartile range 
(IQR) 124–212%, p < 0.001), the AO-genotype increased to 126% (median, IQR 91–144%, 
p < 0.04) and the OO-genotype to 117%, all compared with baseline value. After parturi-
tion MBL levels declined sharply. In the AA-genotype was a decline of 55% of baseline 
concentration (p < 0.0001); in the AO-genotype 60% (p < 0.03) and in the OO-genotype 
65% of baseline concentration. After the decline the MBL levels normalized again. It was 
shown that levels of MBL were strictly related to the maternal, and not the fetal MBL 
genotype. 
The serum concentrations of Ficolin-2, a second initiator of the lectin complement path-
way, as well as the classical complement pathway activity, were hardly infl uenced by 
pregnancy or the postpartum period, indicating a unique eff ect of pregnancy on MBL. 
Moreover, the variations in MBL levels were refl ected by similar changes in the following 
steps of MBL complement pathway activation. It could be concluded that pregnancy and 
the postpartum period profoundly infl uence MBL serum concentration and MBL comple-
ment pathway activity.
In chapter 3 the fi rst of two studies on the association between MBL genotype groups 
and pregnancy outcome in healthy women is described. Since it was demonstrated that 
MBL levels were increased during healthy pregnancy, the role of MBL genotypes in preg-
nancy outcome (birth weight, gestational age and pre-eclampsia) was studied. In a co-
hort of nulliparous women (n = 157 with pre-eclampsia and n = 157 with uncomplicated 
pregnancies) a trend was shown in the association between low-MBL production geno-
types and severe pre-eclampsia (odds ratio (OR) 3.38, 95% CI 0.47 – 24.23) or eclampsia 
(OR 14.70, 95% CI 1.18 – 182.76), but not with pre-eclampsia itself. The association of 
low-MBL production genotypes with severe pre-eclampsia might be explained by the 
following. Hypertensive disorders such as pre-eclampsia during pregnancy are thought 
to result from inadequate formation of the placenta in the beginning of pregnancy. Ad-
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equate formation of the placenta requires continuous tissue remodelling and apoptosis. 
MBL is thought to be involved in the clearance of apoptotic cells and cell debris. When 
MBL levels are low, these apoptotic cells are cleared less effi  ciently. The remaining cell de-
bris could induce excess infl ammation resulting in inadequate formation of the placenta 
and risk of pre-eclampsia.
Chapter 4 presents the second study on the association between MBL genotype 
groups and pregnancy outcome in n = 157 healthy nulliparous women, namely the out-
come measures gestational age and birth weight. The high-MBL production genotype 
group was associated with shorter gestational age (p = 0.002) and subsequently lower 
birth weight. Twelve of the 14 preterm births (87.5%) were from women with the high-
MBL genotype group, while this group forms only 56% of the whole cohort. 
Chapter 5 deals with the previous confl icting results on the association between MBL 
genotypes and RA disease susceptibility and severity. In two large cohorts of n = 375 
and n = 259 RA-patients it was shown that MBL genotype groups are not associated 
with RA susceptibility and disease severity (as defi ned by the need for anti-TNF therapy), 
unrelated to pregnancy. MBL genotype groups were neither associated with RA disease 
characteristics like positive autoantibody titers of anti-CCP, IgA-, IgM- and IgG-rheuma-
toid factor. The strength of this study was the fact that all outcomes were confi rmed by 
a second RA-cohort. Compared with previous smaller studies these results add to more 
defi nite conclusions on the absence of an association between MBL and RA disease sus-
ceptibility and severity. 
Chapter 6 studies galactosylation and sialylation of IgG during pregnancy and in the 
postpartum period, as an alternative hypothesis for pregnancy-induced improvement 
of RA. By applying the MALDI-TOF mass spectrometer it was shown that IgG1 and IgG2 
galactosylation was increased during pregnancy and was decreased in the postpartum 
period, albeit at a lower level than controls (n = 148 RA-patients and n = 32 controls, p 
< 0.001). These IgG galactosylation changes were also associated with disease activity 
changes (DAS28) in RA during pregnancy and postpartum (R between 0.35 and 0.49, p < 
0.005, dependent on timepoint of measurement). Cases that had improved disease activ-
ity during pregnancy (responders) experienced a larger increase in IgG galactosylation 
than non-responders (p < 0.02). The reverse was true for cases that had a postpartum 
fl are of the disease; these cases experienced a larger decrease in galactosylation (p < 
0.0001). Additionally, it was shown that the presence of the sialic acid sugar moiety is 
highly associated with IgG galactosylation (R between 0.57 and 0.69, p < 0.0001). Mul-
tivariate analysis revealed that both RA disease activity and timepoint of measurement 
during pregnancy or postpartum had the largest infl uence on IgG galactosylation levels, 
and not medication use or breast feeding postpartum. 
Chapter 7 aimed to investigate whether increased MBL levels (or high-MBL produc-
tion genotypes) in concert with increased IgG galactosylation are associated with preg-
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nancy-induced improvement of RA. No association was found between MBL genotype 
groups and changes in RA-disease activity (p = 0.89) and changes in IgG galactosylation 
(cases p = 0.75 and controls p = 0.54) during pregnancy and postpartum. Therefore, it 
can be concluded that MBL does not function as a scavenger molecule involved in the 
removal of pathogenic agalactosyl IgG. Furthermore, in RA MBL genotype groups are not 
related to the pregnancy outcome measures gestational age, birth weight, miscarriage, 
and hypertensive disorders. It can therefore be concluded that future studies should 
focus on other mechanisms to explain the pregnancy-induced remission of RA and the 
fl are postpartum.
Chapter 8, the general discussion, starts with presenting the main fi ndings in the light 
of the study objectives, followed by methodological considerations. New insights arisen 
from this thesis into MBL, RA and pregnancy are described. Finally, recommendations for 
future studies are presented, with an emphasis on the possible anti-infl ammatory eff ects 
of IgG galactosylation and sialylation.  
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Samen vatting
Dit proefschrift beschrijft de rol van het complement eiwit mannose-bindend lectine 
(MBL) gedurende de zwangerschap en na de bevalling (postpartum) bij gezonde vrou-
wen en bij vrouwen met reumatoïde artritis (RA). 
RA is een chronische infl ammatoire autoimmuunziekte van de gewrichten waarbij de 
ziekteactiviteit vaak afneemt tijdens de zwangerschap. Na de bevalling vlamt de ziekte 
dikwijls weer op. MBL is een eiwit dat onderdeel is van het aangeboren immuunsysteem 
en zou een rol spelen bij het verwijderen van pathogene autoantistoff en (bijvoorbeeld 
immunoglobulinen, zoals IgG), die ook bij RA bekend zijn. Deze autoantistoff en worden 
deels verantwoordelijk gehouden voor de ziekteactiviteit bij RA. De beste MBL-binding 
zou zijn met die immunoglobulinen, die galactose suikermoleculen missen. Juist deze 
antilichamen zijn pathogeen, in die zin dat ze ziekte-bevorderend werken in RA. De 
stijging van MBL in het bloed tijdens de zwangerschap zou ervoor kunnen zorgen dat 
er minder pathogene immunoglobulinen circuleren, omdat MBL deze zou ‘wegvangen’, 
waardoor er een lagere ziekteactiviteit zou ontstaan tijdens de zwangerschap. Omge-
keerd kan er ook een hogere ziekteactiviteit postpartum ontstaan, als de MBL spiegels 
zijn afgenomen en minder pathogene immunoglobulinen worden weggevangen. 
Als lage MBL serum concentraties vaker gemeten worden bij patiënten met RA of vrou-
wen die een vroeggeboorte of miskraam kregen, zou dit relatieve tekort aan MBL een 
oorzakelijke factor kunnen zijn. 
De volgende vraagstellingen staan centraal in dit proefschrift: (1) Heeft zwanger-
schap invloed op MBL serum concentraties en IgG galactosylering; (2) Zijn MBL en IgG 
galactosylering betrokken bij de pathogenese van RA in het algemeen en meer specifi ek 
bij de zwangerschapgeïnduceerde verbetering van RA; (3) Is MBL betrokken bij zwan-
gerschapsuitkomsten zoals vroeggeboorte, miskramen en laag geboortegewicht bij ge-
zonde vrouwen of bij vrouwen met RA. Hierbij wordt onderzocht of bepaalde genotype 
groepen van MBL, die zorgen voor verschillende serumconcentraties van MBL buiten de 
zwangerschap, geassocieerd zijn met vooraf gedefi nieerde zwangerschapsuitkomsten. 
De eerste doelstelling wordt onderzocht in hoofdstuk 2 en 6, de tweede doelstelling in 
hoofdstuk 5 en 7 en de laatste doelstelling wordt beschreven in hoofdstuk 3, 4 en 7. 
Hoofdstuk 1 geeft een algemene introductie over de onderwerpen beschreven in 
dit proefschrift en plaatst de doelstellingen in een breder kader. Hoofdstuk 2 beschrijft 
de MBL concentraties tijdens de zwangerschap en de postpartum periode van gezonde 
vrouwen. Bij gezonde vrouwen waren de MBL concentraties gedurende de gehele zwan-
gerschap verhoogd. Dit begon al in het eerste trimester. Bij het wildtype AA-genotype 
steeg de MBL concentratie tot 177% (mediaan, interquartile range (IQR) 124-212%, p < 
0.001), het AO-genotype steeg tot 126% (mediaan, IQR 91–144%, p < 0.04) en het OO-
genotype tot 117%, allen vergeleken met de concentratie buiten de zwangerschap. Na 
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de bevalling was er een scherpe daling van MBL spiegels. Voor het AA-genotype was er 
een daling van 55% (p < 0.0001), voor het AO-genotype was dit 60% (p < 0.03) en voor 
het OO-genotype een daling van 65% ten opzichte van de concentratie buiten de zwan-
gerschap. Hierna normaliseerden de concentraties weer. De hoogte van de MBL serum 
concentraties werd uitsluitend verklaard door het maternale, en niet door het foetale 
genotype. 
De concentraties van fi coline-2, een tweede initiator van de lectine complement cas-
cade, werden nauwelijks beïnvloed door zwangerschap of de postpartum periode. Dit 
benadrukt het unieke eff ect van zwangerschap op de MBL concentraties. Tevens werd 
gevonden dat de verhoging en verlaging van de MBL spiegel gevolgen had voor de 
activiteit van de gehele lectine complement cascade. De activiteit van de lectine com-
plement cascade nam toe met het stijgen van de MBL spiegels tijdens de zwangerschap 
en nam af met het dalen van de spiegels in de postpartum periode. Hieruit kan gecon-
cludeerd worden dat zwangerschap en de postpartum periode een belangrijke invloed 
hebben op MBL concentraties en lectine complement cascade activiteit. 
In hoofdstuk 3 wordt de eerste van twee studies gepresenteerd die een mogelijke as-
sociatie tussen MBL genotype groepen en zwangerschapsuitkomst in gezonde vrouwen 
onderzoeken. Aangezien was aangetoond dat MBL concentraties stegen tijdens de zwan-
gerschap van gezonde vrouwen werd besloten de associatie van MBL genotype groepen 
met zwangerschapsuitkomsten (geboortegewicht, zwangerschapsduur en zwanger-
schapsvergiftiging) te onderzoeken. Zwangerschapsvergiftiging (pre-eclampsie) is een 
ernstig ziektebeeld dat zich kenmerkt door een hoge bloeddruk (hypertensie) en eiwit-
ten in de urine (proteïnurie) tijdens de zwangerschap. Deze eerste studie onderzoekt de 
mogelijke relatie tussen MBL genotype groepen en pre-eclampsie. In een onderzoeks-
cohort van vrouwen die nog nooit bevallen waren (nullipara, n = 157 met pre-eclampsie 
en n = 157 met ongecompliceerde zwangerschappen) werd een trend gevonden in de 
associatie tussen de lage-MBL productie genotype groep en ernstige pre-eclampsie (een 
gevorderde vorm van pre-eclampsie, odds ratio (OR) 3.38, 95% betrouwbaarheidsin-
terval (BI) 0.47-24.23) en eclampsie (ernstige pre-eclampsie met epileptische insulten, 
OR 14.70, 95% BI 1.18 – 182.76), maar niet met pre-eclampsie. De associatie tussen de 
lage-MBL productie genotype groep en ernstige pre-eclampsie/eclampsie zou als volgt 
verklaard kunnen worden. Normale gezonde aanleg van de placenta in het begin van de 
zwangerschap wordt gekenmerkt door een continue proces van ombouwen van placen-
taweefsel, waarbij geprogrammeerde celdood (apoptose) een belangrijke rol speelt. MBL 
is betrokken bij de klaring van deze apoptotische cellen en celpuin (débris). Hyperten-
sieve aandoeningen tijdens de zwangerschap, zoals pre-eclampsie, zouden veroorzaakt 
worden door gebrekkige aanleg van de placenta. Als er lage MBL concentraties zijn, kun-
nen de apoptotische cellen minder effi  ciënt weggeruimd worden. Het achterblijven van 
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celdébris zou dan een ontstekingsreactie kunnen veroorzaken en als gevolg daarvan een 
gebrekkige aanleg van de placenta en verhoogd risico op pre-eclampsie. 
Hoofdstuk 4 beschrijft de tweede studie die een mogelijke associatie tussen MBL 
genotype groepen en zwangerschapsuitkomst in n = 157 gezonde nullipara onderzocht. 
Deze studie analyseert de mogelijke relatie tussen MBL genotype groepen en zwanger-
schapsduur en/of geboortegewicht. De hoge-MBL productie genotype groep was ge-
associeerd met een kortere zwangerschapsduur (p = 0.002) en daardoor ook een lager 
geboortegewicht. Twaalf van de 14 vroeggeboorten (85.7%, zwangerschapsduur korter 
dan 37 weken) waren van vrouwen die de hoge-MBL genotype groep bezaten, terwijl 
deze groep slechts 56% van het gehele cohort vormt. 
In hoofdstuk 5 wordt een defi nitiever antwoord gegeven op de vraag of er nu wel 
of geen associatie is tussen MBL genotypen en het ontstaan van RA en ziekte ernst van 
RA. In twee grote onderzoekscohorten van n = 375 en n = 259 RA-patiënten werd aan-
getoond dat MBL genotype groepen niet geassocieerd zijn met het ontstaan van RA en 
RA ziekte ernst (gedefi nieerd als de noodzaak om anti-TNF therapie te gebruiken), onaf-
hankelijk van zwangerschap. MBL genotype groepen waren ook niet geassocieerd met 
RA ziektekenmerken zoals positieve autoantistoff en titers van anti-CCP en subklassen 
van reumafactor (RF) IgA-RF, IgM-RF en IgG-RF. De kracht van de studie lag in het feit dat 
alle resultaten werden bevestigd in een tweede RA-onderzoekscohort. Vergeleken met 
eerdere kleinere studies draagt dit onderzoek bij aan een meer defi nitieve conclusie dat 
er geen associatie is tussen MBL en het ontstaan van RA en ziekte ernst. 
In hoofdstuk 6 is het verloop van de galactosylering en sialylering van IgG tijdens de 
zwangerschap en in de postpartum periode onderwerp van studie. Een toename van 
de galactosylering en sialylering van IgG zou een alternatieve hypothese kunnen vor-
men als oorzaak van zwangerschapsgeïnduceerde verbetering van RA. Het is namelijk 
bekend dat een afname van de galactosylering geassocieerd is met hogere ziekteacti-
viteit. Met behulp van de MALDI-TOF massaspectrometer werd aangetoond dat bij de n 
= 148 bestudeerde RA-patiënten IgG1 en IgG2 galactosylering was toegenomen tijdens 
de zwangerschap en af nam na de bevalling. Dit profi el werd ook waargenomen bij de 
gezonde zwangeren, maar de galactosylering ligt dan op een hoger niveau (p < 0.001). 
Deze veranderingen in IgG galactosylering waren ook geassocieerd met veranderingen 
in RA ziekteactiviteit (DAS28) tijdens de zwangerschap en in de postpartum periode (R 
tussen 0.35 en 0.49, p < 0.005, afhankelijk van het tijdstip). Bij de vrouwen wier ziekteacti-
viteit afnam tijdens de zwangerschap (gedefi nieerd volgens de criteria van de European 
League Against Rheumatism (EULAR), responders), nam de IgG galactosylering juist 
meer toe dan bij vrouwen wier ziekteactiviteit niet verbeterde tijdens de zwangerschap 
(non-responders, p < 0.02). Omgekeerd daalde IgG galactosylering meer bij vrouwen 
die een fl are in de ziekteactiviteit postpartum doormaakten, dan bij vrouwen die geen 
fl are doormaakten, p < 0.0001. Tevens werd aangetoond dat de aanwezigheid van de 
Fleur BW 7.indd   139 10/22/2009   3:52:41 PM
140
Samenvatting
siaalzuur suikergroep (sialylering) sterk gecorreleerd is met de aanwezigheid van IgG 
galactose groepen (galactosylering, R tussen 0.57 en 0.69, p < 0.0001). Tevens werd on-
derzocht welke variabelen IgG galactosylering beïnvloeden. Multivariate analyse wees 
uit dat zowel RA ziekteactiviteit als het meetmoment tijdens de zwangerschap of in 
de postpartum periode de grootste invloed hebben op IgG galactosylering en niet het 
eventuele medicatie gebruik of het borstvoeding geven postpartum. 
Hoofdstuk 7 onderzoekt of hoge MBL spiegels (of hoge-MBL productie genotype 
groepen) samen met toegenomen IgG galactosylering tijdens de zwangerschap geas-
socieerd zijn met zwangerschapsgeïnduceerde verbetering van RA. Er werd geen associ-
atie gevonden tussen MBL genotype groepen en veranderingen in RA ziekteactiviteit 
(p = 0.89) en veranderingen in IgG galactosylering (RA-patiënten p = 0.75 en gezonde 
controles p = 0.54) gedurende de zwangerschap en in de postpartum periode. MBL func-
tioneert dus niet als ‘opruimer’ van het pathogene agalactosyl IgG. Bovendien waren MBL 
genotype groepen bij RA-patiënten niet geassocieerd met zwangerschapsuitkomsten 
zoals zwangerschapsduur, geboortegewicht, miskramen en hypertensieve aandoenin-
gen. Er kan daarom geconcludeerd worden dat toekomstige studies zich waarschijnlijk 
eerder op andere mechanismen dan die van MBL zouden moeten richten om de zwan-
gerschapgeïnduceerde verbetering van RA en de fl are postpartum te verklaren. 
Hoofdstuk 8, de algemene discussie, begint met het presenteren van de belangrijkste 
bevindingen in het licht van de onderzoeksvragen, gevolgd door de methodologische 
beperkingen van de studies die van belang zijn bij de interpretatie van de bevindingen. 
Nieuw verkregen inzichten in de rol van MBL, RA en zwangerschap worden beschreven. 
Hoofdstuk 8 eindigt met aanbevelingen voor toekomstig onderzoek naar zwanger-
schapgeïnduceerde verbetering van RA, waarbij de belofte vooral ligt bij de mogelijk 
anti-infl ammatoire eff ecten van IgG galactosylering en sialylering, dan wel hormoon- of 
cytokine interacties. 
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Dank woord
Hoewel alleen mijn naam op de kaft van dit boek prijkt, zijn er natuurlijk veel meer men-
sen betrokken geweest bij de totstandkoming van dit proefschrift. Niet alleen op het 
werk, maar ook daarbuiten hebben veel mensen mij inhoudelijk of op een andere waar-
devolle manier gesteund bij het afronden van mijn promotieonderzoek en het schrijven 
van dit manuscript. Bij voorbaat wil ik iedereen hiervoor bedanken. 
Ooit heb ik bedacht schrijver te willen worden na mijn pensioen, dus dat er nu al een 
eerste boek ligt, had ik nooit kunnen bedenken. Experimenten doen, vond ik als kind al 
leuk, dus toen dat enthousiasme werd aangewakkerd tijdens mijn farmacie-studiejaren 
en mijn wetenschapsstage in Baltimore lag een promotieonderzoek in de lijn der ver-
wachting. Dat is, getuige dit proefschrift, gelukt, maar zeker niet zonder de bijdrage van 
velen... 
Allereerst mijn promotoren, mw. Prof.dr. J.M.W. Hazes en Prof.dr. J.D. Laman. Beste Mieke, 
bedankt voor je vertrouwen, steun en begeleiding. Ik heb veel geleerd van je scherpe 
blik en ons regelmatige overleg op de vrijdagochtend. Als geen ander kon je me de ge-
heimen van de epidemiologie uitleggen en stimuleren om verder te zoeken. Beste Jon, 
regelmatig bespraken we even informeel de voortgang van mijn promotietraject. Altijd 
stond je klaar met goede adviezen. Dat heb ik zeer gewaardeerd. Ook heb ik me altijd 
thuis gevoeld in het lab, waar je me al snel aan iedereen had voorgesteld. 
Beste Mieke en Jon, bedankt voor alles wat ik van jullie heb geleerd! 
Dan mijn co-promoter, dr. R.J.E.M. Dolhain. Beste Radboud, we kunnen nog een boek 
schrijven over alles wat we hebben besproken en meegemaakt. We leerden elkaar ken-
nen tijdens mijn allereerste sollicitatiegesprek en kwamen uiteindelijk aan de praat over 
de leukste kroegen in Utrecht, waar we allebei hebben gestudeerd. Ook later eindig-
den onze overleggen vaak met anekdotes over niet-wetenschappelijke zaken. Ik ben je 
dankbaar voor je continue inzet, tijd en enthousiasme in de afgelopen jaren. Ik zal de 
suggesties voor verbeteringen (aangeduid als zoz1 en zoz2, etc) nog gaan missen. 
Ik heb heel veel van je geleerd en ik hoop dat we in de toekomst nog eens samenwerken. 
De leden van mijn leescommissie, als eerste Prof.dr. M.R. Daha. Ik heb met veel plezier in 
uw laboratorium in Leiden gewerkt en meerdere technieken geleerd om MBL concentra-
ties en MBL activiteit te meten. Dank ook voor uw adviezen ten aanzien van vervolgexpe-
rimenten en overige artikelen in mijn proefschrift. Ik ben er trots op dat u in mijn promo-
tiecommissie plaats wil nemen. Prof.dr. T.J.M. Helmerhorst, ook u hartelijk dank voor het 
plaatsnemen in de leescommissie en het kritisch beoordelen van het manuscript met uw 
deskundigheid op het gebied van de gynaecologie. Prof.dr. A.G. Uitterlinden, graag wil 
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ik u ook danken dat u ook in de commissie heeft plaatsgenomen met uw deskundigheid 
op het gebied van genetica. 
De leden behorende tot de grote commissie. Prof.dr. P.P Tak, dank dat u als hoogleraar 
uit Amsterdam en deskundige op het gebied van de reumatologie plaats wil nemen in 
de promotiecommissie. Prof.dr. J.L.C.M. van Saase, dank voor uw spontane aanbod om 
plaats te nemen in mijn promotiecommissie. Ik vind het een eer dat u als opleider hierbij 
aanwezig bent. Bedankt ook dat u mij in de gelegenheid heeft gesteld om mijn promo-
tietraject af te ronden tijdens mijn opleiding tot internist. 
Alle deelneemsters aan de PARA-studie samen met hun partners en kinderen, dank voor 
al jullie vertrouwen en gastvrijheid. Wat was het speciaal om als buitenstaander deze 
bijzondere levensfase van zwangerschap tot en met moederschap van zo dichtbij mee 
te mogen meemaken en bestuderen. Ook verdriet bij een miskraam of onvervulde zwan-
gerschapswens was niet slechts een onderwerp van studie. Dankzij jullie enthousiaste 
en trouwe deelname is er nu meer kennis beschikbaar voor patiënten met RA met een 
zwangerschapswens. Ik zal de bijzondere ontmoetingen in alle uithoeken van het land 
nooit vergeten. 
De reumatologen van Nederland wil ik hierbij bedanken voor het aanmelden van pa-
tiënten voor de PARA-studie. Dankzij uw hulp konden wij ons onderzoek opzetten en 
volbrengen. 
Mw. Dr. C.G. de Groot, beste Christianne, graag wil ik je bedanken voor je continue en-
thousiaste steun, geduld en begeleiding van praktisch al mijn artikelen. De late avonden 
bij jou thuis, toen we aan twee van onze gezamenlijke artikelen werkten, zullen me lang 
bijblijven. Ik heb veel van je geleerd, niet alleen op onderzoeksgebied. Veel dank daar-
voor. 
Uiteraard ook dank aan alle co-auteurs, zij die het risico wilden lopen bij te dragen aan 
mijn publicaties. Bedankt voor jullie specifi eke input!
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